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Preamble
This document has been developed as an expert consensus
document by the American College of Cardiology Foundation
(ACCF) and the American Heart Association (AHA), in collab-
oration with the American Academy of Neurology (AAN), the
American College of Physicians (ACP), the American Geriatrics
Society (AGS), the American Society of Hypertension (ASH),
the American Society of Nephrology (ASN), the American
Society for Preventive Cardiology (ASPC), the Association of
Black Cardiologists (ABC), and the European Society of Hy-
pertension (ESH). Expert consensus documents are intended to
inform practitioners, payers, and other interested parties of the
opinion of ACCF and document cosponsors concerning evolv-
ing areas of clinical practice and/or technologies that are widely
available or new to the practice community. Topics chosen for
coverage by expert consensus documents are so designed be-
cause the evidence base, the experience with technology, and/or
clinical practice are not considered sufficiently well developed to
be evaluated by the formal ACCF/AHA practice guidelines
process. Often the topic is the subject of considerable ongoing
investigation. Thus, the reader should view the expert consensus
document as the best attempt of the ACCF and document
cosponsors to inform and guide clinical practice in areas where
rigorous evidence may not yet be available or evidence to date is
not widely applied to clinical practice. When feasible, expert
consensus documents include indications or contraindications.
Typically, formal recommendations are not provided in expert
consensus documents as these documents do not formally grade
the quality of evidence, and the provision of “Recommenda-
tions” is felt to be more appropriately within the purview of the
ACCF/AHA practice guidelines. However, recommendations
from ACCF/AHA practice guidelines and ACCF appropriate
use criteria are presented where pertinent to the discussion. The
writing committee is in agreement with these recommendations.
Finally, some topics covered by expert consensus documents
will be addressed subsequently by the ACCF/AHA Task Force
on Practice Guidelines.
The ACCF Task Force on Clinical Expert Consensus
Documents makes every effort to avoid any actual or
potential conflicts of interest that might arise as a result of
an outside relationship or personal interest of a member of
the writing panel. Specifically, all members of the writing
committee are asked to provide disclosure statements of all
such relationships that might be perceived as relevant to
the writing effort. This information is documented in a
table, reviewed by the parent task force before final
writing committee selections are made, reviewed by the
writing committee in conjunction with each conference
call and/or meeting of the group, updated as changes occur
throughout the document development process, and ulti-
mately published as an appendix to the document. External
peer reviewers of the document are asked to provide this
information as well. The disclosure information for writing
committee members and peer reviewers is listed in Appen-
dixes 1 and 2, respectively, of this document. Disclosure
information for members of the ACCF Task Force on
Clinical Expert Consensus Documents—as the oversight
group for this document development process—is avail-
able online at www.cardiosource.org/ACC/About-ACC/
Leadership/Guidelines-and-Documents-Task-Forces.aspx.
Robert A. Harrington, MD, FACC
Chair, ACCF Task Force on Clinical Expert Consensus
Documents
2436 Circulation May 31, 2011
Executive Summary
This document was written with the intent to be a complete
reference at the time of publication on the topic of managing
hypertension in the elderly. Given the length of the document,
the writing committee included this executive summary to
provide a quick reference for the busy clinician. Because
additional detail is needed, please refer to the sections of
interest in the main text. The tables and figures in the
document also delineate important considerations on this
topic, including the treatment algorithm in Section 4.2.2.1.
General Considerations
Our population is aging, and as hypertension affects most
elderly people (65 years of age), these individuals are more
likely to have organ damage or clinical cardiovascular disease
(CVD). They represent management dilemmas because most
hypertension trials had upper age limits or did not present
age-specific results. However, because the Hypertension in
the Very Elderly Trial (HYVET) documented antihyperten-
sive therapy benefits in persons 80 years of age, it is timely
to place into perspective issues relevant to hypertension
management in elderly patients.
Pathophysiology of Hypertension in the Elderly
Age-associated increases in hypertension prevalence derive
from changes in arterial structure and function accompanying
aging. Large vessels become less distensible, which increases
pulse wave velocity, causing late systolic blood pressure
(SBP) augmentation and increasing myocardial oxygen de-
mand. Reduction of forward flow also occurs, limiting organ
perfusion. These undesirable alterations are enhanced with
coronary stenosis or excessive drug-induced diastolic blood
pressure (DBP) reduction. Autonomic dysregulation contrib-
utes to orthostatic hypotension (a risk factor for falls, syn-
cope, and cardiovascular [CV] events) and orthostatic hyper-
tension (a risk factor for left ventricular hypertrophy [LVH],
coronary artery disease [CAD], and cerebrovascular disease).
Progressive renal dysfunction, because of glomerulosclerosis
and interstitial fibrosis with a reduction in glomerular filtra-
tion rate (GFR) and other renal homeostatic mechanisms such
as membrane sodium/potassium–adenosine triphosphatase,
fosters hypertension through increased intracellular sodium,
reduced sodium–calcium exchange, and volume expansion.
Microvascular damage contributes to chronic kidney disease
(CKD) as reduced renal tubular mass provides fewer trans-
port pathways for potassium excretion; thus elderly hyperten-
sive patients are prone to hyperkalemia. Secondary causes of
hypertension should be considered, such as renal artery
stenosis (RAS), obstructive sleep apnea, primary aldosteron-
ism, and thyroid disorders. Lifestyle, substances, and medi-
cations (tobacco, alcohol, caffeine, nonsteroidal anti-
inflammatory drugs [NSAIDs], glucocorticoids, sex
hormones, calcium, and vitamins D and C) can also be
important contributors.
End-Organ Effects
The following are highly prevalent among the elderly and
associated with poor blood pressure (BP) control: cerebro-
vascular disease (ischemic stroke, cerebral hemorrhage, vas-
cular dementia, Alzheimer’s disease, and accelerated cogni-
tive decline); CAD (including myocardial infarction [MI] and
angina pectoris); disorders of left ventricular (LV) structure
and function (including LVH and heart failure [HF]); cardiac
rhythm disorders (atrial fibrillation [AF] and sudden death);
aortic and peripheral arterial disease [PAD]) (including ab-
dominal aortic aneurysm [AAA], thoracic aortic aneurysm,
acute aortic dissection and occlusive PAD); CKD (estimated
glomerular filtration rate [eGFR] 60 mL/min/1.73 m2);
ophthalmologic disorders (including hypertensive retinopa-
thy, retinal artery occlusion, nonarteritic anterior ischemic
optic neuropathy, age-related macular degeneration, and neo-
vascular age-related macular degeneration); and quality of
life (QoL) issues.
Interactions Between Aging and CV Risk
Conditions Associated With Hypertension
Because dyslipidemia and hypertension are common among the
elderly, it is reasonable to be aggressive with lipid lowering in
elderly hypertensive patients. Elderly patients with hypertension
and diabetes mellitus have a higher mortality risk than similarly
aged nondiabetic controls. Hypertension is an insulin-resistant
state because SBP, fasting glucose, and thiazide diuretic and/or
beta-blocker use are independent risk factors for incident diabe-
tes mellitus. Albuminuria is a predictor of higher mortality risk
among those with diabetes mellitus. Obesity is associated with
increases in LV wall thickness, volume, and mass, independent
of BP. Adipose tissue produces all components of the
renin-angiotensin-aldosterone system (RAAS) locally, leading
to development of obesity-related hypertension. Increased an-
giotensin II (AII) may contribute to insulin resistance. Activation
of tissue RAAS contributes to vascular inflammation and fibro-
sis. Renin and aldosterone may also promote atherosclerosis and
organ failure. Microalbuminuria is associated with CAD, HF,
and mortality. Screening for albuminuria is recommended for all
elderly hypertensive patients with concomitant diabetes mellitus
and for those with mild and moderate CKD. Gout incidence
rates are 3 times higher in hypertensive patients versus normo-
tensive patients; thiazide diuretics increase serum uric acid levels
and may provoke gout. Serum uric acid independently predicts
CV events in older hypertensive persons; therefore, monitoring
serum uric acid during diuretic treatment is reasonable. Arthritis
is a common problem in the elderly, with implications for
hypertension and adverse outcomes related to medications.
NSAIDs are implicated in BP elevation, and a chronic inflam-
matory burden may lead to increased arterial stiffness. Other
drugs such as cyclo-oxygenase-2 inhibitors, glucocorticoids, and
some disease-modifying antirheumatic drugs (eg, cyclosporine,
leflunomide) may increase BP.
Clinical Assessment and Diagnosis
Diagnosis of hypertension should be based on at least 3
different BP measurements, taken on 2 separate office
visits. At least 2 measurements should be obtained once
the patient is seated comfortably for at least 5 minutes with
the back supported, feet on the floor, arm supported in the
horizontal position, and the BP cuff at heart level. Pseudo-
hypertension is a falsely increased SBP that results from
markedly sclerotic arteries that do not collapse during cuff
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inflation (eg, “noncompressible”). Although this occurs more
commonly in the elderly, the actual prevalence is unclear.
Identification of pseudohypertension is necessary to avoid
overtreating high BP and should be suspected in elders with
refractory hypertension, no organ damage, and/or symptoms
of overmedication. White-coat hypertension is more common
in the elderly and frequent among centenarians. Ambulatory
BP monitoring is recommended to confirm a diagnosis of
white-coat hypertension in patients with persistent office
hypertension but no organ damage. Ambulatory BP monitor-
ing (ABPM) is indicated when hypertension diagnosis or
response to therapy is unclear from office visits, when
syncope or hypotensive disorders are suspected, and for
evaluation of vertigo and dizziness. The case for using
out-of-office BP readings in the elderly, particularly home BP
measurements, is strong due to potential hazards of excessive
BP reduction in older people and better prognostic accuracy
versus office BP.
Recommendations for Management
General Considerations
Because there is limited information for evidence-based
guidelines to manage older hypertension patients, the follow-
ing recommendations are based on expert opinion that we
believe provide a reasonable clinical approach. Evaluation of
the elderly patient with known or suspected hypertension
must accurately determine BP, and if elevated: 1) identify
reversible and/or treatable causes; 2) evaluate for organ
damage; 3) assess for other CVD risk factors/comorbid
conditions affecting prognosis; and 4) identify barriers to
treatment adherence. Evaluation includes a history, physical
exam, and laboratory testing. It is most important to focus on
aspects that relate to hypertension, including details concern-
ing the duration, severity, causes, or exacerbations of high
BP, current and previous treatments including adverse ef-
fects, assessment of target organ damage, and other CVD risk
factors and comorbidities, as noted in the preceding text.
There is limited evidence to support routine laboratory
testing. Instead, a more deliberative, reasoned approach to
testing is recommended: 1) urinalysis for evidence of renal
damage, especially albuminuria/microalbuminuria; 2) blood
chemistries (especially potassium and creatinine with eGFR);
3) total cholesterol, low-density lipoprotein cholesterol, high-
density lipoprotein cholesterol, and triglycerides; 4) fasting
blood sugar (including hemoglobin A1c if there are concerns
about diabetes mellitus); and 5) electrocardiogram (ECG). In
selected elderly persons, 2-dimensional echocardiography is
useful to evaluate for LVH and LV dysfunction that would
warrant additional therapy (ie, angiotensin-converting en-
zyme inhibitors [ACEIs], beta blockers).
BP Measurement and Goals
Reliable, calibrated BP measurement equipment is essential for
hypertension management. The BP should also be measured
with the patient standing for 1 to 3 minutes to evaluate for
postural hypotension or hypertension. The general recom-
mended BP goal in uncomplicated hypertension is
140/90 mm Hg. However, this target for elderly hypertensive
patients is based on expert opinion rather than on data from
randomized controlled trials (RCTs). It is unclear whether target
SBP should be the same in patients 65 to 79 years of age as in
patients 80 years of age.
QoL and Cognitive Function
Because symptomatic well-being, cognitive function, physi-
cal activity, and sexual function are diminished by aging and
disease, it is important to give particular attention to QoL
areas when making therapeutic decisions.
Nonpharmacological Treatment
Lifestyle modification may be the only treatment necessary
for milder forms of hypertension in the elderly. Smoking
cessation, reduction in excess body weight and mental stress,
modification of excessive sodium and alcohol intake, and
increased physical activity may also reduce antihypertensive
drug doses. Weight reduction lowers BP in overweight
individuals, and combined with sodium restriction, results in
greater benefit. BP declines from dietary sodium restriction
are generally larger in older than in young adults. Increased
potassium intake, either by fruits and vegetables or pills, also
reduces BP, especially in individuals with higher dietary
sodium intake. Alcohol consumption of 2 alcoholic drinks
per day is strongly associated with BP elevations, and BP
generally declines after reduced alcohol intake, though evi-
dence is limited among older adults. Exercise at moderate
intensity elicits BP reductions similar to those of more
intensive regimens.
Management of Associated Risk Factors and
Team Approach
Many risk stratification tools calculate risk estimates using an
overall or “global” instrument like the Framingham Risk
Score for predicting MI, stroke, or CVD. These instruments
emphasize age and classify all persons70 or 75 years of age
as high risk (ie, 10% risk of CAD in next 10 years), or very
high risk (eg, those with diabetes mellitus or CAD), thus
deserving antihypertensive therapy. Furthermore, analyses
have not suggested that elderly subgroups differed from
younger subgroups in response to multiple risk interventions.
Patient management is often best accomplished by employing
a health care team that may include clinical pharmacists,
nurses, physician assistants, clinical psychologists, and others
(as necessary). Technology enhancements to assist in achiev-
ing and maintaining goals range from simple printed prompts
and reminders to telemedicine and text messaging.
Considerations for Drug Therapy
Drug treatment for elderly hypertensive patients has been
generally recommended but with a greater degree of caution
due to alterations in drug distribution and disposal and
changes in homeostatic CV control, as well as QoL factors.
However, patients in most hypertension trials were80 years
of age. Pooling the limited number of octogenarians from
several trials mainly composed of younger patients, treated
patients showed a reduction in both stroke and CV morbidity,
but a trend toward increased all-cause mortality compared to
controls. Thus, the overall benefits of treating octogenarians
remain unclear despite epidemiological evidence that hyper-
tension remains a potent CV risk factor in this age group.
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Results of HYVET, documenting reduced adverse outcomes
with antihypertensive drugs in persons 80 years of age,
requires updating previous recommendations.
Initiation of Drug Therapy
The initial antihypertensive drug should be started at the
lowest dose and gradually increased, depending on BP
response, to the maximum tolerated dose. An achieved SBP
140 mm Hg, if tolerated, is recommended except for
octogenarians (see special populations in the following text).
If the BP response is inadequate after reaching “full dose”
(not necessarily maximum recommended dose), a second
drug from another class should be added provided the initial
drug is tolerated. If there are adverse effects or no therapeutic
response, a drug from another class should be substituted. If
a diuretic is not the initial drug, it is usually indicated as the
second drug. If the antihypertensive response is inadequate
after reaching full doses of 2 classes of drugs, a third drug
from another class should be added. When BP is 20/
10 mm Hg above goal, therapy should be initiated with 2
antihypertensive drugs. However, treatment must be individ-
ualized in the elderly. Before adding new antihypertensive
drugs, possible reasons for inadequate BP response should be
examined. On average, elderly patients are taking 6 pre-
scription drugs, so polypharmacy, nonadherence, and poten-
tial drug interactions are important concerns.
Specific Drug Classes
Thiazide diuretics (hydrochlorothiazide [HCTZ], chlorthali-
done, and bendrofluazide [bendrofluomethiazide]) are recom-
mended for initiating therapy. They cause an initial reduction
in intravascular volume, peripheral vascular resistance, and
BP, and are generally well tolerated. Several trials demon-
strate reduced CV, cerebrovascular, and renal adverse out-
comes in the elderly. Aging-related physiological changes
can be exacerbated with diuretics. The elderly generally have
contracted intravascular volumes and impaired baroreflexes.
Diuretics cause sodium and water depletion and may promote
orthostatic hypotension. Older people have a high prevalence
of LVH, which predisposes them to ventricular arrhythmias
and sudden death. Thiazide diuretics can cause hypokalemia,
hypomagnesemia, and hyponatremia, which increase arrhyth-
mias. The elderly have a tendency toward hyperuricemia,
glucose intolerance, and dyslipidemia, all of which are
exacerbated by thiazides. Nevertheless, thiazides reduce CV
events in the elderly to a similar extent as other drug classes.
Non-Thiazide Diuretics
Indapamide is a sulfonamide diuretic used for hypertension.
This drug increases blood glucose, but not uric acid, and can
cause potassiumindependent prolongation of the QT interval.
Caution is advised when used with lithium. Furosemide and
analogs (bumetanide or torsemide) are loop diuretics some-
times used for hypertension complicated by HF or CKD.
They increase glucose and may cause headaches, fever,
anemia, or electrolyte disturbances. Mineralocorticoid antag-
onists (spironolactone and eplerenone) and epithelial sodium
transport channel antagonists (amiloride and triamterene) are
useful in hypertension when combined with other agents. In
contrast to thiazides and loop diuretics, these drugs cause
potassium retention and are not associated with adverse
metabolic effects.
Beta blockers have been used for hypertension, but evi-
dence for a benefit in the elderly has not been convincing.
They may have a role in combination therapy, especially with
diuretics. Beta blockers are indicated in the treatment of
elderly patients who have hypertension with CAD, HF,
certain arrhythmias, migraine headaches, and senile tremor.
Although earlier beta blockers have been associated with
depression, sexual dysfunction, dyslipidemia, and glucose
intolerance, these side effects are less prominent or absent
with newer agents. Although the efficacy of alpha blockers is
documented, their usefulness is very limited because doxazo-
sin showed excess CV events compared with chlorthalidone
in ALLHAT (Antihypertensive and Lipid-Lowering Treat-
ment to Prevent Heart Attack Trial) (greater than a 2-fold
increase in HF and 20% increase in stroke). Based on these
findings, alpha blockers should not be considered as first-line
therapy for hypertension in older adults.
Calcium antagonists (CAs) have widely variable effects on
heart muscle, sinus node function, atrioventricular conduc-
tion, peripheral arteries, and coronary circulation. They in-
clude phenylalkylamines (verapamil); benzothiazepines (dil-
tiazem); and dihydropyridines (nifedipine, nicardipine,
nimodipine, amlodipine, felodipine, isradipine, nitrendipine).
Results of controlled trials have demonstrated the safety and
efficacy of CAs in elderly patients with hypertension. They
appear well suited for elderly patients, whose hypertensive
profile is based on increasing arterial stiffness, decreased
vascular compliance, and diastolic dysfunction. Because they
have multiple applications, including treatment of angina and
supraventricular arrhythmias, CAs are useful for elderly
hypertensive patients with these comorbid CV conditions.
Most adverse effects of dihydropyridines relate to vasodila-
tion (eg, ankle edema, headache, postural hypotension).
Postural hypotension is associated with an increased risk of
dizziness and falls and a serious concern for elderly patients.
Short-acting rapid-release dihydropyridines must be avoided.
Verapamil and diltiazem can precipitate heart block in elderly
patients with underlying conduction defects. First-generation
CA (nifedipine, verapamil, and diltiazem) should be avoided
in patients with LV systolic dysfunction.
ACEIs block conversion of AI to AII, both in tissue and
plasma to lower peripheral vascular resistance and BP with-
out reflex stimulation of heart rate and contractility. They
reduce morbidity and mortality in patients with HF, reduce
systolic function post-MI, and retard progression of diabetic
renal disease and hypertensive nephrosclerosis. Main adverse
effects include hypotension, chronic dry cough, and, rarely,
angioedema or rash. Renal failure can develop in those with
RAS. Hyperkalemia can occur in patients taking potassium
supplements, as well those with renal insufficiency. Rarely,
neutropenia or agranulocytosis can occur; close monitoring is
suggested during the first months of therapy. Angiotensin
receptor blockers (ARBs) selectively block AT1-receptor
subtype and, overall, are similar to other agents in reducing
BP, are well tolerated, protect the kidney, and reduce mor-
tality and morbidity in HF patients. In elderly hypertensive
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patients with diabetes mellitus, ARBs are considered first line
and as an alternative to ACEI in patients with hypertension
and HF who cannot tolerate ACEIs.
Direct Renin Inhibitors
Aliskiren is as effective as ARBs or ACEIs for BP lowering
without dose-related increases in adverse events in elderly
patients. Combined with HCTZ, ramipril, or amlodipine,
aliskiren causes greater BP lowering than with either agent
alone. Evidence is lacking combining aliskiren with beta
blockers or maximal dose ACEIs, and only limited data are
available in black hypertensive patients. In patients 75
years of age, including those with renal disease, aliskiren
appears well tolerated. The major side effect is a low
incidence of mild diarrhea, which usually does not lead to
discontinuation. There are no data on treating patients with an
eGFR below 30 mL/min/1.73 m2.
Nonspecific Vasodilators
Because of their unfavorable side effects, hydralazine and
minoxidil are fourth-line antihypertensive agents and only
used as part of combination regimens. As a monotherapy,
both drugs cause tachycardia, and minoxidil causes fluid
accumulation and atrial arrhythmias. Centrally acting agents
(eg, clonidine) are not first-line treatments in the elderly
because of sedation and/or bradycardia. Abrupt discontinua-
tion leads to increased BP and heart rate, which may
aggravate ischemia and/or HF. These agents should not be
considered in noncompliant patients but may be used as part
of a combination regimen if needed after several other agents
are deployed.
Combination therapy provides more opportunity for en-
hanced efficacy, avoidance of adverse effects, enhanced
convenience, and compliance. It is important to consider the
attributes of ACEIs, ARBs, and CAs, in addition to BP
lowering. Some combinations of these agents may provide
even more protective effects on the CV system. One trial of
high-risk hypertensive elders, ACCOMPLISH (Avoiding
Cardiovascular Events in Combination Therapy in Patients
Living with Systolic Hypertension), found an ACEI–longact-
ing CA combination superior to an ACEI–HCTZ combina-
tion in reduction of morbidity and mortality.
Uncomplicated Hypertension
The 2009 updated European Society of Hypertension guide-
lines recommend initiating therapy in the elderly with thia-
zide diuretics, CAs, ACEIs, ARBs, or beta blockers based on
a meta-analysis of major hypertension trials.23 Most elderly
persons with hypertension will need 2 drugs. When BP is
20/10 mm Hg above goal, consideration should be given to
starting with 2 drugs.
Complicated Hypertension
In elderly patients who have CAD with hypertension and
stable angina or prior MI, the initial choice is a beta blocker.
A long-acting dihydropyridine CA should be administered in
addition to the beta blocker when the BP remains elevated or
if angina persists. An ACEI should also be given, particularly
if LV ejection fraction is reduced and/or if HF is present. A
verapamil SR–trandolapril-based strategy is as clinically
effective, in terms of BP control and adverse outcomes, as an
atenolol–HCTZ-based strategy in hypertensive elderly CAD
patients including those with prior MI. Angina was better
controlled with the verapamil SR–trandolapril strategy. With
acute coronary syndromes, hypertension should be treated
with beta blockers and ACEI, with additional drugs added as
needed for BP control. Verapamil and diltiazem should not be
used with significant LV systolic dysfunction or conduction
system disease. Although some guidelines recommend reduc-
ing BP to 130/80 mm Hg in CAD patients, there is limited
evidence to support this lower target in elderly patients with
CAD. Observational data show the nadir BP for risk was
135/75 mm Hg among CAD patients 70 to 80 years of age
and 140/70 mm Hg for patients 80 years of age. Beta
blockers with intrinsic sympathomimetic activity must not be
used after MI.
Hypertension associated with LVH is an independent risk
factor for CAD, stroke, PAD, and HF. A large meta-analysis
found ACEIs more effective than other antihypertensive
drugs in decreasing LV mass. However, all agents except for
direct-acting vasodilators reduce LV mass if BP is controlled.
Elderly patients with hypertension and systolic HF should
receive a diuretic, beta blocker, ACEI, and an aldosterone
antagonist, in the absence of hyperkalemia or significant renal
dysfunction, if necessary. If a patient cannot tolerate an
ACEI, an ARB should be used. Elderly black hypertensive
patients with HF may benefit from isosorbide dinitrate plus
hydralazine. Based on expert opinion, the BP should be
reduced to 130/80 mm Hg in HF patients with CAD.
Elderly patients with hypertension and asymptomatic LV
systolic dysfunction should be treated with ACEIs and beta
blockers. Because HF may improve in hypertensive elderly
patients with RAS after renal revascularization, a search for
RAS should be considered when HF is refractory to conven-
tional management. Diastolic HF is very common in the
elderly. Fluid retention should be treated with loop diuretics,
hypertension should be adequately controlled, and when
possible, comorbidities should be treated.
Although “The Seventh Report of the Joint National
Committee on Prevention, Detection, Evaluation, and Treat-
ment of High Blood Pressure” recommends that elderly
hypertensive patients with cerebrovascular disease (prior
stroke or transient ischemic attack) should be treated with a
diuretic plus an ACEI,22 reduction of stroke risk among
elderly persons with hypertension is related more to reduction
in BP than to type of antihypertensive drug.
Presence of aortic aneurysm requires very intense BP
control to the lowest tolerated level. Therapy should include
an ACEI or ARB plus a beta blocker because, in addition to
lowering BP, beta blockers decrease peak LV ejection rate. In
acute aortic dissection (acute aortic syndrome), control of BP
with multiple drugs, including beta blockers, is needed for
both type A and B (not involving the ascending aorta)
dissections. For PAD, lifestyle interventions include smoking
cessation, weight loss, and a structured walking program.
Management of hypertension as well as coexistent CAD and
HF are essential, as is control of blood glucose and lipids.
ACEIs or ARBs, and antiplatelet therapy are required.
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In the absence of RCT data, guidelines recommend that
patients with diabetes mellitus should have a BP 130/80
mm Hg. If tolerated, multiple drugs are often required.
However, RCT data among those 65 years of age from the
ACCORD BP (Action to Control Cardiovascular Risk in
Diabetes Blood Pressure) trial found no additional benefit
from a target SBP 120 mm Hg versus a target of
140 mm Hg. Observational data from extended follow-up of
the predominantly elderly INVEST (INternational VErapamil
SR/Trandolapril Study) diabetes cohort suggest an increase in
mortality when on-treatment SBP is 115 mm Hg or DBP
65 mm Hg. Reduction of macrovascular and microvascular
complications in elderly hypertensive diabetic patients de-
pends more on reducing BP than on type of drugs used. Drug
choice depends on associated comorbidities. However, thia-
zide diuretics will increase hyperglycemia. Elderly persons
with diabetes mellitus, hypertension, and nephropathy should
be treated initially with ACEIs or ARBs. In ACCOMPLISH,
over the background of ACEI, diabetic patients treated with
amlodipine had a 21% relative risk reduction and 2.2%
absolute risk reduction in CV events compared with HCTZ
plus the ACEI. In elderly persons with prediabetes/metabolic
syndrome, attempts should be made to reduce BP using
lifestyle modification. If drugs are needed, thiazide diuretics
increase risk for incident diabetes mellitus, which has been
associated with increased HF hospitalizations and other CV
events in elderly patients with hypertension.
Based on expert opinion and observational data, elderly
hypertension patients with CKD should have a target BP
130/80 mm Hg, if tolerated. Drug regimens including
ACEIs or ARBs are more effective than regimens without
them in slowing progression of CKD. ACEIs are indicated in
patients with nondiabetic nephropathy. However, there are no
data on outcomes with any class of antihypertensive agent
among elderly patients with hypertension and CKD. Without
proteinuria300 mg/d, there are no data that ACEIs or ARBs
are better than BP control alone with any other antihyperten-
sive agent. ACEIs or ARBs should be administered to elderly
hypertensive patients with CKD if proteinuria is present.
Hypertension and HF are both associated with a more
pronounced decline in renal function in older age. With the
recognition of early renal dysfunction, more patients should
benefit from aggressive therapy. In an observational study of
elderly patients who were hospitalized with acute systolic HF
and advanced CKD, ACEI use was associated with reduced
mortality. A retrospective cohort of elderly individuals with
CKD and acute MI found benefit from aspirin, beta blockers,
and ACEIs.
Aortorenal bypass has been used to treat hypertension,
preserve renal function, and treat HF and unstable angina in
RAS patients with ischemic nephropathy. Advanced age and
HF are independent predictors of mortality. Percutaneous
transluminal renal artery balloon angioplasty with stenting
has replaced angioplasty alone because the stenosis usually
involves narrowing of the ostium. However, there is uncer-
tainty regarding the benefit of stenting on BP control and
CKD.
Other Conditions/Special Populations
Among elderly persons with osteoporosis and calcium regu-
latory disorders, thiazide diuretics may preserve bone density
and raise blood calcium levels. Loop diuretics can decrease
serum calcium. Epithelial sodium transport channel antago-
nists may decrease urinary calcium and may be considered
for people with calcium oxalate kidney stones. Beta blockers
and heart rate–slowing CAs (verapamil or diltiazem) should
be used for ventricular rate control with supraventricular
tachyarrhythmias in elderly persons with hypertension. Beta
blockers should be used for elderly patients with hyperten-
sion, complex ventricular arrhythmias, HF, hyperthyroidism,
preoperative hypertension, migraine, or essential tremor.
Blacks: RAAS inhibitors appear less effective than other
drug classes in decreasing BP in elderly blacks, unless
combined with diuretics or CAs. The initial agent in blacks
with uncomplicated hypertension should be a thiazide diu-
retic. CAs effectively lower BP in blacks and decrease CV
events, especially stroke. A diuretic or CA plus an ACEI
would be a reasonable combination in blacks. Blacks, many
of whom have severe and complicated hypertension, usually
will not achieve control with monotherapy. Aldosterone
antagonists (spironolactone and eplerenone) are often bene-
ficial in resistant hypertension, including blacks.
Hispanics: Recommendations for pharmacological man-
agement of elderly Hispanic patients are the same as for
elderly patients in general.
Women: There is no evidence that elderly women respond
differently than elderly men to antihypertensive drugs.
Available data from HYVET4 and other RCTs suggest that
treatment of hypertension in octogenarians may substantially
reduce CV risk and mortality, but benefits on cognitive
function are less certain. Although a BP 140/90 mm Hg is
recommended for all patients in “The Seventh Report of the
Joint National Committee on Prevention, Detection, Evalua-
tion, and Treatment of High Blood Pressure,” except for a
lower level in special populations,22 randomized trial evi-
dence to support this BP level in the very elderly is not robust.
Secondary analyses from INVEST and ACCOMPLISH
showed no difference in effects of antihypertensive drug
therapy on outcomes among those 80 years of age versus
those 80 years of age. However, ACCORD BP found no
additional benefit, and increased drug-related adverse expe-
riences, targeting a SBP of 120 versus 140 mm Hg in
high-risk patients with diabetes mellitus who were 55 years
of age. Observational data from INVEST in hypertensive
CAD patients showed a nadir for adverse outcomes at a mean
on-treatment SBP of 135 mm Hg for patients 70 to 79 years
of age and at 140 mm Hg for those 80 years of age.
The following recommendations are offered for persons
80 years of age. Initiate treatment with a single drug
followed by a second drug if needed. Achieved SBP 140 to
145 mm Hg, if tolerated, can be acceptable. Low-dose
thiazides, CAs, and RAAS blockers are preferred, but con-
comitant conditions often dictate which drugs are most
appropriate. Octogenarians should be seen frequently with the
medical history updated at each visit. Standing BP should
always be checked for excessive orthostatic decline. Al-
though BP values below which vital organ perfusion is
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impaired in octogenarians are not known, SBP 130 and
DBP 65 mm Hg should be avoided.
Resistant hypertension (eg, BP that remains above goal
when patient adheres to lifestyle measures and maximum
tolerated doses of complementary antihypertensive agents,
including a diuretic) is associated with increasing age. Rea-
sons include higher arterial stiffness, decreased antihyperten-
sive medication efficacy, higher baseline BP, higher inci-
dence of organ damage and comorbidities, excess salt intake,
weight, alcohol, nicotine, poor treatment compliance, volume
overload, pseudohypertension, and NSAID use. Elderly pa-
tients with higher baseline SBP typically have more severe or
longer duration of hypertension that makes it more difficult to
treat because it is often associated with autonomic dysfunc-
tion and organ damage. Volume overload is commonly due to
excessive salt intake, inadequate kidney function, or insuffi-
cient diuretic therapy. Physicians are less aggressive treating
very elderly patients as many believe that hypertension
treatment in an 85 year old has more risks than benefits.
Pseudohypertension represents another reason for resistant
hypertension. Increased arterial stiffness due to heavily cal-
cified arteries that cannot be fully compressed makes BP
readings falsely higher than the intra-arterial BP.
Although therapy of resistant hypertension must be indi-
vidualized, a combination of a RAAS blocker, a CA, and an
appropriately dosed diuretic is frequently effective. These
agents must be given in adequate dosages at appropriate time
intervals. Lifestyle modifications (eg, weight reduction, so-
dium restriction, reduction in alcohol intake, and the DASH
[Dietary Approaches to Stop Hypertension] diet) may be
useful, and secondary causes of hypertension should be
considered.
Adherence to Pharmacological Therapy
Adherence, defined as extent to which a patient takes medi-
cation as prescribed, is a major issue in antihypertensive
therapy in all age groups. A large proportion of elderly
patients will discontinue or take the drugs inappropriately.
Nonadherence often results in failing to reach recommended
BP targets and impacts outcomes. Older age, previous non-
adherence, low risk for CV events, competing health prob-
lems, nonwhite race, low socioeconomic status, treatment
complexity (eg, multiple dosing, pill burden), side effects,
and cost of medications predict nonadherence.
Treatment Initiation and Goals
Elderly patients who have hypertension are candidates for
nonpharmacological interventions; if they remain hyperten-
sive, drug therapy should be considered. Achieved SBP
values 140 mm Hg are appropriate goals for most patients
79 years of age; for those 80 years of age, 140 to
145 mm Hg, if tolerated, can be acceptable.
Future Considerations
Prevention of Hypertension and Its Consequences
Research should include both fundamental and clinical inves-
tigation defining pathogenesis of increased vascular and LV
stiffness; RCTs to define appropriate treatment thresholds
and goals; comparative effectiveness trials testing various
treatment strategies (ie, different regimens and different
intensities of lifestyle modification); and assessing the rela-
tive safety and efficacy of these approaches in the prevention
of mortality and morbidity.
1. Introduction
1.1. Document Development Process and
Methodology
1.1.1. Writing Committee Organization
The writing committee consisted of acknowledged experts in
hypertension among elderly patients representing the ACCF,
AHA, AAN, ABC, ACP, AGS, ASH, ASN, ASPC, and ESH.
Both the academic and private practice sectors were repre-
sented. Representation by an outside organization does not
necessarily imply endorsement.
1.1.2. Relationships With Industry and Other Entities
Prior to finalizing writing committee membership, all poten-
tial authors reported their relevant relationships with industry
and other entities pertinent to this writing effort that began 24
months prior to receiving their invitation letter to participate.
This information was organized into a table and reviewed by
the ACCF Task Force on Clinical Expert Consensus Docu-
ments for writing committee balance across a series of
elements including relationships with industry and other
entities, regional distribution, sex, race, and specialty area.
The ACCF Task Force on Clinical Expert Consensus Docu-
ments approved the constitution of this group. On each
full-committee conference call, authors were asked to review
the disclosure table and verbally disclose any additions to
their information. As noted in the Preamble, relevant rela-
tionships with industry and other entities of writing commit-
tee members are published in Appendix 1 of this document.
In addition, in the spirit of full transparency, author compre-
hensive disclosure information (relationships the author
deemed not applicable to this document) is made available
online as a supplement to this document. For detailed infor-
mation regarding ACCF’s disclosure policy, including the
definitions of relevant relationships with industry, visit
www.cardiosource.org/Science-And-Quality/Practice-Guidelines-
and-Quality-Standards/Relationships-With-Industry-Policy.aspx.
1.1.3. Consensus Development
Prior to the first writing committee conference call, an outline
of the document was drafted, and preliminary writing assign-
ments were made. During the committee’s first call, the
timeline, draft outline and writing assignments, definition of
hypertension, and relationships with industry were discussed
and finalized. A thorough literature review was undertaken on
hypertension and the elderly, results were distributed to
authors, and primary authors drafted their sections for review
by secondary authors prior to submitting their sections for
incorporation into the master draft. The co-chairs edited the
manuscript and sent it back to committee members for further
editing. Several additional conference calls with the entire
committee were held to discuss document issues in order to
achieve consensus. Smaller subgroup meetings were held
when necessary to focus on a particular area (eg, management
of the patient). Each individual contributor of the document
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had his or her initial full written presentation critiqued by all
other members of this writing committee. Considerable dis-
cussion among the group focused on the best and most proper
way to manage the elderly patient with hypertension as the
clinical data are limited for this population. The writing
committee arrived at consensus on the document and signed
off on the draft for external peer review.
1.1.4. External Peer Review
The document was reviewed by 2 official reviewers nomi-
nated by each of the participating societies in this document,
as well as 5 content reviewers, totaling 25 reviewers in all. A
task force lead reviewer was assigned to the review process
to ensure that the writing committee reviewed and re-
sponded to all reviewer comments in a reasonable and
balanced manner. A complete listing of peer reviewers and
their relevant relationships with industry are listed in
Appendix 2.
1.1.5. Final Writing Committee and Task Force Approval
of the Document
The writing committee formally approved the final document.
Subsequently, the task force lead reviewer signed off on the
completeness of the external review process, and the ACCF
Task Force on Clinical Expert Consensus Documents re-
viewed the document for completeness and approved the
document to be sent for final organizational review.
1.1.6. Document Approval
The document was approved for publication by each of the
following participating societies: ACCF, AHA, AAN, AGS,
ASPC, ASH, ASN, and ESH. This document will be consid-
ered current until the task force revises or withdraws it from
distribution.
1.1.7. Document Methodology
An extensive literature search was conducted using the US
National Library of Medicine’s PubMed database that led to
the incorporation of 742 references. Searches were limited to
studies, reviews, and other evidence conducted in human
subjects and published in English. Key search words included
but were not limited to hypertension, aged, elderly, pharma-
ceutical preparations, cost, compliance, diagnosis, physical
examination, tobacco, smoking, drug therapy, family history,
premature CVD, risk factors, complications, dyslipidemia,
obesity, cerebrovascular disease, HF, MI, angina, PAD,
diabetes mellitus, lifestyle, J-curve, adverse drug event, renal
revascularization, osteoarthritis, hypokalemia, prognosis,
microalbuminuria, and retinopathy. Additional relevant ref-
erences have also been identified by personal contacts of the
writing committee members, and substantial efforts were
made to identify all relevant manuscripts that were currently
in press. References selected and published in this document
are representative and not all-inclusive.
The writing committee agreed uniformly that the definition
of elderly would include those65 years of age. Recommen-
dations for management of hypertension in the elderly are
largely based on randomized controlled trials and meta-anal-
yses. However, specific data as they pertain directly to the
elderly population remain limited in some areas, including
specific BP recommendations for patients with comorbid
conditions such as diabetes mellitus, CKD, and PAD. Rec-
ommendations made in these and other areas may be based on
expert consensus opinion or on the limited data available
from observational studies.
The recommendations listed in this document are, when-
ever possible, evidence-based. Unlike ACCF/AHA guide-
lines, there is not a large body of peer-reviewed published
evidence to support most recommendations, which will be
clearly indicated in the text. To ensure concordance across
ACCF clinical documents, the writing committee reviewed
documents related to the subject matter previously published
by the ACCF. Prior ACCF/AHA guidelines contain recom-
mendations for BP management, but none of these recom-
mendations are directed to the elderly.
1.2. Purpose of This Expert Consensus Document
Our population is aging, and hypertension in elderly patients
is increasing in prevalence. Approximately 34 million Amer-
icans are currently 65 years of age; this number is expected
to reach 75 million by 2040, representing more than20% of
the US population. Individuals 85 years of age are the
largest growing subset in the United States,1 and there have
been dramatic improvements in life expectancy in older
adults.2 Also, the clinical importance of treating this subgroup
is emphasized from the National Hospital Discharge Survey
(2000) where the far majority of patients admitted to CV
services are 65 years of age, and nearly 80% to 90% of
those who die on our services are 65 years of age.
Hypertension in elderly patients is a complex CV disorder
that affects women more than men and occurs in essentially
all races, ethnic groups, and countries. Although it appears to
be underdiagnosed in general and particularly among women,
minorities, and underserved populations, clearly it is also
undertreated. Elderly persons are more likely to have hyper-
tension and isolated systolic hypertension (ISH), organ dam-
age, clinical CVD, develop new CV events, and are less likely
to have hypertension controlled.
Hypertension is a very prevalent disorder (about 1 billion
people worldwide),3 and as such, it is the most common
modifiable risk factor for conditions such as atherosclerosis,
stroke, HF, AF, diabetes mellitus, sudden cardiac death, acute
aortic syndromes, CKD, and may cause death and disability
in patients of all ages. Because it increases with aging and is
also compatible with longevity, there is often uncertainty
about its management in older patients. Indeed, hypertension
in elderly patients represents a management dilemma to CV
specialists and other practitioners. Furthermore, with the wide
adoption of multiple drug treatment strategies targeting sub-
groups of hypertension patients with specific risk conditions
to lower BP beyond traditional goals, difficult questions arise
about how vigorously elderly patients should be treated. Until
very recently, this was a particular dilemma for the very
elderly because most hypertension management trials had
upper age thresholds for enrollment and/or did not present
age-specific results. However, HYVET documented major
benefit in those80 years of age,4 and consequently, it seems
particularly timely to clarify and place into perspective
clinical issues relevant to the management of hypertension in
elderly patients. Prior to HYVET, although some clinicians
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favored treating hypertension in the very elderly,5 others did
not.6,7
1.3. General Considerations
This clinical scientific statement represents the consensus of
a panel of experts appointed by the ACCF, AHA, AAN,
ABC, ACP, AGS, ASH, ASN, ASPC, and ESH. The writing
group is composed of CV specialists with extensive experi-
ence in hypertension among elderly patients. The panel
focused largely on management of this complex disease and
derived practical and contemporary treatment strategies for
the many subgroups of patients comprising the broad disease
spectrum. Because of limited published clinical trial data in
elderly patients, the level of evidence governing management
decisions for drugs or other strategies has often been derived
from nonrandomized and observational-type investigations.
Many studies, such as those that have provided important
answers regarding management of CAD and/or HF, had often
limited enrollment of elderly patients. Therefore, treatment
strategies have necessarily evolved based on available data
from younger populations or from observational data, some-
times obtained in relatively small patient groups, or from the
accumulated clinical experience of individual investigators.
Consequently, construction of strict clinical algorithms de-
signed to assess prognosis and dictate treatment decisions for
elderly patients with hypertension has been challenging and
with their multiple comorbidities, management decisions
must be individualized to the particular patient. This data gap
seems to be closing as many recent trials have included older
patients. The age details of these trials are summarized in
Table 1.
Understanding of the clinical course and optimal manage-
ment of hypertension and associated CVD is increasing.
There is growing awareness of the heterogeneity of patients
Table 1. Trials of Antihypertensive Treatment in the Elderly
Trial Name
(Reference) N
Age Range
(y)
Mean
Age
(y) Drug(s)
% Risk Reduction
CVA MI
Hospitalization
for CHF
Total CVD (or
All CV
Events)
All-Cause
Mortality CV Mortality
Response to
Therapy Same
Above Mean Age
ACCOMPLISH8 11 506 55 68 (Benazepril amlodipine)
versus (benazepril 
HCTZ)
16 NR 14 17* 10 20* Yes†
ALLHAT9 33 357 55 67 Amlodipine versus
chlorthalidone
7 No difference 138* 14 4 NR Yes
Lisinopril versus
chlorthalidone
115* 15 119* 110* No difference NR Yes
ANBP 210 6083 65–84 72 ACE inhibitors versus
diuretics
12 14 15 11* 10 NR Yes
Coope and
Warrender11
884 60–79 68 Atenolol 
bendrofluazide
42* 3 32 24 3 22 Stroke only
EWPHE12 840 60 72 HCTZ  triamterence
 methyldopa
36 20 22 29 9 27* NR
HYVET4 3845 80–105 84 Indapamide 
perindopril
30 NR 64* 34* 21* 23 Yes‡
INVEST13 22 576 50 66 Verapamil versus
atenolol
No difference No difference No difference No difference No difference No difference Yes§
LIFE14 9193 55–80 67 Losartan versus
atenolol
25* NR 3 13* 10 11 NR
MRC15 4396 65–74 70 Atenolol  HCTZ or
amiloride
25* 19 NR 17* 3 9 Yes‡
SHEP16 4736 60 72 Chlorthalidone 36* 25 55 32 13 20 NR
STONE17 1632 60–79 67 Nifedipine 57* 6 68 60* 45 26 Yes‡
STOP-HTN18 1627 70–84 76 Atenolol  HCTZ or
amiloride or
metroprolol or
pinodolol
47 13 51 40 43 50 Yes‡
Syst-China19 2394 60 67 Nitrendipine captopril
HCTZ
38* 33 38 37* 39* 39* All but CV
mortality
Syst-Eur20 4695 60 70 Nitrendipine 42 26 36 31 14 27 NR
VALUE21 15 245 50 67 Amlodipine versus
valsartan
115 NR 11 16 14 NR NR
ACE indicates angiotensin-converting enzyme; ACCOMPLISH, Avoiding Cardiovascular Events in Combination Therapy in Patients Living with Systolic Hypertension;
ALLHAT, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; ANBP2, Second Australian National Blood Pressure study; CHF, congestive heart
failure; CV, cardiovascular; CVA, cerebrovascular accident; CVD, cardiovascular disease; EWPHE, European Working Party on High Blood Pressure in the Elderly; HCTZ,
hydrochlorothiazide; HYVET, Hypertension in the Very Elderly; INVEST, International Verapamil SR/Trandolapril Study; LIFE, Losartan Intervention For Endpoint; MI,
myocardial infarction; MRC, Medical Research Council; N, number of randomized patients; NR, not reported; SHEP, Systolic Hypertension in the Elderly Program;
STONE, Shanghai Trial of Nifedipine in the Elderly; STOP-HTN, Swedish Trial in Old Patients with Hypertension; Syst-China, Systolic Hypertension in China; Syst-Eur,
Systolic Hypertension in Europe; VALUE, Valsartan Long-term Use Evaluation; and 1, increase.
*Statistically significant; †65 years of age, HR0.81, 70 years of age, HR0.79; ‡Specific data not reported; §70 years of age, RR1.06, 70 years of
age, RR0.93.
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with hypertension and the many patient subgroups that
inevitably influence considerations for treatment. Some man-
agement strategies are evolving, and this document cannot, in
all instances, convey definitive assessments of their role in
treatment. For some uncommon subsets, there are limited
data currently available to definitively guide therapy. With
these considerations in mind, the panel has aspired to create
a document that is not only current and pertinent, but also has
the potential to remain relevant for years.
1.4. Nomenclature, Definitions, and
Clinical Diagnosis
The usual definitions of hypertension and target BP levels
might not be applicable to the elderly hypertensive popula-
tion. Criteria for categorizing BP vary22–25 and have not been
further characterized for the elderly. In the United States, a
clinical diagnosis of hypertension is established by demon-
strating a SBP 140 mm Hg and/or a DBP 90 mm Hg on
at least 2 occasions as summarized in “The Seventh Report of
the Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure.”22 In
addition, considerable evidence has evolved to classify SBP
130 mm Hg but 140 mm Hg as less than optimal for
individuals with certain conditions. Specific BP goals based
on coexisting conditions (Table 2) have been recommended
for prevention and management of CAD.26 These conditions
include HF or asymptomatic LV dysfunction27 with a BP goal
of 120/80 mm Hg. For patients with diabetes mellitus (and
impaired glucose tolerance without clinical diabetes mellitus
or “prediabetes” and metabolic syndrome) and/or CKD, “The
Seventh Report of the Joint National Committee on Preven-
tion, Detection, Evaluation, and Treatment of High Blood
Pressure,”22 the American Diabetes Association,28 and the
National Kidney Foundation29 recommend a BP goal 130/
80 mm Hg. Many also consider patients with CAD, as well as
those with coronary risk equivalents (ie, CAD, PAD, aortic or
intracerebral artery aneurysm) in this category. Evidence is
evolving to support the suggestion that targeting a BP lower
than traditional goals may prevent or delay progression or
promote stabilization of atherosclerosis.30,31 Thus, although
the traditional BP 140/90 mm Hg will be used herein to
define hypertension, for special populations (Table 2), a
lower BP target may be considered optimal. However, BP
targets are based primarily on observational data in middle-
aged patients, and optimal targets for elderly patients, espe-
cially those with systolic hypertension and normal or low
DBP (eg, ISH) remain to be defined from randomized trial
data. Importantly, ACCORD BP found among patients with
type 2 diabetes mellitus at high risk for CV events targeting
SBP 120 mm Hg, as compared with 140 mm Hg, did not
reduce the rate of fatal and nonfatal major CV events at the
expense of an increase in adverse experiences attributed to
BP medications. Furthermore, results were the same among
the subgroup of 1617 patients 65 years of age.32
It is also important to note that, although a specific BP
level may be used to classify a person as hypertensive, a finite
BP level, per se, is only a biomarker that is somewhat
removed from the complex CV disorder termed hypertension.
In the future, improved descriptors more closely linked to the
disorder itself may evolve to better define who has the
disorder, to better predict those at risk for adverse outcomes,
and also to better target treatment.
Criteria to define elderly also vary, because it is not
possible to develop a specific age-based definition derived
from physiological or pathological data because aging is a
continuous and progressive process for both sexes in all
cultures. In addition, vascular aging rates vary considerably
among individuals as a result of genetic, cultural, environ-
mental, behavioral, and disease-related factors. It is therefore
not possible to define elderly on a purely physiological basis,
and any definition is inherently arbitrary and subjective. For
this document, writing committee members agreed to use the
traditional demographic definition of 65 years of age to
define the elderly population. However, recognizing that
there are clinically relevant physiological differences be-
tween the “young old” (65 to 74 years of age), the “older old”
(75 to 84 years of age), and the “oldest old” (85 years of
age), age-specific subgroup data are presented when avail-
able, and limitations of existing data are noted. It may also be
important to determine whether the elderly individual re-
quires “assisted living” or is “ambulant and free-living”
Figure 1. Prevalence of high blood pressure in adults by age
and sex (NHANES: 2005–2006). NHANES indicates The National
Health and Nutrition Examination Survey. Modified from Lloyd-
Jones et al.34
Table 2. American Heart Association Recommendations for
Prevention and Management of Ischemic Heart Disease: Blood
Pressure Targets
Patient Type
Goal BP
(mm Hg)
Left ventricular dysfunction 120/80
Diabetes mellitus 130/80
Chronic renal disease 130/80
CAD or CAD risk equivalents* 130/80
Carotid artery disease 130/80
Peripheral arterial disease 130/80
Abdominal aortic aneurysm 130/80
High-risk (10-y FRS 10%) 130/80
Uncomplicated hypertension (none of above) 140/90
BP indicates blood pressure; CAD, coronary artery disease; and FRS,
Framingham Risk Score.
Modified from Rosendorff et al.26
*CAD risk equivalents include diabetes mellitus, peripheral arterial disease,
carotid arterial disease, and abdominal aortic aneurysm.
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because these qualifiers begin to describe physiological
impairments and comorbidities associated with the aging
process.
1.5. Magnitude and Scope of the Problem
1.5.1. Epidemiology of Hypertension Related to Aging
Between 1999 and 2004, the prevalence of hypertension in
the US population (18 years of age) was 27% for both men
and women,33 and prevalence increases progressively with
age, so the majority of elderly are hypertensive (Figure 1).34
In the Framingham Heart Study (FHS), 90% of participants
with a normal BP at age 55 years eventually developed
hypertension.35 Hypertension prevalence is greater in older
African Americans, especially women, than in older non-
Hispanic whites, and somewhat higher in non-Hispanic
whites than in Hispanic Americans.34
In older Americans, hypertension is the most important risk
factor for CVD, with estimates that 69% of patients with an
incident MI, 77% with incident stroke, and 74% with incident
HF have antecedent hypertension.34 In addition, hypertension
is a major risk factor for incident diabetes mellitus,36 as well
as for AF37 and CKD.34 In 2005, hypertension was the
primary cause of death for 57 356 Americans, and a primary
or contributory cause for 300 000 of the 2.4 million total
deaths that year.34 Moreover, hypertension death rates in-
creased 25.2% from 1995 to 2005, and the actual number of
deaths rose by 56.4%, in part reflecting increasing numbers of
older Americans and high prevalence of hypertension at older
age.34 In 2009, total direct and indirect costs attributable to
hypertension were estimated to be $73.4 billion.34
People 65 years of age currently comprise 13.0% of the
US population.38 With aging of the “baby boomer”genera-
tion, it is anticipated that by 2030, the number of people in
this age group will increase by almost 80%, and that approx-
imately 1 in 5 Americans will be 65 years of age (Table
3).34 Although older patients with hypertension are more
likely to be aware of their condition and receiving treatment
than middle-aged patients (Figure 2), BP control rates are
lower in the elderly, especially after age 80 years.34 The
marked growth in size of the older population anticipated
over the next decades means the societal burden of hyperten-
sion will rise progressively if we do not develop more
effective strategies for enhancing BP control rates.
1.5.1.1. Isolated Systolic Hypertension
Aging is associated with a progressive increase in aortic
stiffness, in part, related to increased collagen with crosslink-
ing and degradation of elastin fibers. Consequently, SBP rises
gradually throughout adult life, although DBP peaks and
plateaus in late middle-age, declining slightly thereafter
(Figure 3).39 So, the proportion of hypertensive patients with
ISH increases with age—65% of patients with hypertension
60 years of age39 and over 90% 70 years of age (Figure
4).40 The prevalence of ISH is higher in women than in men,
whereas the proportion of hypertension attributable to ISH in
older adults is similar across racial and ethnic groups.34
In decades past, the apparently inexorable rise in SBP with
increasing age fostered the view that this was an adaptive
response essential to support organ perfusion, and an empiric
formula “100  age” was often used to estimate the “appro-
priate” SBP. However, data from the FHS and other epide-
miologic investigations provide compelling evidence that
SBP is a strong independent risk factor for incident CV
events in all decades of life.41,42 Furthermore, as discussed in
Section 4.2, randomized trials document that treatment of
elevated SBP substantially reduces CV risk in cohorts of
elderly patients. As a result, beginning with “The Fifth Report
Table 3. Population Projections by Selected Age Groups and
Sex for the United States: 2010 to 2050 (in 1000 s)
Population Year 2010 Year 2030 Year 2050
Both sexes
65 y of age 40 229 (13.0%) 72 092 (19.3%) 88 547 (20.2%)
85 y of age 5751 (1.9%) 8745 (2.3%) 19 041 (4.3%)
Total 310 233 373 504 439 010
Men
65 y of age 17 292 (11.3%) 32 294 (17.6%) 39 917 (18.5%)
85 y of age 1893 (1.2%) 3284 (1.8%) 7458 (3.5%)
Total 152 753 183 870 215 825
Women
65 y of age 22 937 (14.6%) 39 798 (21.0%) 48 630 (21.8%)
85 y of age 3859 (2.5%) 5461 (2.9%) 11 583 (5.2%)
Total 157 479 189 634 223 185
Modified from US Census Bureau.38
Figure 2. Extent of awareness, treatment, and
control of high blood pressure by age
(NHANES: 2005–2006). Hypertension is
defined as 140/90 mm Hg. Modified from
Lloyd-Jones et al.34
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of the Joint National Committee on Detection, Evaluation,
and Treatment of High Blood Pressure,”43 the focus of
management shifted from a primary emphasis on controlling
DBP to progressively greater emphasis on controlling SBP,
particularly in older patients.22
1.5.1.2. Systolic and Diastolic Hypertension and Pulse
Pressure
After age 70 years, diastolic hypertension accounts for10%
of all patients with hypertension (Figure 4).40 In addition, the
relationship between DBP and CV risk is bimodal in older
individuals, with DBPs of 90 mm Hg associated with
similar increased risk as that associated with DBPs lower than
about 70 mm Hg.40,45 As a result, at any given level of SBP,
CAD risk increases as DBP decreases (Figure 5).46,47
An important implication of this observation is that pulse
pressure (ie, difference between SBP and DBP), which
increases with age (Figure 5) and is a measure of the degree
of age-related vascular stiffness, emerges as a potent risk
factor for CAD events in older individuals. Pulse pressure has
been identified as a stronger risk factor than SBP, DBP, or
mean pressure in older adults in some studies.48–50 In the
FHS, with increasing age, there was a gradual shift from DBP
to SBP and then to pulse pressure as the strongest predictor of
CAD risk. In patients 50 years of age, DBP was the
strongest predictor. Age 50 to 59 years was a transition period
when all 3 BP indexes were comparable predictors, and from
60 to 79 years of age, DBP was negatively related to CAD
risk so that pulse pressure became superior to SBP.49
1.5.1.3. Special Populations
From the standpoint of epidemiology, pathophysiology, and
treatment, there are important subgroups with distinctive
characteristics, including elderly women, blacks, Hispanics,
and Asians that require additional focus. These populations
are discussed in more detail in Section 1.5.2 on pathophysi-
ology and Section 4 on management.
1.5.1.3.1. Elderly Women. Among elderly women, hyperten-
sion is a major risk factor for CAD and stroke and a major
contributor to CV and renal morbidity and mortality.51
Hypertension prevalence is less in women than in men until
45 years of age, is similar in both sexes from 45 to 64 years
of age, and is much higher in women than men 65 years of
age.52 Age-adjusted hypertension prevalence, both diagnosed
Figure 3. Mean blood pressure according to
age and ethnic group in US adults. Reprinted
from Chobanian et al.44
Figure 4. Frequency of untreated hypertension according to
subtype and age. Reprinted from Chobanian et al.44
Figure 5. Joint influences of systolic blood pressure and pulse
pressure on coronary heart disease. Joint influences of SBP and
pulse pressure on CHD risk, from the Framingham Heart Study.
CHD hazard ratio was determined from level of pulse pressure
within SBP groups. Hazard ratios were set to a reference value
of 1.0 for SBP values of 110, 130, 150, and 170 mm Hg,
respectively. All estimates were adjusted for age, sex, body
mass index, cigarettes smoked per day, glucose intolerance,
and total cholesterol/high-density lipoprotein. ThePvalues refer
to the CHD hazard ratios determined from the level of pulse
pressure within the SBP groups. CHD indicates coronary heart
disease; SBP, systolic blood pressure. Reprinted from Franklin
et al.46
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and undiagnosed, from 1999 to 2002, was 78% for older
women and only 64% for older men.53 Both the prevalence
and severity of hypertension increase markedly with advanc-
ing age in women, such that after age 60 years, a majority of
women have stage 2 hypertension (BP 160/100 mm Hg) or
receive antihypertensive treatment.54–57 A substantial propor-
tion of elderly women also have prehypertension or stage 1
hypertension, so the prevalence of normal BP in this group is
very low (15% of those 60 to 79 years and 6% of those 80
years of age in the FHS cohort).55
Further, BP control is difficult to achieve in elderly
women. Data from the FHS showed an age-related decrease
in BP control rates that was more pronounced in women than
men.55 Among the oldest participants (80 years of age) with
hypertension, only 23% of women (versus 38% of men) had
BP 140/90 mm Hg. Gender differences in the pattern of
antihypertensive medications prescribed were noted in this
cohort: 38% of women but only 23% of men were taking
thiazide diuretics. Whether the age-related decline in BP
control among women is related to inadequate intensity of
treatment, inappropriate drug choices, lack of compliance,
true treatment resistance because of biological factors, or to
other factors is unclear.
Data from the NHANES (US National Health and Nutri-
tion Examination Survey) highlight a likely contributory
factor to poor BP control in elderly women: an increased
prevalence of other CV risk factors, including central obesity,
elevated total cholesterol, and low high-density lipoprotein
cholesterol levels.57 Among adults with hypertension in
NHANES 1999 to 2004, women were at higher CV risk
compared with men: 53% of women, but only 41% of men
had 3 of the 6 risk factors studied (P0.001).
Contributions of postmenopausal hormonal changes to BP
elevation in elderly women are controversial, in large part
because determining the role of sex hormones (or their
withdrawal) on BP is complex and confounded by effects of
aging and related alterations in CV risk factors such as body
weight and lipid levels.58–64 Conversely, there is strong
evidence from prospective longitudinal studies that
menopause-related BP elevation is dependent on increased
body mass index (BMI) and aging, rather than ovarian failure,
per se.51,62 The pathophysiology of the menopause-related
increase in BP has been inferred from studies in animals65,66
and human subjects.58 Endothelial dysfunction, increased
arterial stiffness, activation of RAAS, increased salt sensitiv-
ity, oxidative stress, obesity, and genetic factors have been
implicated.58
1.5.1.3.2. Elderly Blacks. Blacks have the highest agead-
justed hypertension prevalence in the United States: about
40% of African-American men and women, versus about
27% of white men and women.33 Hypertension among blacks
is earlier in onset, more severe and uncontrolled, and
contributes to the highest CAD mortality rates in the
United States, in addition to highest morbidity and mor-
tality attributable to stroke, LVH, HF, and CKD.22 Hyper-
tension is a significant factor in the disproportionate
decreased life expectancy for blacks: African-American
men, 70.0 years versus 75.9 years for white men, and
African-American women, 76.8 years versus 80.8 years for
white women.67
Approximately 9 million, or 13.7%, of the total US
hypertensive population is black, 21.2% higher than ex-
pected, based on the percentage of US population (11.3%).68
From the NHANES III (1988 to 1994) versus NHANES 1999
to 2004, there was a significant increase in hypertension
among non-Hispanic black men aged 60 to 69 years and 70
years old, from 65.0% and 69.6% to 74.2% and 83.4%,
respectively odds ratio ([OR]: 1.14; 1.20; P0.05).33 For
non-Hispanic black women, aged 60 to 69 years and 70
years, hypertension prevalence increased from 73.7% and
71.7% to 84.1% and 83.1%, respectively (OR: 1.14, 1.16;
P0.01 and P0.05).33 Overall, age-standardized hyperten-
sion rates are increasing, not completely explained by obe-
sity. Interestingly, non-Hispanic black men and women
showed 14% and 7% significant improvement in hyperten-
sion treatment rates, possibly as a result of focused efforts in
that community.33 Although awareness and treatment have
increased, control rates for those 70 years of age did not
significantly improve from NHANES III to NHANES 1999
to 2004 (21.5% and 28.6%, respectively; PNS).
Compared with whites, blacks are more likely to have
hypertension, more likely to be aware of it, and more likely to
be pharmacologically treated, but less likely to achieve BP
control, especially in middle age (Table 4).69 Hypertension
awareness was higher among blacks than whites60 years of
age in NHANES III and NHANES 1999 to 2002 (76.9%
versus 68.3% in 1998 to 1994 and 81.7% versus 72.3% in
1999 to 2002). Hypertension treatment rates were also higher
in older blacks versus whites (74.0% versus 64.8%, respec-
tively).69 Despite improved control rates, there remains a
racial disparity in BP control, especially in younger blacks.69
In the group 70 years of age, control groups were 20.7% in
blacks but 30.0% in whites.
Table 4. Hypertension Awareness, Treatment, and Control in
the US Adult Hypertensive Population (NHANES 1999–2004)
NHANES Population
(by Age, y)
Awareness
1999–2004,
%
Treatment
1999–2004,
%
Control
1999–2004,
%
MA men, 50–69 67.3 56.1 28.4
NHW men, 50–69 76.5 68.1* 48.1*
NHB men, 50–69 80.7 72.9* 39.6*
MA men, 70 71.2 62.7 25.1
NHW men, 70 73* 65.7* 34.8*
NHB men, 70 75.1 70.2 28.6
MA women, 50–69 72.2 60.0 28.0
NHW women, 50–69 79.6 68.9 39.6
NHB women, 50–69 87.7* 80.3 43.0*
MA women, 70 66.4 58.5* 19.0*
NHW women, 70 70.7 63.9* 25.8
NHB women, 70 81.6 77.7* 26.0
Modified from Cutler et al.33
*Statistically significant. MA indicates Mexican American; NHANES, The
National Health and Nutrition Examination Survey; NHB, non-Hispanic black;
and NHW, non-Hispanic white.
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Education is associated with improved BP control; less
than high school graduate status is an independent risk factor
and a possible proxy for decreased health literacy.69 Control
rates among non-Hispanic blacks 60 years of age were
36.8% in NHANES III (1988 to 1994) and 47.4% in
NHANES 1999 to 2002, a 28.7% change in BP control over
time (P0.01). This was not significantly different from
whites over the same period (38.4% and 50.4%), a 30.3%
increase in the same age group (P0.001).
Blacks have increased rates of overweight and obesity,
physical inactivity, and inadequate potassium intake, espe-
cially in a high sodium dietary environment. Environmental
factors affect differences in rates of elevated BP in popula-
tions of African descent, related to increased BMI and ratio of
sodium-to-potassium intake.70 Sodium restriction, weight
maintenance or loss, increased aerobic activity, decreased
alcohol intake, and high potassium/low sodium diets, such as
the DASH diet, rich in fruits, vegetables, and low-fat dairy
products have all been shown to be beneficial in reducing BP,
as in other populations.22 The beneficial effect of sodium
restriction increased with age in blacks; however, the mean
age of DASH participants was 4410 years.71 Reduced
sodium intake and DASH diet should be advocated for
prevention and treatment of hypertension, especially in
blacks, and response to reduced sodium strengthens with
increasing age.
1.5.1.3.3. Elderly Hispanics. Hispanics constitute the largest
growing ethnic group in the United States, comprising ap-
proximately 15% of the population with a growth rate almost
4 times that of the total population.72 Strategies to reduce
morbidity and mortality from hypertension among elderly
Hispanics are therefore essential.
Hypertension prevalence, treatment, and control rates are
often thought to be worse in Hispanics than in non-Hispanic
whites and blacks; however, data are conflicting.73 This
difference, in part, is because Hispanics are not a homoge-
neous group in terms of genetics, sociodemographics, and
health-related lifestyles. Accordingly, certain Hispanic sub-
populations are characterized by low levels of hypertension
awareness, treatment, and control. In addition, different
Hispanic subgroups may have different levels and frequen-
cies of other CVD risks and health outcomes. For example,
Puerto Ricans have a worse health status than Mexican
Americans and Cuban Americans,74 including consistently
higher hypertension-related mortality rates than other His-
panic subpopulations and non-Hispanic whites.73 Much of
this disparity appears driven by sociodemographic and
health-related lifestyle factors. Poverty, language issues, lack
of education, diet, increased social stress, and high prevalence
of diabetes mellitus and obesity all contribute.
Mexican-American men age 60 to 69 years had a lower
hypertension prevalence than non-Hispanic white men and
non-Hispanic black men33 (Figure 6), and those 70 years of
age had a greater prevalence than non-Hispanic white men
but less than non-Hispanic black men. For Mexican-
American women 60 to 69 years of age, the prevalence was
greater than non-Hispanic white women but less than non-
Hispanic black women. For Mexican-American women 70
years of age, the prevalence was the same as non-Hispanic
white women but less than non-Hispanic black women. In
NHANES 1999 to 2004, hypertension awareness, treatment,
and control rates in Mexican-American men 50 to 69 years of
age were 67.3%, 56.1%, and 28.4%, respectively, and con-
sistently less than in non-Hispanic whites and non-Hispanic
blacks (Table 4).
Older (age 70 years) Mexican and Mexican-American
women have a greater prevalence of hypertension than male
counterparts.75 Also, older Mexican women who migrated to
the United States have greater risk for hypertension than
female counterparts in Mexico.75 Conversely, older Mexican-
American men that immigrated have a lower risk than male
counterparts in Mexico.
Although population-based studies often reveal BP preva-
lence, treatment, and control rates that are worse in Hispanics
than in non-Hispanic whites, these disparities often disappear
when Hispanics are provided with affordable and easy access
to appropriate medical care. Older Hispanics have achieved
similar BP control as non-Hispanic whites and blacks,76–82
and no differences were seen in BP responses or outcomes in
those above the mean age (65.9 years for Hispanics and 68.5
for non-Hispanics). For example, the INVEST compared
8045 Hispanic with 14 531 non-Hispanic hypertensive CAD
Figure 6. Age-specific prevalence of hyper-
tension in US adults (NHANES 1999–2004).
MA indicates Mexican American; NHANES,
The National Health and Nutrition Examina-
tion Survey; NHB, Non-Hispanic Black; and
NHW, Non-Hispanic White. Modified from
Cutler et al.33
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patients randomized to a CA-based or beta-blocker–based
strategy76 with an ACEI or HCTZ as needed for BP control or
organ protection. After 61 835 patient-years follow-up and
adjusting for baseline BP values, Hispanic patients had better
BP control (defined as the proportion with 140/90 mm Hg)
than non-Hispanic patients at 24 months (P0.001). They
also experienced significantly fewer deaths, nonfatal MIs, or
nonfatal strokes. Recommendations for pharmacological
management of elderly Hispanic patients are the same as for
elderly patients in general, as described in Section 4.
1.5.1.3.4. Elderly Asians. Asian Americans (familial origin
Far East, Southeast Asia, or Indian subcontinent) are rapidly
growing in percentage in the United States, and CVD is their
leading cause of death, with perhaps higher stroke mortality
than whites.83 Asians constitute approximately 5% of the US
population; 23.8% are Chinese, 18.3% Filipino, 16.2% Asian
Indian, 10.9% Vietnamese, 10.5% Korean, and 7.8% Japa-
nese, with the remaining in other groups.84 In the 2004 to
2006 National Health Interview Survey, Filipino adults (27%)
and Japanese adults (25%) were more likely than Chinese
(17%) or Korean adults (17%) to have ever been told they
have hypertension, with overall rates similar to whites.85 The
1999 to 2004 NHANES indicated the prevalence of hyper-
tension in Asian Americans was 16.1% and that of white
Americans was 28.5%.83 Among community-dwelling Asian
Americans, mean age 74 years, hypertension rate, awareness
rate, and treatment rate were 51.9%, 37.9%, and 24.9%,
respectively. Hypertension control was worst among the
oldest persons.86
There may be some differences in responses and side
effects to antihypertensive treatments in AsianAmericans
versus whites. Japanese appear to have a higher frequency of
salt sensitivity than whites,87 possibly influenced by more
prevalent polymorphisms of the angiotensinogen, alpha-
adducing, and aldosterone synthase genes. Beta blockers and
CAs may give more robust BP response at lower dosages, and
ACEI-associated cough may be more common than in whites.
Chinese may have greater sensitivity to BP-lowering and
bradycardic effects of propranolol than whites. Genetic vari-
ants in the beta1-adrenergic receptor gene might contribute.88
Eplerenone is very effective at lowering SBP in Japanese
patients with hypertension, including those with low-renin
hypertension.89 A study in Hong Kong found that patients
with hypertension had a larger decrease in BP in response to
isradipine than seen in whites in the United States.90
The Systolic Hypertension in China trial19 assigned 2394
patients 60 years of age (mean 66 years of age) with SBP
160 to 219 mm Hg and DBP 95 mm Hg to either
nitrendipine (10 to 40 mg/d) or placebo, with addition of
captopril (12.5 to 50.0 mg/d), and/or HCTZ (12.5 to 50 mg/d)
as needed for BP control. Stepwise treatment, starting with
nitrendipine, improved prognosis, particularly in patients
with diabetes mellitus. At 2 years, the between-group differ-
ences were 9.1 mm Hg SBP (95% CI: 7.6 to 10.7 mm Hg) and
3.2 mm Hg DBP (95% CI: 2.4 to 4.0 mm Hg). Active
treatment reduced total stroke 38% (P0.01), all-cause mor-
tality 39% (P0.003), CV mortality 39% (P 0.03), stroke
mortality 58% (P0.02), and all fatal and nonfatal CV events
37% (P0.004). The adjusted relative risk for fatal and
nonfatal CV events continued to decline as age increased.
They concluded that treatment of 1000 Chinese patients for 5
years could prevent 55 deaths, 39 strokes, or 59 major CV
events. After 5 years of treatment, the number needed to treat
to prevent 1 major CV event was 16.9 in the Systolic
Hypertension in China trial,19 and 18.9 in the Systolic
Hypertension in Europe trial, which involved white
Europeans.20
1.5.2. Pathophysiology of Hypertension in the Elderly
1.5.2.1. Aorta and Large Arteries
The marked age-associated increase in hypertension preva-
lence is largely attributable to changes in arterial structure
and function that accompany aging. Large vessels such as the
aorta become less distensible,91 and although the precise
mechanisms are incompletely understood, they primarily
involve structural changes within the media, such as fatigue
fracture of elastin, collagen deposition,92 and calcification,93
resulting in increases in vessel diameter and intima-medial
thickness. Calcification may occur in the intima (in conjunc-
tion with atherosclerosis), as opposed to the media (arterio-
sclerosis); although there is an association between these
processes, they are pathologically distinct.94,95 Aortic calcifi-
cation, in addition to hypertension and aging, is associated
with diabetes mellitus, LVH (Section 1.6.3.2), and CKD
(Section 1.6.6).96–99 Arterial stiffness is not only a product of
structural changes in the arterial wall but is also induced by
circulating and endotheliumderived vasoactive mediators
such as norepinephrine and endothelin 1.100 In a group of
elderly patients (686 years of age) compared with young
patients (379 years of age), endothelial dysfunction and
decreased nitric oxide availability was associated with in-
creased arterial stiffness and development of ISH.101
In addition to structural changes, a number of functional
alterations impact the aging CV system. The increased
stiffening increases pulse wave velocity, which has functional
consequences (Figure 7). One is a change in arterial pulse
contour caused by earlier return of reflected waves from the
periphery to the proximal aorta. These returning waves
summate with anterograde waves to produce late SBP aug-
mentation quantified as the augmentation index.102,103 The
late SBP peak creates an additional load against which the
older heart must eject blood thereby increasing LV wall
tension. Another functional alteration with aging is a decline
in flow-mediated arterial dilation, primarily caused by a
decrease in endothelium-derived nitric oxide.104 Reduction in
flow-mediated vasodilator capacity further compromises the
ability of aged arteries to buffer flow-related increases in SBP
such as during vigorous exercise.105
As a result of these and other less well-understood struc-
tural and functional arterial aging changes, there is a gradual
rise in SBP across the adult age span,40,106 which persists even
when overtly hypertensive individuals are excluded.106 The
decline in DBP in older adults (Section 1.5.1.1) is related to
blunted ability of the stiffer aorta and other capacitance
arteries to expand in systole and contract during diastole, to
augment DBP. Thus aging, even in normotensive individuals,
is characterized by an increased pulse pressure, creating
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greater pulsatile stress on the arterial system.107–109 In contrast
to younger patients with hypertension, in whom elevated BP
is determined primarily by increased peripheral arterial resis-
tance, the isolated or predominant elevation of SBP seen in
older adults is mediated by increased conduit artery stiffness.
Because the heart is coupled to the vasculature, the
age-associated increase in arterial stiffness has critically
important effects on cardiac structure and function in the
elderly. (Figure 7) A consistent finding110–112 is a modest
age-associated increase in LV diastolic wall thickness, even
among normotensive individuals. Consequent normalization
of systolic wall stress by the thickened LV wall, in combi-
nation with prolonged contractile activation in the older heart,
helps preserve resting LV systolic function.113 However,
prolonged contractile activation results in less complete
myocardial relaxation at the time of mitral valve opening,
reducing the early diastolic LV filling rate.114,115 Conversely,
late LV filling caused by atrial contraction increases with
age.114–116 This augmented atrial contribution to LV filling,
accomplished by a modest increase in left atrial size,111
preserves LV end-diastolic volume across the age span.110,117
Notably, these aging changes in cardiac structure and func-
tion, including increased LV wall thickness, preserved sys-
tolic LV function, and reduced early diastolic filling with
increased late filling from a larger left atrium, mimic changes
observed in mild hypertension among younger patients. Such
changes also contribute to age-related increase in AF preva-
lence (Section 1.6.4).
Cardiac output is lower and peripheral vascular resistance
is higher in older patients with hypertension than in younger
ones, but postural decreases in cardiac output, stroke volume,
and LV filling pressure in the upright posture are less
pronounced in elderly patients. Elderly patients may also
have reduced venous capacitance, which leads to reduced
blood volume in the lower body during upright posture.118
Stiffening of the aorta also negatively influences myocar-
dial perfusion.119 Because oxygen extraction from blood
perfusing myocardium is very high, an increase in myocardial
oxygen supply can only be met by an increase in coronary
flow. Because most (80%) myocardial blood flow occurs in
diastole, central aortic DBP amplitude and duration of dias-
tole are the principal noncoronary determinants of myocardial
perfusion. Minor changes in diastolic duration may have as
much effect on coronary flow as a severe coronary steno-
sis.120 As central arterial stiffness and wave reflection ampli-
tude increase, SBP rises, pulse pressure widens, and myocar-
dial systolic wall stress and oxygen demand increase while
diastolic (eg, coronary perfusion) pressure decreases.121 Such
changes in ventricular/vascular coupling unbalance the sup-
ply/demand ratio and promote myocardial ischemia. With
normal coronary vessels, however, flow is maintained over a
wide range of perfusion pressures by autoregulation (eg, as
perfusion pressure declines, vasodilation maintains flow).122
In the presence of LVH and other conditions associated with
increased myocardial oxygen demand (eg, increased SBP,
tachycardia), coronary flow increases to meet demands.
When the LV ejects into a stiff aorta, SBP, and hence
myocardial oxygen demand, increases while DBP decreases,
but coronary flow increases to maintain contractile func-
tion.123–125 However, increased aortic stiffness decreases cor-
onary flow reserve, and during increases in myocardial
contractility, endocardial flow becomes impaired, resulting in
subendocardial ischemia.124 These undesirable alterations are
enhanced with coronary stenosis or during reductions in
DBP.123,125,126 In patients with stable angina, there is an
inverse relationship between central aortic stiffness and
coronary flow.127
Although age-associated increases in arterial stiffness and
SBP are often considered an immutable aging change in
industrialized societies, there is accumulating evidence that
these “normative” aging changes are markedly attenuated in
populations not exposed to a lifestyle of high sodium,
high-calorie diets, low physical activity levels, and increasing
obesity rates. For example, populations with habitually low
sodium intake demonstrate less arterial stiffening with age
than those with high sodium consumption.128 Improvement in
Figure 7. Conceptual framework for cardiovas-
cular adaptations to arterial stiffening that occur
with aging. CBF indicates coronary blood flow;
DBP, diastolic blood pressure; EF, ejection
fraction; LA, left atrial; LV, left ventricular; SBP,
systolic blood pressure; 1, increased; and 2,
decreased. Modified from Fleg.146
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arterial distensibility has been observed after a low sodium
diet.129 In addition, arterial distensibility102 and flow-
mediated vasodilator capacity are enhanced130 in older endur-
ance athletes compared with their sedentary peers of similar
age. A less atherogenic lipid profile, thinner carotid artery
wall, markedly lower BP, and better preserved early diastolic
LV filling have been observed in lean middleaged and older
adults practicing voluntary caloric restriction of approxi-
mately 30% for several years compared with persons with
more typical dietary patterns.131,132 It is therefore likely that
the striking age-associated rise in SBP and incident hyper-
tension in developed countries, and certain individuals in the
United States, could be substantially reduced by adoption of
a healthier lifestyle.
1.5.2.2. Autonomic Dysregulation
Age-associated reduction in baroreflex function and increase
in venous insufficiency contribute to a high prevalence of
orthostatic hypotension in the elderly, which is a risk for CV
events as well as falls and syncope.133–137 In contrast, ortho-
static hypertension, where BP increases with postural change,
is also prevalent among the elderly.138–142 This is part of the
orthostatic BP dysregulation associated with aging. The
orthostatic SBP increase can exceed 20 mm Hg. These
patients are generally older, have a greater frequency of LVH,
CAD, and silent cerebrovascular disease by magnetic reso-
nance imaging (MRI) than elderly patients with hypertension
with or without orthostatic hypotension. The orthostatic BP
increase is blocked by alpha-adrenergic blockade, indicating
that alpha-adrenergic activity may be a predominant patho-
physiological mechanism.143
Yet the neurohormonal plasma profile of older patients
with hypertension is similar to that observed in normotensive
older individuals. Plasma norepinephrine increases with age,
though to a greater degree in normotensive patients.144,145 The
age-associated rise in plasma norepinephrine is thought to be
a compensatory mechanism for reduction in beta-adrenergic
responsiveness with aging.145,146 In contrast, plasma renin
activity declines with age and is lower in older than younger
patients with hypertension;144,146 this has been attributed to
the effect of age-associated nephrosclerosis on the juxtaglo-
merular apparatus. Thus, hypertension in the elderly is
usually associated with low plasma renin levels. Plasma
aldosterone levels also decline with age, resulting in greater
risk for hyperkalemia, especially when coupled with an
age-associated decline in GFR.146
1.5.2.3. Renal Function and Cation Balance
Between 30 and 85 years of age, renal mass, particularly the
cortex, declines 20% to 25%.147 The aging kidney is charac-
terized by progressive development of glomerulosclerosis
and interstitial fibrosis, which is associated with a decline in
GFR and reduction of other renal homeostatic mecha-
nisms.147,148 Age-associated declines in membrane sodium/
potassium–adenosine triphosphatase may also contribute to
geriatric hypertension because this results in increased intra-
cellular sodium that may reduce sodium– calcium exchange
and thereby increase intracellular calcium and vascular resis-
tance. Reductions in cellular calcium efflux caused by re-
duced calcium–adenosine triphosphatase activity may simi-
larly increase intracellular calcium and vascular resistance.149
Latent volume expansion in the elderly also contributes to
suppression of plasma renin activity and low aldosterone
levels.148
Renal hemodynamics are impaired in elderly patients with
untreated ISH. Lower GFR and effective renal plasma flow
characterize the older hypertension patient with a BMI26.5
kg/m2.150 In the elderly, pulse pressure is inversely related to
GFR, suggesting that increased vascular stiffness may accel-
erate age-related decline of GFR and renal plasma flow,
which is a probable reflection of preglomerular resistance. In
elderly patients with untreated ISH,151 increasing SBP was
associated with the greatest risk of decline in renal function;
whereas DBP, pulse, and mean arterial pressure had no
significant association with decline in kidney function. Thus,
elevated SBP and pulse pressure are strong risk factors for
declining kidney function among older persons with ISH.
Because renal arterial resistance is very low, high flow and
low resistance to flow expose the small vessels to large
pressure fluctuations that may increase up to 4-fold with
aging.152 This exposure to high flow and pulsatile pressure
causes microvascular damage, contributing to CKD.
1.5.2.3.1. Sodium. Mechanisms underlying hypertensive re-
sponses to high salt intake and salt sensitivity are controver-
sial. Earlier studies have shown the central role that kidneys
play in BP control, as well as the relationship between
alterations in BP and the ability of kidneys to modulate fluid
volume through rapid increase in natriuresis or “pressure
natriuresis.”153 Salt sensitivity, characterized by an increase
in BP in response to positive salt balance, occurs in obese and
elderly populations.154 Low natriuretic activity in salt-
sensitive individuals may stimulate the RAAS; thus, together
with vasoconstrictor effects of endothelin, inhibition of nitric
oxide regulation of renal flow, natriuresis, and increase in
SNS activity may explain the relationship between sodium
sensitivity, obesity, and aging and hypertension.155 The ca-
pacity of the kidney to excrete a sodium load is impaired with
age, contributing to BP elevation.148,156 Increased fractional
reabsorption of sodium in the proximal tubule in the elderly
may contribute to their tendency to exhibit an expanded
sodium space resulting in salt-sensitive BP, and eventually
fluid overload.148,156 There is a significant positive associa-
tion between 24-hour sodium excretion as well as urinary
sodium/potassium ratio and SBP.157 The relation between
sodium excretion and SBP is stronger for older than younger
adults, perhaps reflecting longer exposure with aging or
diminished capacity to handle sodium.
A chronic high-sodium diet in elderly individuals with
hypertension is associated with an increase in BP that is more
marked for SBP than DBP.158 Moderate sodium restriction in
elderly patients with hypertension significantly decreases
SBP.159,160
Age-related increases in salt sensitivity result, in part, from
reduced ability to excrete a salt load due to reduction in both
kidney function and generation of natriuretic substances such
as prostaglandin E2 and dopamine.149 Failure of a sodium
pump inhibitor, marinobufagenin, in older persons may be
involved in the increased salt sensitivity with aging.161 An
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increase in BP with increasing salt load appears most pro-
nounced in ISH and could be modulated by angiotensin
genotype.162 Additionally, the cytoskeleton protein alpha-
adducin polymorphism has been associated with excess risk
among elderly patients with hypertension and CAD.163 This
polymorphism is implicated in renal sodium handling and BP
regulation,164 elastic properties of conduit arteries,165 and
hypertension,166 as well as ischemic stroke in elderly
women.167
1.5.2.3.2. Potassium. Potassium excretion is limited in the
aged normal individual.147 The decrease in kidney mass that
occurs with aging includes reduction in tubular mass, provid-
ing fewer transport pathways for potassium excretion.147
Plasma aldosterone levels also decline with age, conse-
quently, elderly patients with hypertension are more prone to
drug-induced hyperkalemia.147
1.5.3. Secondary Causes of Hypertension Important in
the Elderly
1.5.3.1. Renal Artery Stenosis
The demographics of patients with RAS are shifting toward
older ages and more severe comorbid disease. The incidence
of RAS increases with age, and RAS is a risk factor for poor
kidney function, but there is very limited evidence-based
information about effective screening or treatment strategies.
RAS occurs in ostial segments extending from adjacent
aortic plaque.168 Hemodynamically significant RAS is de-
fined as 70% diameter narrowing of the renal artery that
results in significant reduction of renal blood flow (70%),
decreased intraglomerular pressure, activation of the RAAS
to increase BP, and decreased kidney size. Increases in
plasma AII levels result in vasoconstriction and increase BP.
A key role for AII is to maintain perfusion pressure within the
intraglomerula through constriction of efferent arterioles and
increases in systemic BP.168 Increases in intrarenal AII also
cause transient sodium retention, through AII effects on
proximal tubules, which culminates in pressure natriuresis
secondary to increases in BP over time and reestablishes
sodium balance. When RAS is bilateral, the mechanism of
hypertension is through volume expansion.
In autopsy studies, RAS prevalence ranges from 4% to
50% and increases with increasing age. A population-based
study of subjects 65 years of age (mean 77.2 years of age)
without recognized kidney disease, found RAS (60% lumen
narrowing by ultrasound) in 6.8%.169,170 Elderly patients with
widespread PAD have RAS rates ranging from 35% to
50%.171 Evaluation of the entire renal arterial tree of both
kidneys172 showed a RAS prevalence of 87% for those 75
years of age with PAD. Aortic angiography identified RAS in
38% of patients with aortic aneurysm, 33% of those with
PAD, and 39% of those with lower limb occlusive disease.173
The functional significance of RAS in older adults is
unclear. When elderly patients (mean age 73.28.1 years,
median eGFR 51.2 mL/min/1.73 m2) undergoing nonemer-
gent coronary angiography were angiographically screened
for RAS, and those with 50% RAS referred for nuclear
renography, about half had evidence of reduced perfusion to
1 kidney.174,175 Of these, 13% were discordant with the
angiographic lesion, and only 9% had positive captopril
renograms. A positive captopril renogram was associated
with severe (70%) unilateral RAS. Thus, presence of
known anatomic lesions does not correlate with captopril
renogram positivity. It is unclear whether nuclear renography
is a poor functional test in this population or the stenotic
lesions are not functionally significant.174
The importance of “incidental” RAS identified at nonemer-
gent cardiac angiography has been examined.175 Patients with
50% stenosis underwent nuclear renography and were
managed with or without stenting as recommended by their
nephrologist and/or cardiologist. Of the 140 patients, 67
(48%) were stented, mostly for “preservation of kidney
function” (70.1%) and/or resistant hypertension (53.7%).
Patients who received stents were younger and had higher
SBP and more severe RAS. After follow-up (median 943
days), there was no difference between groups in rate of GFR
decline; presence of cerebrovascular disease was the only
factor associated with a poor outcome. Although there was no
evidence of either harm or benefit of stenting, the significance
of these lesions and how they are best managed remains
unclear.175 The ASTRAL (Angioplasty and Stenting for
Renal Artery Lesions) trial of 806 patients found substantial
risks, but no evidence of meaningful clinical benefit from
revascularization in patients with atherosclerotic RAS.669
Additional information should come from the ongoing
CORAL (Cardiovascular Outcomes in Renal Atherosclerotic
Lesions) trial to determine whether stenting atherosclerotic
RAS in patients reduces cardiovascular and/or renal events
(www.coralclinicaltrial.org). Knowledge about natural his-
tory of atherosclerotic RAS in the elderly is limited because
of variation of study cohorts and potential selection and/or
follow-up (survivor) bias. Data on progression of RAS were
provided from the Cardiovascular Health Study using
follow-up renal ultrasound for an elderly cohort (mean age
82.83.4 years277). The overall estimated change in renovas-
cular disease among all 235 kidneys studied was 14.0%, with
progression to significant RAS in only 4.0%. Longitudinal
increase in DBP and decrease in kidney size were signifi-
cantly associated with progression to new (ie, incident)
significant renovascular disease but not prevalent disease.
This was the first prospective, population-based estimate of
incident renovascular disease and progression of prevalent
disease among elderly Americans living in the community. In
contrast to previous reports among selected patients with
hypertension, these participants had a low frequency of
hypertension and an annualized rate of only 1.3% per year for
significant RAS and 0.5% per year for progression to signif-
icant RAS as no prevalent RAS progressed to occlusion over
8 years.176
The risks of RAS are related both to declining kidney
function and to accelerated CVD, with increased morbidity
and mortality.177 Recent studies reemphasize the predictive
value of clinical variables, including age, symptomatic vas-
cular disease, elevated serum cholesterol, and presence of
abdominal bruit, as the most powerful predictors of detecting
lesions of at least 50% stenosis.178,179 Additional clues in-
clude hypertension requiring 3 agents that is controlled
only to have significant increases in BP over the next 4 to 6
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months requiring higher doses or additional medications.
Another clue is “flash pulmonary edema,” when BP spikes
occur. Bilateral RAS may be signaled by a serum creatinine
increase 50% within the first month after starting RAAS
blockers. This serum creatinine increase can be associated
with hyperkalemia. If testing fails to reveal RAS, intrarenal
ischemia must be considered. Antihypertensive therapy, es-
pecially with RAAS blockers, may result in underperfusion of
the kidneys and loss of function.177 This is particularly true
when bilateral stenosis is present or in those with a solitary
kidney.
1.5.3.2. Obstructive Sleep Apnea
Approximately 30% of adults with hypertension have ob-
structive sleep apnea,180 and its prevalence more than doubles
for each 10-year increase in age in both sexes.181 Obstructive
sleep apnea is associated with a high prevalence of isolated
diastolic hypertension,182 and there is a significant association
between the incidence of combined systolic and diastolic
hypertension and obstructive sleep apnea in patients 60
years of age but not in older patients.183,184 Thus, elderly
obstructive sleep apnea patients may be less susceptible to
consequent hypertension than younger patients. Alterna-
tively, these findings may represent survivor bias for a
life-threatening disorder. Interestingly, a population-based
study, investigating stroke risk in people 70 to 100 years of
age, found severe obstructive sleep apnea independently
associated with increased stroke risk (adjusted HR: 2.52) over
6 years.185
1.5.3.3. Primary Aldosteronism
Although most cases are in younger patients, rare cases with
primary aldosteronism in elderly patients have been re-
ported.186,187 Primary aldosteronism prevalence varies from
1% to 11%, increases according to hypertension severity,188
and cross-sectional and prospective studies report primary
aldosteronism in10% of patients with hypertension,189 with
approximately 70% caused by adrenal adenomas.190 The
adenoma is usually unilateral and comprised of glomerulosa
cells in the adrenal cortex. Rarely, primary aldosteronism is
caused by adrenal carcinoma or hyperplasia. Adrenal hyper-
plasia is more prevalent among older men, and both adrenals
are overactive without adenoma. Diagnosis is suspected in
patients with hypertension with persistent hypokalemia con-
firmed by elevated plasma aldosterone levels and low plasma
renin activity (PRA) without drugs that affect the RAAS (eg,
ACEIs, ARBs, beta blockers, even thiazide diuretics).
Laparoscopic adrenalectomy is recommended for tumors
shown to be aldosterone-secreting by adrenal vein sampling.
After adenoma removal, BP decreases in all patients, with
complete hypertension remission in 50% to 70%. With
adrenal hyperplasia, however, approximately 70% will re-
main hypertensive after bilateral adrenalectomy, so surgery is
not recommended. Medical recommendations include a min-
eralocorticoid receptor antagonist (Section 4.2.2.1.1.2).
1.5.3.4. Thyroid Status and Hypertension
With aging, changes in thyroid homeostasis interact with
age-related CV factors to complicate the usual interactions
between thyroid homeostasis and BP regulation. In a study of
688 consecutive patients (ages 15 to 70 years) referred for
hypertension management, 3.8% were found to have unrec-
ognized hyperthyroidism, whereas 3.6% had serum levels
indicative of hypothyroidism.191
1.5.3.4.1. Hyperthyroidism and Blood Pressure. Relatively
few studies have investigated BP alterations in hyperthyroid-
ism in older patients. Although the prevalence of hyperten-
sion itself increases with age, no studies indicate an age-
related alteration in prevalence of hypertension with
hyperthyroidism. Subclinical hyperthyroidism, defined as
reduced thyroid stimulating hormone (TSH) in the presence
of normal serum thyroid hormone levels, has a prevalence in
patients older than 60 estimated between 1% and 5%.192 The
link between risk of hypertension in patients with subclinical
hyperthyroidism remains controversial. One study (4087
German subjects, mean age 49 years, range 35 to 63) found
no association between suppressed TSH levels and hyperten-
sion,193 but there was a trend toward higher pulse pressures in
older ages, independent of TSH levels. Another study (2033
patients ages 17 to 89 years) found a higher prevalence of
hypertension in patients with subclinical hyperthyroidism
than in euthyroid subjects.194 It is likely that inclusion of
elderly patients in the latter study increased the power to
detect an association.
1.5.3.4.2. Hypothyroidism and Blood Pressure. The preva-
lence of subclinical hypothyroidism clearly increases with
age: a study of 3607 community-living Japanese (ages 17 to
89 years) found 14.6% of subjects age 70 to 80 years and
20.1% of subjects 80 years of age with elevated TSH and
normal free T3 and free T4.195 In this study, no association
was found between subclinical hypothyroidism and BP.
In other studies, hypothyroidism was associated with
diastolic hypertension,196 which may return to normal with
thyroxine treatment.191 Hypertension incidence increased
with age in both euthyroid and hypothyroid women with
thyroiditis, but hypothyroid patients had significantly higher
DBP in the fifth and sixth decades of life than did euthyroid
controls. Patients who achieved therapeutic levels of
L-thyroxine replacement (13 of 14) exhibited reductions in
BP (1575/996 mm Hg versus 1433/903 mm Hg).197
A study of subjects not being treated for hypertension or
thyroid disease (mean age 5614 years, range 29 to 89 years)
showed an association between SBP and DBP with increasing
TSH within the normal range of TSH levels.198 Another study
of community-dwelling subjects (4140 of whom were 70
years of age) found a small but consistent rise in SBP
(approximately 2 mm Hg) and DBP (approximately
1.5 mm Hg) with increases in TSH levels which remained
within the reference range. Interestingly, men 70 years of
age with increased TSH levels failed to show an increase in
SBP, while still manifesting the increase in DBP.
Studies in primary care settings have yielded differing
results. In a study of postmenopausal women 50 years of
age, 45.4% had hypertension, and 10.9% had hypothyroid-
ism. Although hypertension was correlated with diabetes
mellitus and use of NSAIDs, no association was observed
between hypertension and either untreated or treated hypo-
thyroidism.199 A study of patients referred to an academic
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geriatrics clinic identified elevated TSH levels in 122 pa-
tients; compared with age-matched controls, the hypothyroid
patients showed no significant difference in SBP or DBP, and
linear regression analysis of TSH and DBP showed no
association.200
Although lower levels of T4/T3 or higher TSH levels seem
to be associated with a rise in DBP, this effect may be blunted
in the oldest old.201 Treatment of overt hypothyroidism can
reduce DBP levels to normal. However, the literature describ-
ing asymptomatic, subclinical hypothyroidism does not show
a consistent, clinically significant association with hyperten-
sion, especially in older patients.
1.5.3.5. Lifestyle, Substances, and Medications That Affect
Blood Pressure
1.5.3.5.1. Tobacco. Tobacco use is the most common avoid-
able cause of death and illness in our society, and 4.5 million
adults65 years of age smoke cigarettes.202 There are complex
interactions between hypertension and smoking that increase the
risk of CVD, PAD, cerebrovascular disease, and kidney disease
at all BP levels. Smoking increases vascular damage by increas-
ing sympathetic tone, platelet aggregability and reactivity, free
radical production, damage to endothelium, and surges in arterial
pressure.203 Smoking increases SBP, especially in those 60
years of age,204 and smoking cessation reduces SBP.205 These
hemodynamic changes are caused, in part, by changes in
sympathetic nervous system activity. Elderly patients have a
longer duration of exposure to these risk factors, as well as a
diminished capacity to adjust to them, resulting in an increased
incidence of CV events at any level of CVD risk factors
compared with younger candidates.206
CAD, the most common cause of death in individuals with
hypertension, occurs at a rate 2 to 3 times higher in hyper-
tensive versus normotensive individuals, and smoking in-
creases this risk by an additional 2- to 3-fold. For every
increment of 10 cigarettes smoked per day, CV mortality
increases by 18% in men and 31% in women.207 In a Chinese
study involving patients 60 years of age (mean age 67
years) followed for 3 years (median), both smoking and SBP
were associated with a higher risk of stroke.208 Smoking 10 to
20 or 20 cigarettes per day increased stroke risk about
2-fold (risk ratios [RR]: 1.78 and 2.23, respectively). When
moderate (10 to 20 cigarettes per day) and heavy (20
cigarettes per day) smokers were combined and compared
with those that had never smoked, the risk ratio for fatal
stroke was 2.66. Smoking 20 cigarettes per day also
increased the risk of all-cause mortality, non-CV mortality,
and cancer mortality (RR: 2.04, 4.66, and 4.74, respectively).
1.5.3.5.2. Alcohol. Several mechanisms have been suggested
for the relationship between alcohol and elevated BP, but
these are not known to differ among the elderly. Proposed
mediators include: neurohormonal (sympathetic nervous sys-
tem, endothelin, RAAS, insulin/insulin resistance, corticotro-
phin, or cortisol); inhibition of vascular relaxing substances
(nitric oxide); calcium depletion; magnesium depletion; in-
creased intracellular calcium or other electrolytes in vascular
smooth muscle cells; and increased plasma acetaldehyde.209
Drinking, especially outside meals, is significantly associated
with hypertension. There is no difference in risk between
beer, wine, and liquor.
1.5.3.5.3. Caffeine/Coffee. Because of the greater proportion
of adipose tissue to lean body mass in older subjects, and
because caffeine is distributed through lean body mass, a dose
of caffeine expressed as milligrams per kilogram of total
bodyweight may result in a higher plasma and tissue concen-
tration in elderly compared with younger individuals.210
Metabolism of, and physiological responses to, caffeine are
similar in elderly and younger individuals, but there is limited
evidence that responses to caffeine in some systems may be
greater in the elderly at doses in the 200- to 300-mg range.210
One small study found a 4.8 mm Hg (P0.03) higher mean
24-hour SBP and a 3.0 mm Hg (P0.010) mean 24-hour
DBP in elderly coffee drinkers compared with abstainers.
Findings suggest restriction of coffee intake may be benefi-
cial in some older individuals with hypertension.211
1.5.3.5.4. Nonsteroidal Anti-Inflammatory Drugs. NSAIDs,
including cyclo-oxygenase-2 inhibitors, are frequently used
to provide analgesia and anti-inflammatory benefits,212 but
are not without adverse effects in elderly hypertensive pa-
tients.213 In fact, NSAIDs may negatively impact hyperten-
sion control in elderly individuals as NSAID users have
higher SBP versus nonusers that are not explained by age,
weight, and type or dose of antihypertensive regimen.214 In
persons 65 years of age, NSAID use increased the risk for
initiation of antihypertensive therapy. Compared with nonus-
ers, low daily NSAID doses significantly increased the risk
1.55 times, medium daily doses increased risk 1.64 times, and
high daily doses increased risk 1.82 times.213 A meta-analysis
found that NSAIDs elevated mean supine BP by 5.0 mm Hg
(95% CI: 1.2 to 8.7 mm Hg).215 Not all NSAIDs affect BP in
the same way. Rofecoxib significantly increases SBP com-
pared with celecoxib.216 Piroxicam seems to produce more
marked elevation in BP (6.2 mm Hg) compared with sulindac
or aspirin.215
There are several mechanisms by which NSAIDs may
influence BP elevation. Use of NSAIDs or cyclooxygenase-2
inhibitors influences production of prostaglandins: This de-
creases inflammation but also results in renal side effects.217
In the setting of physiological stress, renal function becomes
dependent upon prostaglandins, and NSAID use may be
associated with acute deterioration of kidney function, includ-
ing sodium retention, decreased GFR, edema, hyperkalemia,
and/or papillary necrosis, as well as hypertension.218–221
NSAIDs may also contribute to increased vascular resis-
tance due to increased ET-1 synthesis and/or altered arachi-
donic metabolism.222–226 They also interfere with BP control
in the elderly through partial reversal of antihypertensive
effects of diuretics,218,227–230 beta-receptor antagonists, and
ACEIs231–233 and ARBs, but not CAs. NSAIDs antagonize
antihypertensive effects of beta blockers more than vasodila-
tors or diuretics.234 Effects of NSAIDs on antihypertensive
drug effects vary with the specific NSAID and dose.235
Caution must be taken when prescribing NSAIDs to
elderly patients with hypertension. Close monitoring for BP
changes, weight gain, fluid retention, and kidney dysfunction
are required. Changing class of antihypertensive drug, keep-
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ing NSAID doses as low as possible, or up-titrating antihy-
pertensive drugs may be necessary.
1.5.3.5.5. Glucocorticoids. Glucocorticoid-induced hyper-
tension occurs more often in the elderly236 compared with
younger patients. Oral glucocorticoids can increase SBP as
much as 15 mm Hg within 24 hours.236 Mineralocorticoids
and other compounds, such as licorice and carbenoxolone,
that inhibit 11-beta hydroxysteroid dehydrogenase enzyme
increase exchangeable sodium and blood volume, induce
hyperkalemia and metabolic alkalosis, and suppress plasma
renin and AII.236
Potential complications of corticosteroid use among elders
(mean age 67 years) with Crohn’s disease237 include an
increased risk for developing BP 160/90 (RR: 1.46, 95%
CI: 1.09 to 1.95). Analyses stratified by patient age showed a
similar risk of complications for patients 65 years of age
and patients 65 years of age.
1.5.3.5.6. Sex Hormones. Estradiol treatment effects on SBP
in healthy postmenopausal women238 differ significantly by
age, suggesting an increase in SBP in younger postmeno-
pausal women, while having the opposite effect in older
postmenopausal women. (Section 1.5.1.3.2)
In a cohort of men 60 to 80 years of age who did not have
diabetes mellitus, did not smoke, were not obese, and were
untreated for hypertension, testosterone levels decreased with
increasing age in normotensive individuals, those with ele-
vated SBP and DBP hypertensive treatments, and those with
elevated SBP only (ISH).239 Testosterone levels were signif-
icantly lower in hypertensive treatments (15%) and ISH
men (21%) than in normotensive men (P0.05). Adjusting
for BMI confirmed a significant difference in plasma testos-
terone levels between ISH and normotensive men, but not
between hypertensive treatments and normotensive men.
Multiple regression analysis confirmed a strong relationship
between testosterone levels and SBP in all 3 groups, whereas
a significant relationship between testosterone levels and
DBP was found only in normotensive men. Although further
studies are needed, findings suggest that in elderly men with
ISH, reduced plasma testosterone levels may contribute to
increased arterial stiffness typical of these subjects. However,
available data do not suggest a significant effect of testoster-
one supplementation on BP.240 The relationship between
serum testosterone levels, testosterone replacement, and ar-
terial BP and other clinical outcomes among elderly men is
under investigation in a large randomized by trial by the
National Institutes of Health’s National Institute on Aging.
1.5.3.5.7. Calcium and Vitamins D and C. Investigators
examined the effect of calcium plus vitamin D supplementa-
tion on BP and the incidence of hypertension in postmeno-
pausal women;241 calcium plus vitamin D3 supplementation
did not reduce either BP or risk of developing hypertension
over 7 years of follow-up. Others have found high intakes of
ascorbic acid in older adults may have modest effects on
lowering high SBP.242 With increasing baseline BP, the
magnitude of the decline in BP with vitamin C supplemen-
tation increased.
1.6. End-Organ Effects of Hypertension in
the Elderly
1.6.1. Cerebrovascular Disease and
Cognitive Impairment
Hypertension in the elderly is a risk factor for both ischemic
stroke and cerebral hemorrhage. ISH is as an important
component of BP-related stroke risk.243 The strength of the
association between BP level and stroke decreases with
increasing age.244 But because of the increased risk of
stroke-related mortality and morbidity with increasing age
(Figure 8),42 and evidence of benefit from antihypertensive
treatment, hypertension remains critically important relative
to stroke risk in the elderly.
The benefit of BP reduction for stroke risk was demon-
strated in SHEP (Systolic Hypertension in the Elderly Pro-
gram) evaluating active treatment of ISH with chlorthalidone
with or without atenolol or reserpine (with nifedipine as
third-line therapy) compared with placebo (RR: 0.64; 95%
CI: 0.50 to 0.82; P0.003) on nonfatal and fatal stroke with
active treatment for over 5 years.16 Patients in the active
treatment arm had reduced incidence of both ischemic (37%)
and hemorrhagic stroke (54%).245 In the PROGRESS (Perin-
Figure 8. Absolute risk of stroke mortality in
relation to blood pressure. (A) Systolic blood
pressure. (B) Diastolic blood pressure.
Stroke mortality rate in each decade of age
versus usual blood pressure at the start of
that decade. Rates are plotted on a floating
absolute scale, and each square has area
inversely proportional to the effective vari-
ance of the log mortality rate. For diastolic
blood pressure, each agespecific regression
line ignores the left-hand point (ie, at slightly
75 mm Hg), for which the risk lies signifi-
cantly above the fitted regression line (as
indicated by the broken line below
75 mm Hg). The y-axis is logarithmic. CI
indicates confidence interval. Reprinted from
Lewington et al.42
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dopril Protection Against Recurrent Stroke Study), over 4
years of perindopril plus indapamide significantly reduced
ischemic stroke 24% (10% to 35%) and hemorrhagic stroke
50% (26% to 87%) compared with placebo.246 The Syst-Eur
trial of patients (mean age was 70.2 years) with ISH con-
firmed stroke prevention with BP control using nitrendipine
with possible addition of enalapril, HCTZ, or both. This study
was stopped after 2 years instead of the planned 5 years
because of a 42% reduction in total stroke in the treatment
arm (P0.003).20 A large number of these patients were then
enrolled in a 4-year follow-up study with open-label treat-
ment that assessed the benefits of early or delayed treatment
on stroke risk. The placebo arm from the earlier study
received active treatment as the delayed treatment arm. The
initial treatment group continued active treatment as the early
treatment arm. Early treatment remained more protective
against stroke than delayed treatment, with a 28% reduction
in stroke (P0.01).247 These findings support the suggestion
that earlier antihypertensive treatment is associated with
better outcome. The LIFE (Losartan Intervention For End-
point Reduction) study showed a 25% reduced overall risk of
stroke in the losartan arm versus atenolol, despite similar
reduction in BP in both groups.14
Patients in the aforementioned studies consisted predomi-
nantly of the “early elderly.” In HYVET, patients in the “late
elderly” group (80 years of age with elevated SBP) were
randomized to indapamide, with addition of perindopril if
needed, or placebo and followed over 2 years. Patients in the
indapamide arm had a 30% risk reduction in fatal or nonfatal
stroke (P0.06). Although there have been consistent bene-
fits in reduction of stroke with antihypertensive therapy in
elderly patients, some reports have suggested that these
benefits may be offset by an increase in death in treated
patients.248,249 The HYVET, however, found benefits consis-
tent with a 21% risk reduction (95% CI: 4% to 35%; P0.02)
of all-cause death in the indapamide arm.4
In the majority of studies to date, benefits in stroke
reduction appear related to BP reduction, as a 10 mm Hg
reduction in SBP was associated with a 20% to 30% lower
risk of stroke in individuals 70 years of age. Furthermore,
there is greater benefit with greater reduction in BP (9250). It
is unclear whether the benefits are related solely to BP
reduction or whether there are additional benefits conferred
by class of BP medication. Although there is consistent
benefit in stroke reduction when drugs were compared with
placebo, there is little difference between drug classes.250 In
addition, there are no differences in benefits conferred by
different classes of antihypertensive agents comparing
younger and older adults. A meta-analysis of 31 randomized
trials showed no difference between younger (65 years of
age) and older patients (65 years of age) in protection
against major vascular events provided by major drug
classes.251
The prevalence of both hypertension and dementia in-
creases with advancing age. Hypertension is considered a risk
factor for vascular dementia and Alzheimer’s disease. Poor
BP control is associated with an even greater cognitive
decline.252,253 Observational studies report a long-term in-
creased SBP with paradoxical BP reduction in years imme-
diately preceding dementia onset.254,255 In older patients with
hypertension, nocturnal nondipping of BP occurred in 35%
and was associated with mild cognitive impairment in about
half of the cases compared to dippers (256), where this
impairment occurred in only 13%.
Three randomized studies evaluated dementia as an out-
come with treatment of hypertension in elderly patients. In
Syst-Eur and PROGRESS, active treatment was associated
with 50% and 19% reduction in dementia incidence, respec-
tively.246,257 The SCOPE (Study on Cognition and Prognosis
in the Elderly) assessed candesartan compared with placebo
in 70 to 89 year olds with hypertension, and over 44 months
(mean); there were no differences in cognitive outcome
between the 2 groups.258 However, a SCOPE post hoc
analysis reported less cognitive decline among those with
only mild cognitive impairment (Mini-Mental State Exam
score 24 to 28) at baseline in the candesartan-treated group
(P0.04).259 The SHEP showed no significant difference in
dementia incidence between active and placebo; however, the
SBP target was 160 mm Hg, and results indicated that in
those with mild cognitive impairment, better BP control may
reduce cognitive decline. The HYVET-COG, a HYVET
substudy, found a nonsignificant 14% decrease in dementia
with active treatment versus placebo.260 Although no specific
class of antihypertensive drugs have been definitively linked
with cognitive decline in the elderly, inadequate BP reduction
is associated with cognitive decline.
There is a theoretical risk that BP control may impair
cerebral perfusion and negatively impact cognitive function.
Although benefits in HYVET-COG were limited to CV
outcomes, hypertension treatment was not associated with
negative effects on cognition. Although there is clear evi-
dence of the benefits of hypertension treatment in reduction
of both ischemic and hemorrhagic stroke, the benefits in
reducing cognitive impairment and dementia have only been
demonstrated in the early elderly. In patients, mean age
6410 years, in PROGRESS, a perindopril-based BP-
lowering regimen among patients with previous ischemic
stroke or transient ischemic attack significantly reduced
stroke-related dementia (34%) and severe cognitive decline
(19%).261
1.6.2. Coronary Artery Disease
CAD is highly prevalent among the elderly. Elderly patients
with hypertension have a higher prevalence of MI than
elderly patients without hypertension. According to 2004
AHA statistics, 83% of CAD deaths occurred in persons 65
years of age.34 The median age of occurrence of a first MI is
approximately 65 years for men and 74 for women. In the
very old, the male predominance in MI observed among
younger elderly is attenuated as the rate in women approxi-
mates that of men. Among autopsies in persons with average
age 80 years, the age-related increase in atherosclerosis was
evident even after age 80.262 Atherosclerosis was more severe
in men than in women 60 to 70 years of age, but this gender
difference diminished with increasing age and disappeared in
the nineties. Centenarians have lower prevalence of CVD and
are less likely to have the usual CV risk factors. This has been
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attributed to both genetic and lifestyle factors as well as
pharmacotherapy263 and survivor bias.
Hypertension precedes MI and angina in a large majority
of the elderly with these conditions. In the case of angina,
hypertension may play a causal role (as a risk factor for
underlying CAD and as a precipitating factor by increasing
myocardial oxygen demand). For persons 60 to 69 years of
age, a 20 mm Hg SBP increase doubles CAD risk, and the
absolute risk difference for a given BP difference increases
with age.42 However, the positive relationship between abso-
lute risk increase and SBP increase becomes less steep with
each decade increase in age,42 so the absolute benefit for a
given SBP reduction would be expected to decrease among
the very elderly. Benefits of BP lowering on incidence of
angina and MI are generally similar with different antihyper-
tensive drug classes, and overall, better BP control is associ-
ated with better outcomes; effects were not different among
older individuals.251,264 A more detailed analysis of the
influence of age from INVEST265 compared patients 60
years of age (n6668), 60 to 69 years of age (n7602), 70 to
79 years of age (n6126), and 80 years of age (n2180),
and showed that for 70 to 79 and 80 years of age, higher
SBP (135 and 140 mm Hg, respectively) was associated with
less risk for death, MI, or stroke than SBP 130 mm Hg
(Figure 9). The oldest patients appeared to tolerate a higher
SBP better and a lower SBP worse compared with younger
patients, and patients 70 years of age had a relatively
narrow range of optimal DBP.
Another study in 12 000 patients (mean age 66 years)
suggested that hypertension recorded during admission for
acute MI is not independently associated with higher mortal-
ity.266 Although crude hospital mortality in this study was
higher in patients with hypertension (14.4% versus 12.4%,
P0.001), hypertension was not an independent predictor of
mortality on multivariate analysis. Of note, patients with
hypertension had a 17% lower risk of ventricular fibrillation
but a 26% greater risk of AF in this analysis.
Hypertension is an established risk factor for sudden
cardiac death among the elderly, and both ECG and echo
evidence for LVH are also predictors.267 Treatment for
hypertension reduces the risk of sudden cardiac death in the
elderly.14
The optimal BP level in hypertension patients with prior
MI is not definitely established. In INVEST, a J-curve
between BP and all-cause mortality, MI, or stroke, as well as
total MI, was observed with a nadir of 119/84 mm Hg.268
Results were particularly strong for DBP and were the same
for those above and below the mean age of 65 years.
Interestingly, this relationship was not observed for total
stroke (fatal and nonfatal) and was not present among patients
who had undergone coronary revascularization. Because
there were no differences in BP control (70% with 140/
90 mm Hg) comparing the randomized CA versus beta-
blocker treatment strategies, the entire cohort was analyzed.
After 61 835 patient-years, 2269 patients suffered an adverse
outcome (as death, or stroke). The adjusted hazard ratios for
these events were related to on-treatment SBP and DBP as a
“J-shaped” curve for each age group (Figure 9). But the
optimal BP level for these very elderly post-MI individuals is
unknown and may be 140/90 mm Hg.
Our understanding of the growing population of elderly
patients with hypertension with prior coronary revasculariza-
tion is limited. An analysis of patients with prior revascular-
ization from INVEST found that they were older (mean age
67 years) and had higher frequencies of prior MI, HF,
stroke/transient ischemic attack, PAD, and diabetes mellitus
compared with those who were not revascularized.269 They
also had worse outcomes: death, MI, or stroke, 14.2% versus
8.5% among those without prior revascularization. Interest-
ingly, both SBP and DBP were more difficult to control
Figure 9. Risk of adverse outcomes by age
and blood pressure. BP indicates blood pres-
sure; DBP, diastolic blood pressure; and SBP,
systolic blood pressure. Reprinted from
Denardo et al.13
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among those with prior revascularization, suggesting more
severe vascular disease, and again the J-curve between BP
and mortality, MI, or stroke was observed even with propen-
sity score adjustment.
1.6.3. Disorders of Left Ventricular Function
1.6.3.1. Heart Failure
Aging and hypertension are both strongly associated with
development of HF.270 In 1 study, approximately 82% of
incident HF occurred among individuals 65 years of age
and 55% among those 75 years of age. Hypertension may
lead to HF through different but frequently overlapping
pathways. These include development of LVH, impaired LV
filling, and increased wall thickness as discussed in the
preceding text, especially when coexistent with diabetes
mellitus (see Section 2.3), obesity, AF, and/or CAD with MI.
After MI, neurohormonal activation results in LV remodel-
ing, systolic dysfunction, and elevated filling pressures. In
addition to hypertension and CAD, HF with depressed
ejection fraction may occur in dilated cardiomyopathies of
alcoholic and other etiologies.
Aging and hypertension result in decreased arterial com-
pliance, initially with impaired systolic and diastolic CV
reserve and impaired responsiveness to catecholamines. At a
later stage, LV dilation occurs. Thus, development of HF
among patients with hypertension occurs in the presence of
decreased LV systolic function (eg, LV ejection fraction
45% or 50%), as well as with preserved LV systolic
function, where it is attributed to impairment of diastolic
function (eg, from LVH) as described previously. HF with
preserved systolic function is important in the elderly and
probably related to progressive fibrosis and myocardial stiff-
ening associated with CAD, diabetes mellitus, and age per se
plus LVH attributable to hypertension.
In a cross-sectional study of patients with hypertension
65 years of age with LV ejection fraction 45%, HF was
observed in 22.6% and diastolic dysfunction in 25.8%.271 In
ALLHAT, persons 55 years of age developing HF with
preserved systolic function were more likely to be women
and to have higher BMI, SBP, and high-density lipoprotein
cholesterol than those who developed HF with impaired LV
systolic function.272 In this study, HF symptoms and signs
were similar among those with and without impaired LV
systolic function. Ankle edema was present in a higher
percentage of patients with preserved ejection fraction,
whereas S3 gallop, hepatomegaly, and paroxysmal nocturnal
dyspnea were present in a smaller percentage in this group
compared with those with impaired LV systolic function.272
Patients with HF and preserved ejection fraction are in
general less likely to have CAD and more likely to have
diabetes mellitus than patients with HF and depressed ejec-
tion fraction.273
Although hospital mortality of elderly patients (65 years
of age) with first MI has declined in the last decade, HF
developed in over three fourths of them over 5 years of
follow-up.274 In addition, new-onset HF significantly in-
creased the mortality of MI survivors.274 In a population
study from Scotland, mean age at first discharge increased
from 70.7 years in 1986 to 72.4 years in 2003 for men and
from 76 to 77.3 years for women, whereas the age-
standardized rate decreased after 1994 in both sexes.275 Also,
case fatality rates decreased in parallel with an increase in HF
therapies. In another study of patients with hypertension or at
high CV risk, the rate of HF was 8.5 events per 1000 and the
rate for stroke was 9.1 events per 1000 patients, because HF
was more likely to occur in patients 65 years of age and
those with diabetes mellitus (OR: 4.91; 95% CI: 4.40 to
5.43).276
1.6.3.2. Left Ventricular Hypertrophy
As discussed previously, aging and hypertension-related aor-
tic and conduit artery stiffening (Figure 7) increase LV
loading and promote LVH. Among the older population
included in the Cardiovascular Health Study, LV mass index
was an independent predictor of incident HF not related to
prevalent or incident MI.277 LVH is associated with adverse
outcomes, including CAD, stroke, and especially HF.277 The
association of LVH with CV events is especially strong in the
elderly.278,279 After a 36-year follow-up in FHS, the relative
risk related to LVH in those 65 to 94 years of age for CVD
in general was 2.82 for men and 4.13 for women. The risk
imposed by LVH is not totally explained by development of
CAD, but regression of LVH with BP control is associated
with reduced risk of CVD, especially development of HF.280
ECG LVH was present in 23.4% of 782 patients (mean age 66
years, BMI 28.2 kg/m2, baseline BP 155.717.7/
90.810.6 mm Hg), and predictors of LVH were age, male
sex, and grade II hypertension.281
Myocardial fibrosis and diastolic dysfunction precede
LVH development in hypertension.282 In the LIFE study,
regression of LVH was associated with a 36% reduction in
the rate of new HF,283 and BP lowering improved diastolic
function.284 In the same study, regression of LVH during
therapy was related to reduced risk for sudden cardiac death
after adjustment for BP reduction, CAD, antihypertensive
treatment modality, and other cardiovascular risk factors.285
1.6.4. Atrial Fibrillation
AF is primarily a disorder of older age, with a prevalence as
high as 10% in octogenarians;286–288 hypertension is a major
risk factor for AF. Aging of the population, more sensitive
diagnostic modalities such as ambulatory electrocardiogra-
phy, and increased prevalence of hypertension, obesity, and
HF have contributed to a growing number of elderly persons
diagnosed with AF. In those 65 years of age, the risk for
new onset of AF is approximately 2% per year.289 In the
Cardiovascular Health Study, among patients 65 years of
age, incidence of a first episode of AF during average
follow-up of 3.28 years, was 19.2 per thousand person-
years.277 This was associated with age, male sex, and the
presence of CVD. For men 75 to 84 years of age, the
incidence of AF was 42.7 per thousand patient years. Use of
diuretics, older age, higher SBP, glucose, left atrial size,
height, and history of valvular or CAD increased the risk.290
In the elderly, the pathophysiology of AF is related to
increased arterial stiffness and reduced LV compliance,
findings often predicted by elevated pulse pressure, a surro-
gate for increased proximal aortic stiffness, higher BMI, and
prevalent diabetes mellitus.291 Occurrence of AF is associated
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with increased mortality, cardiac sudden death, HF, embolic
stroke, and reduced QoL.
Control of BP is associated with reduced occurrence or
recurrence of AF in patients with hypertension. In SHEP
(average age 72 years), AF increased CV mortality risk at 4.7
and 14.3 years.292 In the STOP-Hypertension-2 trial (Swedish
Trial in Old Patients with Hypertension) (mean age 76 years,
range was 72 to 84 years with ISH), AF was present in
approximately 5% at baseline. During follow up, “newer”
antihypertensive therapy (ACEI, CA) was significantly better
than “conventional” (diuretic/beta blockers) in preventing
stroke. However, there were more new cases of AF in patients
randomized to newer agents, especially CAs (RR: 1.53; 95%
CI: 1.05 to 2.21).293 The conventional agents were associated
with less new AF. Others, however, have reported lower AF
recurrence rates with agents affecting the RAAS. A meta-
analysis of 22 studies including 56 309 patients showed that
ACEI and ARBs significantly reduced the risk of AF by 28%,
with a 44% significant reduction in AF in patients with
congestive HF.294 This benefit was limited to patients
with reduced LV ejection fraction or LVH. In patients with
diabetes mellitus, hypertension, and paroxysmal AF, combi-
nation valsartan and amlodipine was associated with a lower
rate of recurrence than combination amlodipine and atenolol
with similar BP reductions.295 However, in the GISSI-AF
(Gruppo Italiano per lo Studio della Sopravvivenza
nell’Infarto Miocardico-Atrial Fibrillation) trial, symptomatic
AF patients (average age 68 years) with diabetes mellitus,
CVD, or enlarged left atrium, valsartan did not prevent AF
recurrence compared with placebo. This secondary preven-
tion trial addresses a different population than the earlier
prevention studies.296 Regardless of treatment, survival is
worse for those 65 years of age as well as for patients with
history of CAD, HF, or abnormal ejection fraction.297
1.6.5. Abdominal Aortic Aneurysm and Peripheral
Arterial Disease
1.6.5.1. Abdominal Aortic Aneurysm
AAAs, defined as dilation of the aorta with a minimum
anteroposterior diameter of 30 mm, occur with increasing
frequency with increasing age. The prevalence of AAAs is
12.5% among men 75 to 84 years of age.298 Usually AAAs
are due to aortic medial degeneration associated with abnor-
malities in tissue metalloproteinases, metalloproteinase inhib-
itors, elastase, and other proteinases. Risk factors for asymp-
tomatic AAAs resemble those for obstructive PAD and
include older age, male sex, smoking, hypertension, diabetes
mellitus, family history of AAA, history of MI, and PAD.
1.6.5.2. Thoracic Aortic Disease
Thoracic aortic aneurysm is increasingly prevalent in the
elderly and, although the pathology is denegation of the aortic
wall, hypertension is a major risk factor for development
along with smoking, chronic obstructive pulmonary disease,
and several genetic syndromes.299 Acute aortic dissection
(acute aortic syndrome) is a catastrophic complication in the
elderly patient. Chest and or back pain are the classic
symptoms, although older patients can present without chest
or back pain. The incidence varies from 5 to 30 cases per
million persons per year, but hypertension and age are major
risk factors.300 Surgery is indicated for type A dissections
(those involving the ascending aorta). Control of BP, includ-
ing beta blockade, is needed for both type A and B (not
involving the ascending aorta) dissection. Endovascular tech-
niques may be used in patients with high operative risk.301
1.6.5.3. Peripheral Arterial Disease
PAD, or occlusive arterial disease distal to the aortic arch and
including arterial narrowing usually caused by atherosclerotic
disease as well as aneurysmal dilation with or without
dissection, may lead to intermittent claudication, rest pain,
critical limb ischemia, and amputation. PAD is usually not
limited to the peripheral arterial system, but often associated
with CAD as well as cerebrovascular disease. It is estimated
that 10 million persons have PAD in the United States, the
prevalence among persons75 years of age is approximately
20% and is 50% in persons 85 years of age.302,303
PAD is associated with a 4-fold increase in MI risk and a
3-fold increase in stroke or transient ischemic attack
risk.304,305 Among persons with PAD, average age 66 years,
the 5-year mortality risk approaches 25% and the 10-year risk
approaches 48%.305 Mortality adjusted for age, sex, and CVD
risk factors is 2 to 3 times higher than that of persons without
PAD. Although about 1 of 3 persons with symptomatic PAD
has typical claudication, 50% have leg pain on exertion,
and about 5% to 10% have critical limb ischemia.306
Age and hypertension, along with risk factors for athero-
sclerosis, are also associated with PAD. In addition, hyper-
homocysteinemia,307–309 high plasma lipoprotein (a), and
AAAs are associated with increased risk of PAD.310,311 In
persons screened for AAAs, increasing age, male sex, and
PAD were independent predictors. The prevalence in persons
60 years of age was 4% for men and 1.2% in women.311
Patients with combined CAD and PAD in the REACH
(REduction of Atherothrombosis for Continued Health) reg-
istry (German cohort, mean age 67.3 years) were older and
more likely to be treated with antithrombotic agents, statins,
and ACEIs.312
Hypertension is associated with more rapid progression of
PAD.313 Therefore, elderly patients with hypertension and
exertional limitation involving lower extremity muscles, non-
or poorly healing lower extremity wounds should be screened
for PAD298 by comprehensive examination of the pulses,
measurement of the ankle-brachial index, and careful exam-
ination of the feet. A clinical prediction model (PREVA-
LENT) giving 1 point per 5 years of age starting at age 55
years, 2 points for smoking history, 7 for current smoking,
and 3 for hypertension identifies a subset of individuals in
whom PAD is highly prevalent and who may benefit from
ankle-brachial index measurement.314 The risk of PAD in-
creased from 7% in patients with a score of 0 to 3 to 41% in
those with a score of 13. A strategy to screen for cerebro-
vascular disease and CAD, as well as limb preservation and
claudication relief, needs to be included in the evaluation.
1.6.6. Chronic Kidney Disease
Hypertension and aging both impact renal function. Elderly
patients are more likely to have CKD, usually defined by a
measured eGFR 60 mL/min/1.73 m2. Multiple studies over
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the past 2 decades have shown that CKD is a powerful CVD
risk factor. Unless GFR is eGFR, CKD is often unrecognized
in elderly patients. Patients 75 years of age have more than
a 2-fold risk of CKD versus younger patients, and a 60% risk
for further loss of kidney function independent of baseline
function.315 Prevalence of CKD ranges from 11% to 14% in
the United States, and 75% of the CKD population is 65
years of age.316 However, it should be noted that the equation
for eGFR has not been validated in this age group.317 Thus,
although this group is more vulnerable to renal injury as a
result of surgical or diagnostic procedures, the actual estima-
tion of CKD in the population may be inaccurate.
In the elderly, CKD is an independent risk factor for
congestive HF.318 CV outcomes increase in patients with
hypertension as GFR decreases.319 Moreover, SBP is a strong
independent predictor of decline in kidney function among
older persons with ISH.151 Reduced kidney function in
elderly people is a marker for adverse outcomes.318,320–322
Substantial proteinuria is associated with a rapid decline in
kidney function. A progressive decline in kidney function is
more prevalent in elderly patients with diabetic nephropa-
thy.323 Hypertension and HF are associated with a more
pronounced decline in renal function in older age.324
1.6.7. Ophthalmologic Impairment
1.6.7.1. Age-Associated Retinal Changes
The major cause of vision limitation in patients with hyper-
tension of all ages is retinopathy, defined as arteriolar
narrowing (generalized and focal), arteriovenous nicking,
flame and blot hemorrhages, cotton-wool spots, and optic
disk edema.325,326 Based on population studies, markers of
hypertensive retinopathy (eg, arteriovenous nicking, focal
arteriolar narrowing) were found in 3% to 14% of those 40
years of age.327 Retinal lesion prevalence increased with
higher SBP, but not necessarily with DBP. The specificity of
retinal changes, however, decreases with age: Arteriolar
narrowing is common in normotensive elders, and focal
arteriolar sclerosis has been reported in 2% to 15% of
normotensive patients 40 years of age.326,328
In a study of people with nonmalignant hypertension of at
least 10 years duration, 33% had no fundoscopic changes,
37% had slight arteriolar narrowing (especially in older
patients), and 6% had hemorrhages or lipid deposits.329 In
older patients, retinal vessel changes are less reliable indica-
tors of the presence or duration of hypertension. For individ-
ual patients with hypertension, retinal findings may be
reasonable indicators of organ damage. Significant retinal
damage (eg, hemorrhages, exudates, or disc edema) is more
significantly associated with stroke and warrants prompt
evaluation and treatment of elevated BP.
1.6.7.2. Pathophysiology
A series of retinal changes in response to increased BP
includes generalized arteriolar narrowing due to alterations in
local auto-regulatory vasoconstrictive responses (some medi-
ated by nitric oxide). Persistent BP elevation produces intimal
thickening, medial hyperplasia, and hyaline degeneration
(sclerosis). These later changes are associated with focal
narrowing, disturbed arteriovenous nicking, and widening of
the arteriolar light reflex (“copper wiring”). Aging itself is
also associated with most of these “early” changes, which
makes grading of retinal pathology in older patients less
reliable versus younger patients. The final stages of retinal
disease are caused by disruption of the retinal/blood barrier
and lead to hemorrhages and lipid exudates. Optic disk
swelling usually indicates severely elevated BP330 and can be
associated with visual impairment, and this is extremely
serious in a patient of any age. Papillidema associated with
hypertension is an extremely serious condition.
Hypertension is also associated with retinal artery occlu-
sion and nonarteritic anterior ischemic optic neuropathy.331
Other than a general increase in prevalence with age, infor-
mation is limited about age-related changes in these 2
conditions. Little to no correlation of hypertension with the
prevalence of glaucoma is reported.332 Older population-
based studies failed to show consistent association of hyper-
tension and age-related macular degeneration,333 but more
recent studies have linked neovascular age-related macular
degeneration with moderate to severe hypertension, particu-
larly among elderly patients (median age 72 years) receiving
antihypertensive treatment.334,335 In addition to SBP, pulse
pressure is also a strong predictor of neovascular age-related
macular degeneration.334 These findings support the hypoth-
eses that neovascular and nonneovascular age-related macu-
lar degeneration have a different pathogenesis, and that
neovascular age-related macular degeneration and hyperten-
sive vascular disease have a similar underlying systemic
process. Age-related macular degeneration is the most com-
mon cause of blindness in the Western world.
1.6.8. Quality of Life Issues
Hypertension is often portrayed as a “silent killer” because
patients with mild or moderate hypertension are often asymp-
tomatic. When symptoms appear as a result of organ damage,
therapeutic options are limited. Although the symptoms
produced by these organ complications (MI, HF, stroke, or
chronic renal failure) are associated with decreased QoL,
possible alterations in QoL in patients with mild to moderate
hypertension who do not have such complications remain
controversial. Declines in QoL seen in aging populations
complicate the analysis of a potential relationship between
“asymptomatic” hypertension and QoL in older patients.
The INVEST study examined a measure of subjective
well-being, which was validated in a substudy,336,337 in
22 576 CAD patients 50 years of age (mean age 6610
years) with hypertension.338 Patients were asked a single
question rating their overall feeling of well-being in the prior
4 weeks. Data were collected at baseline and at each
follow-up visit before BP was measured. Measures of sub-
jective well-being were highly negatively correlated with
SBP measured during treatment. Age had minimal effect on
measured subjective well-being, but the presence of angina
was also a predictor.
QoL alterations were examined in hypertensive patients
from hospital-based clinics in China using a standard QoL
instrument focusing on self-report of symptoms across sev-
eral domains;339 2331 were 65 years of age. Whereas
hypertension prevalence was highest in those 65 years of
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age (65%), as expected, decreases in QoL with age were seen
in almost all domains, with older hypertensive subjects
reporting more stress, worries about health, and difficulties
with coping. Although contributions to QoL changes by other
comorbid conditions were not assessed, treatment of hyper-
tension resulted in modest improvement in these scales. Two
additional studies reported decreases in QoL scores with
hypertension. In another study, although older hypertensive
patients had more comorbid conditions, subanalysis showed
small decreases in selected physical health QoL measures.340
Yet another study found increasing prevalence of hyperten-
sion and comorbid conditions in older patients but the
presence of any illness was correlated with decreased QoL.
Conversely, a study of community-based Finns found no
correlation between QoL symptoms and hypertension,341 and
2 additional studies found QoL changes correlated with age,
more so than with hypertension.342,343
Some question the effects of labeling a patient with the
diagnosis of hypertension, and the effects of that diagnostic
label on QoL.340,342 Although small changes in QoL scales in
younger patients with the solitary diagnosis of hypertension
might be measurable, the additional effect of a diagnosis of
hypertension on the lower QoL scores seen in older patients
is likely minimal. In “younger old” patients in the seventh
decade, control of systolic hypertension has been associated
with modest improvement in QoL scores, a conclusion also
supported by previously discussed findings from INVEST.344
Finally, excessive reduction in BP is an important cause of
symptoms that impair QoL and is linked to adverse outcomes
among the elderly. In older persons, orthostatic hypotension
(decrease of SBP 20 mm Hg after 3 minutes of standing) is
common and is associated with increased CV risk. In the
Honolulu Heart Program, orthostatic hypotension was present
in 6.9% of 3522 Japanese-American men 71 to 93 years of
age and was a significant independent predictor of 4-year
all-cause mortality.137 Postprandial hypotension, defined as a
fall in SBP of 20 mm Hg 1 hour after a meal while sitting,
was associated with advanced age, higher baseline BP, and
use of vasodilating antihypertensive drugs,345 as well as with
increased overall total mortality (RR: 1.79; 95% CI: 1.19 to
2.68) among elderly individuals.346
2. Interactions Between Aging and Other CV
Risk Conditions Associated
With Hypertension
2.1. Family History of Premature Coronary
Artery Disease
Premature coronary disease is defined as a first-degree male
relative with established CAD at 55 years of age or a
first-degree female relative with established CAD at age 65
years.347 Although several studies have shown that the pres-
ence of a family history of premature coronary events
increases an individual’s risk for CV events anywhere from
2- to 12-fold,348,349 data on this relationship in older adults are
sparse. In the FHS, history of parental premature CAD in
persons 60 years of age was associated with a doubling of
CAD risk compared with a 3-fold risk increase in persons 30
to 59 years of age.350 Of note, this increased risk in older
persons was seen only in women. Thus, the limited data
available suggest an attenuated risk associated with a family
history of premature CAD in older adults.
2.2. Dyslipidemia
Concordance of dyslipidemia and hypertension is common;
both increase with aging and hence are management tar-
gets.351–354 The specific approach to management of dyslip-
idemia in the elderly, however, has rarely been consolidated
with that for hypertension.355 In the PROSPER (Prospective
Study of Pravastatin in the Elderly at Risk) trial, 60% of
subjects (mean age 75 years) had elevated low-density
lipoprotein cholesterol. In HYVET, the mean total cholesterol
was 205 mg/dL.4 Given the independent CVD risk associated
with both conditions and proven benefits of treatment across
age,356 it is reasonable to be aggressive with lipid lowering in
elderly patients with hypertension.
Elderly persons with hypertension are often treated with
statins because of concomitant hypercholesterolemia. The
CAFE´-LLA (Conduit Artery Function Evaluation-Lipid-
Lowering Arm) substudy of the ASCOT (Anglo-
Scandinavian Cardiac Outcomes Trial) included 891 patients,
mean age 63 years, randomized to atorvastatin or placebo,
with central aortic pressures and hemodynamic indices (radial
artery applanation tonometry) repeated over 3.5 years.357
Statin therapy, sufficient to significantly decrease CV events
in treated patients with hypertension in ASCOT, did not
influence central aortic BP or hemodynamics.357
However, in the UCSD (University of California, San
Diego) Statin Study, simvastatin and pravastatin significantly
lowered SBP by 2.2 mm Hg and DBP by 2.4 mm Hg in 973
adults without known CVD.358 A meta-analysis of 12 trials
including 69 984 patients, mean ages 55 to 75 years, treated
for at least 2 years, found that statin therapy significantly
reduced CV morbidity and mortality to the same extent in
patients with hypertension (by 22%) and nonhypertensive
patients (by 24%).359 Meta-regression also showed that the
efficacy of statins on reducing adverse outcomes was not
moderated by presence of hypertension at baseline.359
2.3. Diabetes Mellitus
Cumulative life-time risk for diabetes mellitus in the United
States increases exponentially between about 35 and 70 years
of age but then plateaus.360 Overall risk of diabetes mellitus
ranges from approximately 25% to 45% in men and approx-
imately 30% to 55% in women and is frequently associated
with hypertension. Risk of diabetes mellitus is higher in
Hispanics and non-Hispanic blacks versus non-Hispanic
whites. Elderly patients with hypertension and diabetes mel-
litus have a higher mortality risk than similarly aged controls
without diabetes mellitus.361,362
Hypertension is well recognized as an insulin-resistant
state. Among patients with hypertension, SBP level, fasting
glucose level, and thiazide diuretic and/or beta-blocker use
are independent risk factors for incident diabetes mellitus.363–
365 Although several of the previously referenced hyperten-
sion trials were comprised mostly of elderly patients, increas-
ing age was associated with less incident diabetes
mellitus.365,366
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Diabetes mellitus is a risk factor for development of HF
among those 65 years of age.367 The ONTARGET/ TRAN-
SEND (Ongoing Telmisartan Alone and in combination with
Ramipril Global Endpoint/Telmisartan Randomized Assess-
ment Study in ACE Intolerant Subjects With Cardiovascular
Disease) trials of 31 546 high-risk subjects (mean age 67
years, about 70% with hypertension, coronary, peripheral, or
cerebrovascular disease or diabetes mellitus with organ dam-
age) found fasting plasma glucose level was an independent
predictor of HF hospitalization.598 These data provide theo-
retical support for potential direct beneficial effects of low-
ering blood glucose in reducing HF risk and suggest need for
specific studies targeted at this issue.368
Elderly patients with diabetes mellitus have a higher
prevalence and incidence of microvascular and macrovascu-
lar complications,369 as well as excess mortality risk com-
pared to age-matched controls without diabetes mellitus.370
Albuminuria is a predictor of higher mortality risk among
those with diabetes mellitus.371 In older patients with type 2
diabetes mellitus, both high-office SBP and high-awake
ambulatory SBP independently predict albuminuria.372
2.4. Obesity and Weight Issues
Obesity and its clinical consequences have been described for
centuries,373 and obesity has reached epidemic proportions
worldwide.374 In the United States, the prevalence of obesity,
defined as a BMI30 kg/m2 in adults, has doubled from 15%
to 32.9% in the last 24 years, and 66.6% of adults are now
overweight (BMI 25 to 30 kg/m2) or obese.375 When ORs
were calculated to determine the prevalence of hypertension
in the period from 1999 to 2004 before and after adjustments
for BMI, the increases in BMI adjusted for age accounted for
nearly all the increases in hypertension in men and much of
the increase in women.33 Thus, in overweight or obese
elderly, including those with metabolic syndrome, obesityre-
lated health risks add to the pathophysiologic changes of
aging. These changes ultimately affect the structure of the
heart, blood vessels, and the kidneys and may adversely
affect CV and renal morbidity and mortality.376
2.4.1. Structural and Hemodynamic Changes
Obesity may be associated with increases in LV wall thick-
ness, volume, and mass independent of a patient’s BP.377
Pressure overload leads to thickening of the LV wall without
increasing cavity size. Myocyte thickening then leads to
concentric hypertrophy, and volume overload causes cavity
dilation, fiber elongation, and eccentric hypertrophy. Each of
these factors leads to elevated stroke work.377 Patients with
obesity-related hypertension have high intravascular volume,
high cardiac output, and a normal total peripheral resistance
when compared with lean patients with hypertension. The
high stroke volume in obese subjects is caused by increased
intravascular volume in the context of normal heart rate.378
Obese patients with hypertension are also characterized by a
circadian rhythm that does not show the expected BP drop
during sleep time (nondipping), and they respond to mental
stress with a higher increase in total peripheral resistance and
smaller increase in heart rate, stroke volume, and cardiac
output than lean patients with hypertension.379
In the LIFE study, the association of Cornell ECG voltage
criteria with greater body mass supported the known associ-
ation of anatomic LVH with obesity380 and showed obese,
elderly patients with hypertension had similar cardiac
changes previously described in younger patients: LVH with
a high prevalence of geometric abnormalities, especially
eccentric hypertrophy.381
2.4.2. Vascular Changes
Several metabolic and hormonal changes that occur in
obesity–hypertension are associated with impaired endothe-
lial function and premature atherosclerosis.382 Metabolic
syndrome and obesity have been linked to altered vasodila-
tion. Other markers such as arterial stiffness or intima-media
thickness increase in overweight or obese subjects and in
aging individuals. However, the contribution of obesity to
adverse outcome among elderly hypertensive patients is
unclear. An analysis from INVEST showed that in a well-
treated cohort with hypertension with CAD, increased BMI in
the elderly population was associated with decreased morbid-
ity and mortality compared with normal BMI.383
2.4.3. Role of the Sympathetic Nervous System
Increased sympathetic activity in obese subjects is associated
with an increased incidence of hypertension, arrhythmias, and
angina pectoris.384 This mechanism may also be important in
overweight or obese elderly subjects, as studies have shown
an age-dependent increase in plasma norepinephine levels in
individuals 50 years old385 and an increase in renal norepi-
nephine spillover in obese individuals.386 Plasma epinephrine
levels, by the contrary, tended to decrease with age.385
Furthermore, the reduction in baroreflex sensitivity in aging
may further stimulate norepinephrine production.387
This increased sympathetic nervous system activity in
obese subjects may be explained by dysregulation of the
hypothalamic-pituitary-adrenal axis and inappropriate re-
sponse to cortisol.388 Another mechanism that may increase
sympathetic nervous system activity in obese and elderly
subjects might be sleep apnea and resultant hypoxia and
hypercapnia.389 Sympathetic hyperactivity increases BP,
heart rate, cardiac output, and renal tubular sodium reabsorp-
tion, changes that occur as a consequence of increased alpha-
and beta-adrenergic receptor stimulation with a consequent
increase in RAAS activity.390
2.4.4. Role of the Renin-Angiotensin-Aldosterone System
In obesity, adipose tissue may contribute to RAAS activa-
tion,391 and a positive correlation has been found between
plasma angiotensin levels, plasma renin activity, angiotensin-
converting enzyme activity, and BMI.392 Adipose tissue
produces all components of the RAAS locally and may play
an autocrine, paracrine, and/or endocrine role in the develop-
ment of obesity–hypertension. Angiotensin II may also con-
tribute to the development of insulin resistance through its
effect on glucose metabolism.393
The RAAS may also contribute to systolic hypertension in
the elderly.394 Activation of the RAAS system at the tissue
levels contributes to the vascular inflammation and fibrosis
triggered by AII; renin and aldosterone may also contribute.
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These changes eventually induce vascular atherosclerosis and
organ failure.395
Recent studies have explored the genes that encode com-
ponents of the RAAS. Homozygosity for the D allele of the
ACE gene was found to be associated with abdominal
adiposity, obesity, and BP in individuals 54 years of age.396
In TONE (Trial of Nonpharmacological Intervention in the
Elderly), obese subjects with DD genotype had a significant
decrease in BP after weight loss, suggesting that this geno-
type may be linked with obesity–hypertension in the elderly
through an increase in AII activity and aldosterone produc-
tion.397 These findings reinforce the concept that obesity
within genetically susceptible individuals will cause
hypertension.
2.5. Microalbuminuria
Microalbuminuria, or urinary albumin excretion expressed as
an albumin-to-creatinine ratio 30 and 300 mg albumin/g
creatinine,398 on 2 separate first morning-voided collections,
is a marker for heightened CVD risk399–402 and may be a
marker for abnormal endothelial function. In people 60 to 74
years of age, an association between urinary albumin excre-
tion rate and mortality has been described.403 In elderly
subjects who did not have diabetes mellitus and were fol-
lowed for 3.5 years, microalbuminuria was a strong predictor
of CAD events.404,405 A separate prospective study of 70-
year-old men in the community support the observation that
microalbuminuria is a marker of subclinical CV damage that
predisposes to future HF.406 Specific prevalence data for
albuminuria focused on the elderly are lacking.407,408 Screen-
ing for albuminuria is recommended for all patients with
hypertension and concomitant diabetes mellitus and for those
with early CKD.23,409
2.6. Hyperhomocysteinemia
Hyperhomocysteinemia is a risk factor for endothelial dys-
function.410 Investigators have reported a positive association
between homocysteine levels and both SBP and DBP,411,412
including a possible causal relationship to ISH in older
individuals.413 Mechanisms that could explain the relation-
ship between homocysteine and BP include homocysteine-
induced arteriolar constriction, renal dysfunction and in-
creased sodium reabsorption, and increased arterial
stiffness.414 More research is needed to confirm these mech-
anisms and to establish whether lowering homocysteine with
folic acid is an effective treatment for older patients with
hypertension.
2.7. Gout
Gout incidence rates are 3 times higher for hypertensive
patients than for normotensive patients (P0.01).415 Thiazide
diuretics, often the preferred initial agent for treatment of
hypertension, increase serum uric acid levels and may pro-
voke gout.22,416,417 Both hypertension and diuretic use are
independent risk factors for gout.418 Serum uric acid indepen-
dently predicts CV events in older persons with ISH;419–421
therefore, monitoring serum uric acid change during diuretic
treatment is reasonable. Diuretics should be used cautiously
in elderly patients with hypertension with gout.22
2.8. Osteoarthritis and Rheumatoid Arthritis
Arthritis is a common problem in the elderly with important
implications for hypertension. Osteoarthritis affects approxi-
mately 10% of men and 20% of women 60 years of age,
and they may need medications to reduce pain and inflam-
mation.422 These medications usually include NSAIDs, which
are implicated in BP elevation that is proportional to the level
of BP prior to starting medication. Individuals with rheuma-
toid arthritis have excess risk for morbidity and mortality
from CVD, which in part may be due to hypertension,423 with
prevalence ranging between 52% and 73%.424–426 In rheuma-
toid arthritis, the chronic inflammatory burden may lead to
increased arterial stiffness, a physical cause of elevated
SBP.427 Drugs commonly administered to patients with rheu-
matoid arthritis, such as NSAIDS, cyclo-oxygenase-2 inhib-
itors,234 oral steroids,236 and some disease-modifying anti-
rheumatic drugs (eg, cyclosporine, leflunomide) may also
raise BP levels.428,429 Additionally, insulin resistance and
dyslipidemia are common comorbidities in rheumatoid arthri-
tis and are also associated with hypertension.430,431 Hyperten-
sion may be poorly controlled in older patients with rheuma-
toid arthritis compared with younger patients, possibly
because of suboptimal therapy or noncompliance.426 Thus,
hypertension cannot be addressed in isolation in the elderly
arthritis patient but must be considered in the context of other
CV risk factors and arthritis treatment.
3. Clinical Assessment and Diagnosis
3.1. Measurement of Blood Pressure
BP should be accurately and reliably measured and docu-
mented. The diagnosis of hypertension should be based on at
least 3 different BP measurements, taken on 2 separate
office visits to account for the natural variability of BP and
other factors that can affect BP. To confirm the validity and
reliability of the measurement, at least 2 measurements
should be obtained once the patient is comfortable and settled
for at least 5 minutes. BP should be measured in the sitting
position with the back supported, feet on the floor, arm
supported in the horizontal position, and the BP cuff at heart
level. The BP should also be measured with the patient
standing for 1 to 3 minutes to evaluate for postural hypoten-
sion or hypertension. This is particularly important in the
elderly because of stiff large arteries, age-related decreases in
baroreflex buffering, and autonomic dysregulation22 (see
Section 1.5.2.2). In the initial evaluation, BP should be
measured in each arm, and the arm with the highest BP used
for future BP monitoring. It is important to use an appropri-
ately sized cuff with a bladder that encircles at least 80% of
the upper arm circumference. An auscultatory gap, as defined
by the period during which sounds indicating true systolic
pressure fade away and reappear at a lower pressure point, is
more common in the elderly and is associated with vascular
disease. This is a common source of underestimating SBP in
the elderly. Elderly patients should also be evaluated for
post-prandial hypotension,345,432 which is especially common
in frail elderly patients on multiple antihypertensive and
psychotropic drugs.433 Pseudohypertension, discussed in de-
2464 Circulation May 31, 2011
tail in the following section, is another source of inaccurate
BP measurement in the elderly.
3.1.1. Pseudohypertension
Pseudohypertension refers to a falsely increased SBP that
results from markedly sclerotic arteries that do not collapse
during inflation of the BP cuff. Pseudohypertension occurs in
1.7% to 70% of the elderly,434–438 and this extreme range in
prevalence is likely due to methodological differences be-
tween studies. Thus, the actual prevalence is unclear. In the
elderly, the brachial arteries may become very thickened and
stiff due to arterial medial sclerosis and calcification.434,439
The BP reading measured with indirect techniques may be
falsely high if the artery is excessively thickened and there-
fore noncompressible.439 Although the Osler maneuver (ie,
the presence of a radial artery pulse that is still palpable after
the cuff is inflated above the systolic pressure) has been
recommended as a means to screen for pseudohypertension,
investigators have reported it to have questionable accuracy
and usefulness.438,439 Correct identification of pseudohyper-
tension is necessary to avoid overtreating high BP and should
be suspected in elders with refractory hypertension, no organ
damage, and/or symptoms of overmedication.440 Confirma-
tion of pseudohypertension requires direct intraarterial mea-
surement of BP.441
3.1.2. White-Coat Effect and White-Coat Hypertension
When assessing BP in the elderly, both the white-coat effect
and white-coat hypertension need to be considered, with
prevalence rates between 15% and 25%.442,443 Elderly indi-
viduals tend to exhibit more white-coat effect (ie, transient
BP elevations when in a medical environment) than younger
individuals.444,445 White-coat hypertension, a term reserved
for those not on antihypertensive medication but with persis-
tently elevated office BP (140/90 mm Hg) together with a
normal daytime ambulatory BP (135/85 mm Hg), is also
more common in the elderly and is more frequent among
centenarians.446,447 Ambulatory BP monitoring is recom-
mended to confirm a diagnosis of white-coat hypertension in
patients with office hypertension but no organ damage.22
3.1.3. Ankle Blood Pressure
Ankle BPs measure subclinical atherosclerosis.448 In healthy
individuals, ankle SBPs are slightly higher than the arm, but
as occlusive disease develops in the lower extremities, the
systolic pressure at the level of the ankle decreases.448,449 The
finding of a reduced ankle-to-brachial artery BP ratio (ankle-
brachial index) indicates atherosclerosis of the lower extrem-
ity arteries. The prevalence of an abnormal ankle-brachial
index (0.9) increases dramatically with age. In 1 study, this
prevalence increased from 5.6% in persons 38 to 59 years of
age, to 15.9% in persons 60 to 69 years of age, and to 33.8%
in persons 70 to 82 years of age.303 The prevalence of PAD,
defined by an ankle-brachial index 0.9, was 29% in 6979
men and women (mean age 69 years) screened because they
were 70 years of age or were 50 to 69 years of age with
either a history of cigarette smoking or diabetes mellitus.
Among these patients with PAD, classic claudication was
present in only 11%.450 An ankle-brachial index of 0.9 is
associated with a significantly increased risk of CVDs (in
particular MI and stroke) that is independent of other risk
factors.449,451 At 10-year follow-up of 565 men and women
(mean age 66 years), PAD significantly increased the risk of
all-cause mortality (RR: 3.1), CV mortality (RR: 5.9), and
mortality from CAD (RR: 6.6).305 High values of an ankle-
brachial index also carry risk for mortality in adults, including
the elderly.451,452 An ankle-brachial index 1.30 suggests a
noncompressible, calcified vessel.306 Among older adults,
low and high ankle-brachial index values carry elevated risk
for CV events (coronary heart disease, stroke, and congestive
HF).451 Noncompressible leg arteries carry elevated risk for
stroke and congestive HF specifically.451
3.2. Ambulatory Blood Pressure Monitoring
Application and feasibility of automated ambulatory BP
monitoring in the elderly are comparable to younger age
groups.443 Major side effects are sleep disturbances and pain
during cuff inflation.443 Main indications for ambulatory BP
monitoring are for patients in whom the diagnosis of hyper-
tension or response to therapy is unclear from office visits.
Further indications include suspected syncope or hypotensive
disorders, evaluation of vertigo, and dizziness.443 Ambulatory
BP monitoring is also important for avoiding overtreatment in
the elderly with whitecoat hypertension and also to ensure
diagnosis and treatment of those with masked
hypertension.453
Ambulatory BP is a better predictor of risk than clinic or
office BP measurement in older patients with ISH.454,455 After
adjustment for clinical BP measurements, ambulatory day
time, night time, and 24-hour SBP all independently predict
CV mortality.454 For each 10 mm Hg increase in daytime SBP
and nighttime SBP, CV death increased 10% and 18%
respectively, but the same increase in clinic SBP was not
associated with a significant mortality increase.455 Elevated
SBPs, while awake and/or asleep, by ambulatory BP moni-
toring, in subjects (mean age 70.49.9 years) over 5023
months predicted increased risk of CVD more accurately than
clinic BP in those with or without diabetes mellitus,456 and
others have confirmed these findings.454 Heart rate dipping
ratios, and an ambulatory arterial stiffness index using am-
bulatory BP monitoring may add significantly to prediction of
mortality in the elderly population who do not have diabetes
mellitus.457
3.3. Out-of-Office Blood Pressure Recordings
The case for using out-of-office BP readings with the elderly,
particularly home BP measurements, is strong due to the
potential hazards of excessive BP reduction in older peo-
ple.458 Home BP monitoring alone may be as useful as clinic
measurements for treatment decisions in the elderly.459 Oth-
ers have suggested that home BP measurement has a better
prognostic accuracy than office BP measurement.460 The
difference between the office and home BP (the white-coat
effect) increases progressively with age, so that the office BP
tends to overestimate the out-of-office BP more in older than
younger people; variability of systolic home BP also in-
creases with age.461 Monitors that measure BP with an upper
arm cuff are the most reliable.458 Wrist monitors provide
convenience and the potential advantage of use with elderly
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patients who are obese in whom putting on an upper arm cuff
is difficult,458 but these monitors must be held at the level of
the heart when a reading is taken. If this does not occur, there
is an increased possibility of erroneous readings. Addition-
ally, most wrist monitors that have been tested have failed
validation studies; thus, they are not usually recommended
for routine clinical use.458
Home BP measurement has disadvantages that need to be
considered before advising elderly patients to purchase and
take their BPs at home. Individuals with cognitive and
physical disabilities are potentially unable to operate a home
BP monitor.462 Although automatic electronic devices are
more convenient and easier to use, aneroid manometers with
a stethoscope require manual dexterity and good hearing.
Additionally, the automated devices available for self-
measurement all use the oscillometric technique where small
oscillations in cuff pressure are used to identify SBP, mean,
and DBP.463,464 Unfortunately, oscillometric techniques can-
not measure BP in all patients, especially patients with
arrhythmias, such as rapid ventricular rate in a patient
with AF, an arrhythmia common among the elderly patients
with hypertension.463
Finally, there can be substantial observer error in reporting
of self-measured BP values.465 Diaries completed by patients
recording BP over time lack reliability. Erroneous reporting
occurs more often in cases of uncontrolled BP and heart rate,
conditions more common in the elderly.466 Memory-equipped
devices and/or telemonitoring are strategies to overcome
unreliable reporting, but both strategies add to nonreimburs-
able costs of providing care for elderly patients.
3.4. Clinical Evaluation
There is limited evidence to provide evidence-based recom-
mendations on history, physical examination, or testing for
evaluating elderly patients with hypertension.22,23,467,468 As
such, the following recommendations are based on expert
opinion, rather than evidence, but we believe they provide a
reasonable clinical approach.
Typical evaluation includes a history and physical exami-
nation and ordering laboratory or other diagnostic or prog-
nostic tests. A good history and examination are the starting
point for the clinical evaluation.468 However, given the time
constraints of a typical outpatient encounter, often in the
range of 10 to 15 minutes, it is most important to hone in on
aspects of the history and examination that relate to hyper-
tension. These include historical issues such as duration and
severity of high BP, causes or exacerbations of high BP,
current and previous treatments (including adverse effects of
medications or other interventions), target organ damage,
other CVD risk factors and overall CVD risk, and comorbidi-
ties that can affect hypertension management and prognosis.
Because high BP is a risk factor for CV, peripheral vascular,
cerebrovascular, renal, and ophthalmologic disease, the his-
tory and examination should look for evidence of organ
damage in these systems. The examination, in addition to the
organ systems noted above, should include the patient’s
weight and waist circumference at the level just above the
anterior superior iliac crests.
Many guidelines advocate “routine laboratory testing” in
evaluation of patients with high BP. Despite such recommen-
dations, there is little evidence to support routine laboratory
testing, and clinicians should take a more deliberative and
reasoned approach to ordering tests. Routine testing in-
creases costs and may have adverse effects such as anxiety,
pain/discomfort, additional testing, complications from
such testing, and time and travel burden. In elderly
patients, the burden of getting to appointments is often
greater, and the elderly may suffer more discomfort during
testing. Many elderly patients also will have had laboratory
tests performed recently for other reasons, so obtaining
copies of these tests is more cost-effective than repeating
them. In general, tests should only be ordered if they will
help the clinician make a diagnosis or establish a prognosis
and if the result is likely to affect decisions regarding
management.
The most important role for testing in an elderly patient
with hypertension is to assess for organ damage and modifi-
able CVD risk factors, including tobacco smoking, hypercho-
lesterolemia, diabetes mellitus, and excessive alcohol in-
take.469–472 Information on the following laboratory tests
should be available:
1. Urinalysis to look for any evidence of renal damage,
especially albuminuria/microalbuminuria
2. Blood chemistry to assess electrolytes and renal func-
tion, especially potassium and creatinine with eGFR
3. Total cholesterol, low-density lipoprotein cholesterol,
high-density lipoprotein cholesterol, and triglycerides,
preferably fasting levels
4. Fasting blood sugar and, if there are concerns about
diabetes mellitus, hemoglobin A1c
5. ECG
At this time, we cannot routinely recommend other labo-
ratory tests unless there are other indications for such testing.
In selected elderly persons, 2-dimensional echocardiography
should be considered because it is more sensitive and more
specific in diagnosing LVH than is ECG and has a greater
prognostic value. In addition, echocardiography may detect
abnormalities in LV function that would warrant additional
therapy (ie, ACEIs, beta blockers). Future studies could lead
to additional tests being recommended if evidence becomes
available that such testing leads to improvements in important
health outcomes.
A 12-lead ECG is recommended to assess for evidence of
underlying cardiac abnormalities or previous cardiac damage
and to provide a baseline for future comparison. However,
many elderly patients will have had a recent ECG performed
for a variety of reasons, so obtaining a copy of a recent ECG,
especially if it is less than a year old, should at least be
attempted before ordering another ECG. Additional testing to
identify specific causes of high BP are generally not indicated
unless the history, physical examination, or testing reveals an
abnormality that arouses suspicion or if BP is not well
controlled despite adequate dosing of multiple medications
and good patient compliance.
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4. Recommendations for Management
4.1. General Considerations
4.1.1. Blood Pressure Measurement and Goal
Reliable, calibrated BP measurement equipment is critical for
hypertension management in any age group, and these con-
siderations are detailed in Section 3.1. As discussed, the
general recommended goal BP in persons with uncomplicated
hypertension is 140/90 mm Hg. However, this target for
elderly patients with hypertension is based on expert opinion
rather than on data from RCTs, and it is unclear whether the
target SBP should be the same in 65 to 79 year olds versus
older patients.
4.1.2. Quality of Life and Cognitive Function
The decision to initiate antihypertensive therapy in the elderly
should include consideration of potential impact on QoL.
Although the high rate of comorbid conditions and need for
polypharmacy influence compliance, these factors also have
QoL and economical impacts for patients and their families.
Because symptomatic well-being, cognitive function, activ-
ity, and sexual function have already been diminished by
aging and disease, it is important to give particular attention
to these QoL areas when making therapy decisions.473 In
general, trials confirm long-term antihypertensive treatment
does not necessarily negatively impact QoL; however, some
specific drug classes may do so. The TONE study474 found
benefits were similar among hypertension patients treated
with diuretics, beta blockers, CAs, and ACEIs, but beta
blockers increased depressive symptoms. Conversely, other
antihypertensive medications may be associated with benefi-
cial effects on QoL. For example, among elderly patients with
hypertension with mild cognitive impairment (Mini-Mental
State Exam score 24 to 28), SCOPE475 found no difference in
cognitive outcomes between treatment groups overall, with
evidence suggesting that candesartan may prevent cognitive
decline. However, BP reduction was greater (2.5/1.9 mm Hg)
with candesartan, also suggesting that better BP control may
delay cognitive decline.259 A SCOPE substudy reported that
“good” health-related QoL was preserved in the presence of
substantial BP reduction with an advantage among
candesartan-treated patients in 4 health-related QoL vari-
ables.476 Existing data do not associate hypertension treat-
ment in the elderly with significant impairment in QoL, but
there is potential for differences in adverse and beneficial
effects among drug classes.336
4.1.3. Nonpharmacological Treatment:
Lifestyle Modification
Lifestyle modifications may be the only treatment necessary
for preventing or even treating milder forms of hypertension
in the elderly (Table 5).469 Smoking cessation, reduction in
excess body weight and mental stress, modification of sodium
and alcohol intake, and increased physical activity may also
reduce antihypertensive drug doses needed for BP con-
trol.470,471,477–479 Unfortunately, national surveys indicate that
nutrition and exercise counseling are provided at only 35%
and 26% of visits, respectively, in hypertension patients, and
patients 75 years of age are least likely to receive such
counseling.480
Smokers 65 years of age benefit greatly from absti-
nence.202,481–484 Older smokers who quit reduce their risk of
death from CAD, chronic obstructive pulmonary disease,
lung cancer, and osteoporosis.485–487 Age does not appear to
diminish the desire to quit488 or the benefits of quitting.489,490
Treatments shown effective in the US Department of Health
and Human Service’s Guideline have also been shown to be
effective in older smokers.481 Medicare has expanded benefits
for tobacco cessation counseling and prescription medica-
tions for treating tobacco dependence.491 However, smokers
65 years of age are less likely to be prescribed smoking
cessation medications.492 Because of issues common in the
elderly, such as difficulty with mobility and travel, use of
interventions such as telephone counseling may be particu-
larly applicable.
Weight reduction lowers BP in overweight individuals: A
meta-analysis of 18 trials concluded that loss of 3% to 9% of
body weight reduces systolic and DBP about 3 mm Hg
each.493 In the TONE study, a diet that reduced weight by a
3.5 kg lowered BP by 4.0/1.1 mm Hg among 60- to
Table 5. Lifestyle Modifications to Manage Hypertension
Lifestyle Modifications to Manage Hypertension*
Modification Recommendation Approximate Systolic BP Reduction, Range
Weight reduction Maintain normal body weight (BMI, 18.5–24.9 kg/m2) 5–20 mm Hg/10-kg weight loss160,514,515
Adopt DASH eating plan Consume a diet rich in fruits, vegetables, and low-fat dairy products with
a reduced content of saturated and total fat
8–14 mm Hg516,517
Dietary sodium reduction Reduce dietary sodium intake to no more than 100 mEq/L (2.4 g sodium
or 6 g sodium chloride
2–8 mm Hg160,516–518
Physical activity Engage in regular aerobic physical activity such as brisk walking (at least
30 min/d, most days of the week)
4–9 mm Hg477,511,519
Moderation of alcohol consumption Limit consumption to no more than 2 drinks/d (1 oz or 30 mL ethanol
[eg, 24-oz beer, 10-oz wine, or 3-oz 80-proof whiskey]) in most men
and no more than 1 drink/d in women and lighter-weight persons
2–4 mm Hg478
BMI indicates body mass index calculated as weight in kilograms divided by the square of height in meters; BP, blood pressure; and DASH, Dietary Approaches
to Stop Hypertension.
Modified from Chobanian et al.22
*For overall cardiovascular risk reduction, stop smoking. The effects of implementing these modifications are dose and time dependent and could be higher for
some individuals.
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80-year-old patients with hypertension.494 Combining weight
reduction with sodium restriction in TONE resulted in greater
benefit.
Dietary sodium restriction is perhaps the best-studied
lifestyle intervention for BP reduction. A meta-analysis of 56
RCTs found mean BP reduction of 3.7/0.9 mm Hg for a
100 mmol/day decrease in sodium excretion; BP declines
were generally larger in older adults.495 Strongest evidence
for sodium restriction in older persons comes from TONE.160
In patients 60 to 80 years of age with BP 145/85 mm Hg
while taking 1 antihypertensive drug, mean BP reduction of
4.3/2.0 mm Hg occurred after 3 months of sodium restriction
to 80 mmol/d coupled with medication withdrawal and 30 to
45 minutes brisk walking most days.494 However, BP and
adverse outcome reductions did not achieve statistical signif-
icance in 70 to 80 year olds. Other studies have confirmed
benefits of lifestyle modification in older subjects for BP
control.496–501
Increased potassium intake, either by fruits and vegetables
or pills, reduces BP. In a meta-analysis of 33 RCTs, potas-
sium supplements significantly lowered BP by 3.1/2.0 mm
Hg, and this effect was enhanced in persons with higher
sodium intake.502 Two trials in this meta-analysis confirmed
significant BP reductions (4.3/1.7 mm Hg and 10.0/
6.0 mm Hg, respectively503,504) among elderly patients with
hypertension. The DASH diet showed a mean BP decrease of
11.4/5.5 mm Hg in patients with hypertension (mean age 47
years) with a diet enriched with fruits and vegetables and low
in saturated and total fat.505 Similar BP reductions were seen
in those 45 years of age.506 The DASH combination diet
lowered SBP more in African Americans (6.8 mm Hg) than in
whites (3.0 mm Hg) (P0.05) and in persons with hyperten-
sion (11.4 mm Hg) than in persons without hypertension
(3.4 mm Hg) (P0.05). Potassium supplementation
(90 mmol [3500 mg] daily) reduces BP in individuals with
and without hypertension,502,507 and effects are greater in
individuals with higher dietary sodium levels.469 In elderly
patients with substantially impaired renal function, serum
potassium should be monitored when supplementation is
given.
Calcium and magnesium supplementation results in mini-
mal to no change in BP. However, it is prudent to include
adequate calcium in the diet.469,508 There is no evidence that
vitamin, fiber, or herbal supplements influence BP in the
elderly.469,470,509
Consumption of 2 alcohol drinks per day is strongly
associated with BP elevations in epidemiologic studies.
Although several small RCTs demonstrate significant BP
declines after reduced alcohol intake, few older patients are
included. In the multicenter PATHS (Prevention and Treat-
ment of Hypertension Study), reduction of alcohol intake by
a mean of 1.3 drinks/d in patients (mean age 57 years)
resulted in a nonsignificant BP decrease of 1.2/0.7 mm Hg;
similar BP reductions of 1.9/0.6 mm Hg occurred in hyper-
tension patients.510 Thus, evidence for meaningful BP reduc-
tion from lowering alcohol intake is limited in older adults.
Among the benefits of aerobic exercise training is BP
reduction. A meta-analysis of 54 RCTs found aerobic exer-
cise programs reduced BP about 3.8/2.6 mm Hg among 21 to
79 year olds, but an analysis by age was not provided.477
Exercise modality, frequency, intensity, and presence or
absence of hypertension did not significantly affect the
magnitude of BP decline. Trials in older patients with
hypertension show BP reductions from aerobic training. In 33
such individuals 60 to 69 years of age, 9 months of training
3 times weekly at either 53% or 73% peak aerobic capacity
elicited BP reductions averaging 7/3 mm Hg and 6/9 mm Hg,
respectively.511 In 70 to 79 year old patients with hyperten-
sion, BP reductions of 8/9 mm Hg occurred after 6 months
training at 75% to 85% peak aerobic capacity.512 In sedentary
men (mean age 59 years) with prehypertension, 9 months of
aerobic training 3 days per week elicited a BP reduction of
9/7 mm Hg; men who combined exercise and a weight loss
diet had a 11/9 mm Hg decline.513 Thus, aerobic exercise
alone or combined with a weight reduction diet reduces BP in
older adults with hypertension. The finding that exercise at
moderate intensities elicits BP reductions similar to those of
more intensive regimens is especially meaningful for the
elderly.
4.1.4. Management of Associated Risk Factors and
Team Approach
Most guidelines for treatment of hypertension or dyslipid-
emia emphasize risk estimates obtained from an overall or
global instrument such as the Framingham Risk Score for
predicting MI, stroke, or CVD in general520 or its modifica-
tions such as the Reynolds score521 or scores developed in
other countries, including Q-risk derived from practices in the
United Kingdom.522 These algorithms emphasize age and
classify all persons 70 or 75 years of age as high risk (ie,
10% risk of CAD in next 10 years), thus deserving therapy.
Therefore, older patients with hypertension may be classified
at high or very high risk (eg, those with diabetes mellitus).
Patient preferences and values are also important in deciding
on the advisability and mode of therapy, especially in older
individuals where QoL sometimes becomes more important
than duration.
Several trials including some subjects with hyperten-
sion351,353,355,523–525 have evaluated multiple risk interven-
tions. Subgroup post hoc analyses have not suggested that
elderly subgroups differed from younger subgroups in re-
sponse to risk factor management. This management is
fostered by behavioral interventions that focus on re-
enforcement techniques to enhance engagement of elderly
individuals in their own care employing a team. The team
should ideally be composed of clinical pharmacists, nurses,
physician assistants, clinical psychologists, and others (as
necessary). Communication with and compliance by elderly
patients might be facilitated by interactions at group visits
with caregivers or counselors. Technology enhancements to
achieve these goals span the spectrum from simple printed
prompts and reminders through complex systems of telemedi-
cine and text messaging.
4.2. Pharmacological Management
4.2.1. Considerations for Drug Therapy
4.2.1.1. Evidence Before Hyvet
In the mid-1980s, the EWPHE (European Working Party on
High Blood Pressure in the Elderly)526 demonstrated that,
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among patients 60 years of age with BPs 160 mm Hg
systolic and/or 90 mm Hg diastolic, drug treatment reduced
CV events. Other studies extended beneficial effects of
antihypertensive drugs to patients 70 years of age11,15,18,527
and elderly patients with ISH (ie, SBP160 mm Hg but DBP
95 or 90 mm Hg).20,528,529 Meta-analyses45,249 are the basis
on which to recommend drug treatment for elderly patients
with hypertension.22,23,530,531 A greater degree of caution is
required in older patients because of alterations in mecha-
nisms responsible for drug disposal as well as changes that
occur in homeostatic CV control532 as well as QoL factors
discussed in the preceding text.
Most patients recruited in antihypertensive trials in the
elderly were 80 years old, thus limiting information about
octogenarians. Pooling the limited number (n1670) of
patients 80 years of age from trials mainly composed of
younger patients249 provided data difficult to interpret. Com-
pared with controls, treated patients showed a reduction in the
incidence of both stroke and CV morbidity but a trend toward
increased all-cause mortality. So the overall benefits of
treating a cohort 80 years old seemed questionable. Thus,
despite epidemiologic evidence that hypertension remains a
risk factor in 80 to 89 year olds,533,534 guidelines avoided firm
recommendations on drug treatment in octogenarians with
statements like “in subjects aged 80 years or over, evidence
for benefits of antihypertensive treatment is as yet inconclu-
sive.” However, they added that “there is no reason for
interrupting successful and well-tolerated therapy when a
patient reaches 80 years” (p. 1497).534a
4.2.1.2. Evidence After Hyvet
Results of HYVET4 modify previous recommendations for
patients 80 years of age. In HYVET, 3845 patients 80
years of age with SBP160 mm Hg were randomly assigned
to placebo or drug therapy. The latter included a non-thiazide
sulphonamide diuretic (indapamide) supplemented by an
ACEI (perindopril) when needed for target SBP of
150 mm Hg. After 2 years, with about one fourth of the
patients using monotherapy and three fourths combination
therapy, the trial was stopped because drug treatment, al-
though decreasing BP compared with the placebo group
(144/78 mm Hg versus 161/84 mm Hg), reduced adverse
outcomes. This consisted of reductions in the incidence of
stroke (30%), congestive HF (64%), and CV morbid and
fatal events (23%). Most impressively, there was a signif-
icant reduction (21%) in the incidence of all-cause death.
Of importance, drug treatment was well tolerated. The reduc-
tion in BP in the standing position was similar to that in the
sitting position. Furthermore, serum electrolyte and biochem-
ical values were similar in drug- and placebo-treated groups.
In fact, fewer serious adverse events were reported in the
drug-treated than in placebo-treated patients.4
The HYVET results provide clear evidence that BP low-
ering by drugs is associated with definite CV benefits in
patients 80 years of age. They not only refute concern that
this may lead to an increase, rather than a decrease in
mortality, but also show that in this stratum of the population,
there is a prolongation of life. This finding is highly relevant
for public health because subjects 80 years of age represent
the fastest growing fraction of the population; the prediction
is that by 2050, they will account for more than one fifth of
all elderly individuals.535
However, HYVET has some limitations that should be
taken into account when considering antihypertensive treat-
ment in very elderly patients. Patients with stage 1 hyperten-
sion were not included. Patients on whom HYVET results are
based are not representative of the general very elderly
population. First, to limit dropouts, recruitment focused on
patients in relatively good physical and mental condition and
with a low rate of previous CVD. This is at variance from the
high rate of frail and medically compromised patients typical
in this very old age range. Second, because identifying
appropriate subjects was difficult, recruitment required about
6 years and was only possible through participation of
Eastern European countries and China, which together ac-
counted for 98% of the patients. Furthermore, premature
interruption of the trial (because of mortality benefit) made
average follow-up relatively short (median 1.8 years). It
remains unknown whether benefits of antihypertensive treat-
ment persist or diminish after 2 or 3 years. Also, the mean age
was 83 years, and only a small fraction was85 years of age,
which leaves open the question whether the benefit extends to
ages much older than those investigated in previous trials.
Compared with placebo, drug treatment was not accompanied
by significant improvement in the incidence of dementia or
cognitive dysfunction.260 Finally, the optimal BP goal for
reducing CV events and mortality was not investigated.
4.2.2. Initiation of Drug Therapy
The initial antihypertensive drug should be started at the
lowest dose and gradually increased depending on the BP
response to the maximum tolerated dose. If the antihyperten-
sive response to the initial drug is inadequate after reaching
full dose (not necessarily maximum recommended dose), a
second drug from another class should be added, provided the
initial drug is tolerated. If the person is having no therapeutic
response or significant adverse effects, a drug from another
class should be substituted. If a diuretic is not the initial drug,
it is usually indicated as the second drug. If the antihyperten-
sive response is inadequate after reaching the full dose of 2
classes of drugs, a third drug from another class should be
added. When the BP is 20/10 mm Hg above goal, drug
therapy should generally be initiated with 2 antihypertensive
drugs, 1 of which should be a thiazide diuretic; however, in
the elderly, treatment must be individualized.22
Before adding new antihypertensive drugs, possible rea-
sons for inadequate BP response should be examined. These
include noncompliance, volume overload, drug interactions
(eg, use of NSAIDs, caffeine, antidepressants, nasal decon-
gestants containing sympathomimetics), and associated con-
ditions such as obesity, smoking, excessive intake of alcohol,
insulin resistance, and pseudoresistance.22 Pseudoresis-
tance536 is an inadequate response to antihypertensive therapy
because the BPs measured in the physician’s office are falsely
high compared with those measured at home or by 24-hour
ambulatory BP monitoring. Causes of secondary hyperten-
sion should be identified and treated.22,537
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Polypharmacy and potential drug interactions are a greater
concern in the elderly than in younger patients. The average
elderly patient is taking 6 prescription drugs. Medications
likely to be used in the elderly that increase BP include
NSAIDS, corticosteroids, erythropoietin, amphetamines, er-
gotamine, and anabolic steroids. Agents that increase the
antihypertensive effect of beta blockers and CAs include
cimetidine, antifungal azolides, and grapefruit juice.538,539 A
detailed list of drug interactions is included (Table 6).
4.2.2.1. Specific Drug Classes
This section reviews the rationale for pharmacological treat-
ments in elderly subjects, some general considerations, and
experiences with specific drug classes. There is strong clini-
cal trial–based evidence that elderly patients with hyperten-
sion benefit greatly from pharmacological BP reduction.541–
546 This evidence shows that treatment reduces both CV and
cerebrovascular morbidity and mortality. A meta-analysis (31
trials with 190 606 participants) showed that BP reduction
produces benefits in older adults with no strong evidence that
protection against major CV events afforded by different drug
classes varies substantially with age.251 Individual drug
classes are reviewed in the following text, and their suggested
use in treating hypertension is summarized in Figure 10.
Age-related physiologic changes that may affect absorp-
tion include reduced gastric acid secretion and emptying rate,
reduced splanchnic blood flow, and decreased mucosal ab-
sorptive surface area (Table 7). Yet, oral absorption of CV
drugs is not significantly affected by aging, probably because
most drugs are absorbed passively.547 Drug distribution may
be altered in the elderly secondary to decreased lean body
mass and relative increased body fat. Age-related declines in
renal or hepatic function alter drug disposition in elderly
patients, mostly as a result of declines in first-pass metabo-
lism. This decline decreases total body clearance and in-
creases elimination half-life. Individualized dose adjustments
or dosing schedules help to decrease adverse effects.548
Pharmacokinetic changes, route of elimination, and dosage
adjustment for antihypertensive drugs used among the el-
derly, are summarized in Table 8.
4.2.2.1.1. Diuretics
4.2.2.1.1.1. Thiazides. Thiazide diuretics, such as HCTZ,
chlorthalidone, and bendrofluazide (bendroflumethiazide), a
mainstay of antihypertensive treatment in the elderly, are
recommended for initiating therapy.22 Chlorthalidone differs
from HCTZ by its longer duration of action and greater
potency, and for this reason, may be associated with a higher
risk of metabolic adverse effects. Diuretics cause an initial
reduction in intravascular volume, peripheral vascular resis-
tance,551–553 BP in 50% of patients, and are generally well
tolerated and inexpensive. Several trials demonstrate their
ability to also reduce CV, cerebrovascular, and renal adverse
outcomes in the elderly.
Aging-related, physiological changes can be exacerbated
with diuretics. The elderly have contracted intravascular
volumes with impaired baroreflexes, and diuretics cause
sodium and water depletion (hypovolemia) and orthostatic
hypotension. Older people have a high prevalence of LVH,
which predisposes to ventricular ectopy and sudden death.
Diuretics can cause hypokalemia, hypomagnesemia, and
hyponatremia, which can increase arrhythmias. Hypokalemia
and hypomagnesemia can develop within the first few days of
treatment. However, after that, the body can achieve a new
homeostatic balance, and loss of these ions is lessened.
Nevertheless, these agents are not advised in patients with
baseline electrolyte abnormalities, and when they are used,
serum potassium levels should be monitored and supplemen-
tation given if needed.554 With aging, renal blood flow and
GFR decrease; diuretics can further decrease renal blood
flow, creatinine clearance, and GFR. The elderly have a
tendency toward hyperuricemia and glucose intolerance. The
latter is a particular concern for hypertension patients because
many have insulin resistance and related coronary vascular
dysfunction.555,556 Diuretics can increase uric acid levels and
need for antigout therapy in patients 65 years of age with
hypertension,364,417 as well as glucose intolerance, and dys-
lipidemia.557 However, their long-term use has been associ-
ated with an overall decrease in serum cholesterol levels.
Because of side effects, about 3.6% of patients withdrew
from the MRC (Medical Research Council) trial (less than the
beta-blocker group)15 and 15% (comparable to other drug
groups) withdrew from ALLHAT.9 In SHEP, the most
frequent adverse event was abnormal serum electrolyte lev-
els.16 Despite these side effects, diuretics have reduced CV
events in the elderly to a similar extent as other drug classes,
except for findings in ACCOMPLISH,8 when combined with
an ACEI discussed elsewhere.
4.2.2.1.1.2. Other Diuretics. Indapamide, a non-thiazide
sulfonamide diuretic, was used in several hypertension trials
that included elderly patients (HYVET, PROGRESS, etc.).
This drug also increases blood glucose but not uric acid and
may cause hyponatremia. Because indapamide reduces the
renal clearance of lithium, caution is advised in using this
combination. Furosemide and its analogs (bumetanide or
torsemide) are loop diuretics used for hypertension (AASK
[African American Study of Kidney Disease])558 when com-
plicated by HF or CKD. They also increase blood sugar
levels, and may cause headaches, fever, anemia, and/or
electrolyte disturbances.
Potassium-sparing diuretics, mineralocorticoid antagonists
(spironolactone and eplerenone), and epithelial sodium trans-
port channel antagonists (amiloride and triamterene) are
useful in hypertension when combined with other agents.
Because vascular stiffness and endothelial nitric oxide pro-
duction are influenced by sodium ion under control of the
mineralocorticoid receptor, these agents reduce vascular stiff-
ness and SBP.559 Alternately, an increase in potassium softens
vascular endothelium and increases nitric oxide release.
These drugs are also useful for patients with hypertension
with HF or primary aldosteronism. Gynecomastia and sexual
dysfunction are limiting adverse reactions for men treated
with spironolactone, but these are less frequent with epler-
enone.189 The epithelial sodium transport channel inhibitors
have minimal effects on BP as monotherapy and are most
useful for their potassium-sparing effects when combined
with another diuretic. The combination of a HCTZ and
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Table 6. Drug Interactions
Drug Class/Drug Interacting Drug Mechanism Consequence Prophylaxis
Beta blockers
All beta blockers (hemodynamic
interactions)
Calcium antagonists, especially
nifedipine
Added hypotension Risk of myocardial ischemia BP control, adjust doses
Verapamil or diltiazem; flecainide;
most anesthetics
Added negative inotropic effect Risk of myocardial failure; hypotension Check for CHF; adjust doses;
flecainide levels
(electrophysiologic interactions) Verapamil; diltiazem Added inhibition of SA, AV nodes;
added negative inotropic effect
Bradycardia, systole, complete HB,
hypotension
Exclude “sick-sinus”
syndrome; AV nodal disease,
LV failure
Amiodarone Added nodal inhibition Bradycardia, HB Exclude nodal disease
All lipid-soluble beta blockers (hepatic
interactions): carvedilol, labetalol,
metoprolol, propranolol, probably timolol
Inhibitors of hepatic CYP2D6;
cimetidine, ritonavir, quinidine
Decreased hepatic breakdown of the
lipid-soluble beta blocker
Excess beta-blocking effects Avoid interaction or reduce
beta-blocker dose
Calcium antagonists
Verapamil (V) Beta blockers SA and AV nodal inhibition; myocardial
failure
Added nodal and negative inotropic
effects
Care during cotherapy; check
ECG, BP, heart size
Digitalis poisoning Added SA and AV nodal inhibition Asystole; complete HB after IV V Avoid IV V
Digoxin (D) Decreased D clearance; inhibition of
P-glycoprotein
Risk of D toxicity Halve D dose; blood D level
Disopyramide Pharmacodynamic Hypotension, constipation Check BP, LV, and gut
Flecainide (F) Added negative inotropic Hypotension Check LV; F levels
Prazosin and other alpha blockers Hepatic interaction Excess hypotension Check BP during cotherapy
Quinidine (Q) Added alpha receptor inhibition; V
decreased Q clearance
Hypotension; increased Q levels Check Q levels and BP
Beta blockers Added SA nodal inhibition; negative
inotropism
Bradycardia Check ECG and LV function
Diltiazem Digoxin (D) Some fall in D clearance Only in renal failure Check D levels
Flecainide (F) Added negative inotropic effects Hypotension Check LV; F levels
Nicardipine (see also nifedipine) Digoxin (D) Decreased D clearance Blood D doubles Decrease; check D levels
Beta blockers; propranolol (P) Added negative inotropism N and P
have opposite effects on blood liver
flow
Excess hypotension N decreased P
levels; P increases N levels
Check BP, use low initial
dose; readjust P and N
doses if needed
Digoxin (D) Minor/modest changes in D Increased D levels Check D levels
Nifedipine (N) Prazosin (PZ), other alpha
blockers
PZ blocks alpha-reflex to N Postural hypotension Low initial dose of N or PZ
or other alpha blockers
Quinidine (Q) N improves poor LV function; Q
clearance faster
Decreased Q effect Check Q levels
Diuretics
Loop and thiazide NSAIDs Pharmacodynamic Decreased anti-hypertensive effect Adjust diuretic dose or add
another agent
Probenecid Decreased intratubular secretion of
diuretic
Decreased diuretic effect Increased diuretic dose
ACEI, ARBs Excess diuretics, high renins Excess hypotension; prerenal uremia Lower diuretic dose; initial
low-dose ACEI or ARB
Captopril Possible interference with tubular
secretion
Loss of diuretic efficacy of furosemide Change to another ACEI
Loop Aspirin Inhibition of acute vasodilator response Presumed less efficacy in HF Delay aspirin when initiating
acute therapy for HF
Potassium sparing ACEI, ARBs Both retain potassium Hyperkalemia Monitor potassium, reduce
ACEI dose
Aldosterone receptor antagonist
Eplerenone ACEI Retains potassium Hyperkalemia Monitor potassium, reduce
ACEI dose
Direct renin inhibitors
Aliskiren ACEI, ARB, potassium-sparing
diuretics
Retain potassium Hyperkalemia Monitor potassium, reduce or
eliminate ACEI, ARB, or
potassium-sparing diuretic
(Continued)
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amiloride was equivalent to nifedipine gastrointestinal thera-
peutic system in preventing CV adverse outcomes in IN-
SIGHT (Intervention as a Goal in Hypertension Treatment)560
among patients 55 to 80 years of age with hypertension.
4.2.2.1.2. Beta-Adrenergic Blockers. Although beta blockers
have been used for hypertension in the elderly for years, evidence
for benefit has not been convincing.14–16,18,327 A meta-analysis of 10
studies comparing beta blockers and diuretics in patients60 years
Figure 10. Algorithm for treatment of
hypertension in the elderly. ACEI indi-
cates angiotensin-converting enzyme
inhibitor; ALDO ANT, aldosterone an-
tagonist; ARB, angiotensin receptor
blocker; BB, beta blocker; CA, calcium
antagonist; CAD, coronary artery dis-
ease; CVD, cardiovascular disease;
DBP, diastolic blood pressure; RAS,
renin-angiotensin system; SBP, systolic
blood pressure; and THIAZ, thiazide
diuretic. Modified from Chobanian
et al.22
Table 6. Continued
Drug Class/Drug Interacting Drug Mechanism Consequence Prophylaxis
Angiotensin-converting enzyme inhibitor
ACEI class effect Excess diuretics; rare in
hypertension
High renin levels in overdiuresed
patients; volume depletion
First-dose hypotension; risk of renal
failure
Reduce diuretic dose; correct
volume depletion
Potassium-sparing diuretics;
spironolactone
Added potassium retention Hyperkalemia Avoid combination or use
with care
NSAIDs Less vasodilation Less BP and 2 less antifailure effect Avoid if possible
Aspirin Less vasodilation Less HF effects Low-dose aspirin
Loop diuretics Possible interference with tubular
secretion
Lessened diuretic effect of furosemide Consider alternate ACEI
Captopril (C) Immunosuppressive drugs,
procainamide-hydralazine
Added immune effects Increased risk of neutropenia Avoid combination; check
neutrophils
Probenecid (P) P inhibits tubular secretion of C Small rise in C levels Decrease C dose
Angiotensin receptor blockers
ARB class effect Excess diuretics; rare in
hypertension
High renin levels in overdiuresed
patients; volume depletion
First-dose hypotension; risk of renal
failure
Reduce diuretic dose; correct
volume depletion
Vasodilators Beta blockers (hepatically
metabolized)
Hepatic shunting Beta-blocker metabolism 2; blood
levels 1
Propranolol; metoprolol dose
2
Hydralizine Nitrates (N) Renal blood flow 1; added
vasodilation; free radicals scavenged
Less N tolerance (benefit); risk of
excess hypotension
Start with low dose of an
alpha blocker or
dihydropyridine; calcium
blocker
Verapamil Hepatic metabolism Synergistic antihypertensive effect Adjust doses
Cilostazol (C) Inhibition of P450 3A4; diltiazem,
verapamil, erythromycin,
ketoconazole, cyclosporine
2 hepatic interaction 1 C levels, risk of increased mortality
in HF
Lessen C dose or avoid
ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; AV, atrioventricular; BP, blood pressure; CHF, congestive heart failure;
CYP2D6, cytochrome P450 2 D6; ECG, electrocardiogram; HB, heart block; HF, heart failure; IV, intravenous; LV, left ventricle; NSAIDs, nonsteroidal anti-inflammatory
drugs; SA, sinoatrial; 1, increase; and 2, decrease.
Modified from Opie and Frishman.540
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of age showed two thirds of the patients assigned diuretics were well
controlled on monotherapy.561 Diuretics were superior to beta
blockade with regard to all clinical outcomes, and were more
effective in preventing CV adverse outcomes.
Therefore, clinical benefits of beta blockers as mono-
therapy in the uncomplicated elderly patient are poorly
documented, although they may have a role in combination
therapy, especially with diuretics. Beta blockers have an
established role in the treatment of elderly patients with
hypertension complicated by certain arrhythmias, migraine
headaches, senile tremor, CAD, or HF. Consideration should
be given to adding beta blockers in patients with hypertension
and these comorbid conditions.562–566 In older patients with
ISH, a clinic heart rate 79 bpm was a significant predictor
for an increase in all-cause, CV, and non-CV mortality,
suggesting a role for beta blockers and rate-lowering CAs in
this population.567 But in the INVEST, with more than 11 000
CAD patients 66 years of age with hypertension, those
randomized to a beta-blocker strategy had lower on-treatment
heart rates, but there was no difference in death, MI, or stroke
compared with a verapamil strategy.568 Although earlier
generation beta blockers have been associated with depres-
sion, sexual dysfunction, dyslipidemia, and dysglycemia, no
such associations were found with nebivolol.569 Nebivolol
also produced favorable outcomes in SENIORS (Study
of Effects of Nebivolol Intervention on Outcomes and
Rehospitalization in Seniors With Heart Failure) 70
years of age with HF, the majority of whom also had
hypertension.570
4.2.2.1.3. Alpha-Adrenergic Blocking Agents. In comparative
trials, the efficacy and safety of alpha blockers have been
documented,562 but their usefulness is limited. Doxazosin 2
mg to 8 mg daily in the ALLHAT showed 25% excess CV
events compared with chlorthalidone, largely driven by a
204% increase in HF571 and a 19% increase in stroke. Based
on this study, alpha blockers should not be considered as
first-line therapy for hypertension in older adults. These drugs
are used for urinary symptoms related to prostate hypertro-
phy, and caution should always be exercised for orthostatic
hypotension. In addition, alpha-beta blockers are important in
hypertensive urgencies (labetalol) and congestive HF (carve-
dilol). However, due to concern for orthostatic hypotension in
the elderly, their use is discouraged.
4.2.2.1.4. Calcium Antagonists. CAs are a heterogeneous
group of drugs with widely variable effects on heart muscle,
sinus node function, atrioventricular conduction, peripheral
arteries, and coronary circulation.572–575 Chemically, they can
be divided into phenylalkylamines (verapamil); benzothiaz-
epines (diltiazem); and dihydropyridines (nifedipine,
nicardipine, nimodipine, amlodipine, felodipine, isradipine,
nitrendipine). Despite their heterogeneity, they all block
influx of calcium ions into the cells of vascular smooth
muscle and myocardial tissue,576 and are significantly more
effective inhibiting contraction in coronary and peripheral
arterial smooth muscle than in cardiac and skeletal muscle.
Vascular smooth muscle is more dependent on external
calcium577 entry for contraction, whereas cardiac and
skeletal muscle rely on a recirculating internal pool of
calcium. Because CAs are membrane active, they reduce
calcium entry into cells and therefore exert a much greater
effect on vascular tissue. This preferential effect allows
CAs to dilate coronary and peripheral arteries in doses that
do not severely affect myocardial contractility or skeletal
muscle.573
CAs appear well suited for elderly patients whose hyper-
tensive profile is based on increasing arterial stiffness and
diastolic dysfunction secondary to decreased atrial and
ventricular compliance.578 –580 Because they have multiple
clinical applications, including treatment of angina and
supraventricular arrhythmias, CAs hold promise for treat-
ment of elderly patients with hypertension and comorbid
CV conditions.
In general, CAs appear well tolerated by the elderly. Most
adverse effects of the dihydropyridines relate to vasodilation
(eg, ankle edema, headache, and postural hypotension). Pos-
tural hypotension is associated with an increased risk of
dizziness and falls; thus, a serious concern for elderly
patients. Peripheral edema also may be confused with HF.581
Verapamil, which may be useful for LV diastolic dysfunc-
tion, may increase constipation.582 Verapamil and diltiazem
Table 7. Physiologic Changes With Aging Potentially Affecting the Pharmacokinetics of Antihypertensive Drugs
Process Physiological Change Result Drugs Affected
Absorption Reduced gastric acid production Reduced tablet dissolution and decreased
solubility of basic drugs
. . .
Reduced gastric emptying rate Decreased absorption for acidic drugs . . .
Reduced GI motility, GI blood flow, and absorptive surface Less opportunity for drug absorption . . .
Distribution Decreased total body mass; increased proportion of body
fat
Increased Vd of highly lipid-soluble drugs Beta blockers, central alpha agonists
Decreased proportion of body water Decreased Vd of hydrophilic drugs ACE inhibitors
Decreased plasma albumin, disease-related increased
1-acid glycoprotein, and altered relative tissue perfusion
Changed percent of free drug, Vd, and
measured levels of bound drugs
Propranolol
Metabolism Reduced liver mass, liver blood flow, and hepatic
metabolic capacity
Accumulation of metabolized drugs Propranolol, diltiazem, labetalol,
verapamil
Excretion Reduced glomerular filtration, renal tubular function, and
renal blood flow
Accumulation of renally cleared drugs ACE inhibitors, atenolol, sotalol,
nadolol
Ellipses indicate no drugs affected. ACE indicates angiotensin-converting enzyme; GI, gastrointestinal; and Vd, volume of distribution. Modified from Hui.549
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can precipitate heart block in elderly patients with underlying
conduction defects. Results of controlled trials have demon-
strated the safety and efficacy of CAs in elderly patients with
hypertension.9,17,19,20,583,584 First-generation CAs (nifedipine,
verapamil, and diltiazem) should be avoided in patients with
LV systolic dysfunction.
4.2.2.1.5. Angiotensin-Converting Enzyme Inhibitors. ACEIs
block conversion of angiotensin-I to angiotensin-II both
systemically and locally in multiple tissues as well as plasma.
The latter lowers total peripheral vascular resistance, and BP
is reduced without reflex stimulation of heart rate and cardiac
output. As aging occurs, angiotensin levels are lower, and
Table 8. Pharmacokinetic Changes, Route of Elimination, and Dosage Adjustment of Selected Antihypertensive Drugs in the Elderly
Drug Class/Drug Half-Life
Volume of
Distribution Clearance
Primary Route(s) of
Elimination Dosage Adjustment
Alpha-adrenergic agonists, centrally acting
Guanfacine 1 . . . 2 Hepatic/renal Initiate at lowest dose; titrate to response
Alpha1 selective adrenergic antagonists, peripherally acting
Doxazosin 1 1 * Hepatic Initiate at lowest dose; titrate to response
Prazosin 1 . . . . . . Hepatic Initiate at lowest dose; titrate to response
Terazosin 1 . . . . . . Hepatic Initiate at lowest dose; titrate to response
Angiotensin-converting enzyme inhibitors
Benazepril 1 . . . 2 Renal No adjustment needed
Captopril NS . . . 2 Renal Initiate at lowest dose; titrate to response
Fosinopril . . . . . . . . . Hepatic/renal No adjustment needed
Lisinopril 1 . . . 2 Renal Initiate at lowest dose; titrate to response
Perindopril . . . . . . 2 Renal Initiate at lowest dose; titrate to response
Ramipril . . . . . . . . . Renal Initiate at lowest dose; titrate to response
Angiotensin II receptor blockers
Candesartan . . . . . . . . . Hepatic/renal No adjustment needed
Eprosartan . . . . . . 2 Hepatic/biliary/renal No adjustment needed
Irbesartan NS . . . . . . Hepatic No adjustment needed
Losartan . . . . . . . . . Hepatic No adjustment needed
Valsartan 1 . . . . . . Hepatic No adjustment needed
Beta-adrenergic blockers
Nonselective without ISA
Nadolol NS . . . . . . Renal Initiate at lowest dose; titrate to response
Propranolol 1 NS 2 Hepatic Initiate at lowest dose; titrate to response
Beta1 selective without ISA
Atenolol 1 NS 2 Renal Initiate at lowest dose; titrate to response
Metoprolol NS NS NS Hepatic Initiate at lowest dose; titrate to response
Beta1 selective with ISA
Acebutolol 1 2 . . . Hepatic/biliary Initiate at lowest dose; titrate to response
Dual acting
Carvedilol . . . . . . . . . Hepatic/biliary Initiate at lowest dose; titrate to response
Labetalol . . . . . . NS Hepatic Initiate at lowest dose; titrate to response
Nebivolol . . . . . . . . . Hepatic/renal No adjustment needed
Calcium antagonists
Amiodipine 1 . . . 2 Hepatic Initiate at lowest dose; titrate to response
Diltiazem 1 NS 2 Hepatic Initiate at lowest dose; titrate to response
Felodipine . . . NS 2 Hepatic Initiate at lowest dose; titrate to response
Nicardipine NS . . . . . . Hepatic No initial adjustment needed
Nifedipine 1 NS 2 Hepatic Initiate at lowest dose; titrate to response
Verapamil 1 NS 2 Hepatic Initiate at lowest dose; titrate to response
Diuretics
Loop
Bumetanide . . . NS . . . Renal/hepatic No initial adjustment needed
Furosemide 1 NS 2 Renal No initial adjustment needed
Torsemide . . . . . . . . . Hepatic No initial adjustment needed
Potassium sparing
Eplerenone . . . . . . . . . Hepatic No initial adjustment needed
Triamterene 1 . . . . . . Hepatic/renal Initiate at lowest dose; titrate to response
Spironolactone . . . . . . . . . Hepatic/biliary/renal No initial adjustment needed
Ellipses indicate no information is available. NS indicates nonsignificant; 1, increase; and 2, decrease. Reprinted from Frishman.550
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theoretically, ACEI should not be as effective as other
therapies, but multiple studies have shown otherwise. Addi-
tional benefits of ACEI are reduction in morbidity and
mortality in patients with MI, reduced systolic function
HF,585–588 progression of diabetic renal disease,589 and pro-
gression of hypertensive nephrosclerosis.558
In the HOPE (Heart Outcomes Prevention and Evaluation)
study, ramipril significantly reduced CV death 26%, all-cause
mortality 16%, stroke 32%, and HF 23% in high-risk older
patients with pre-existing CVD or diabetes mellitus.524 In
PROGRESS, perindopril plus indapamide reduced stroke-
related dementia 34% and cognitive decline 45% in patients
with prior stroke or transient ischemic attack (mean age 64
years, 64% with prior hypertension).246 Available data indi-
cate ACEIs should be considered drugs of choice in elderly
patients with hypertension with HF and/or diabetes mellitus
or CKD.22 The main adverse effects of ACEIs include
hypotension, chronic dry cough, and, rarely, angioedema or
rash. Renal failure can develop in those with RAS. Hyperka-
lemia can occur in patients with renal insufficiency or those
taking potassium supplements or potassium-sparing diuretics.
Therefore, these agents must be used carefully in patients
with renal impairment. Rarely, neutropenia or agranulocyto-
sis can occur; therefore, close monitoring is suggested during
the first months of therapy.
4.2.2.1.6. Angiotensin Receptor Blockers. ARBs selectively
block the AT1-receptor subtype that mediates all known
physiological effects of angiotensin-II believed relevant to
CV and cardiorenal homeostasis.590,591 Overall, ARBs are
similar to other agents in reducing BP and are well tolerated.
ARBs protect the kidney in type 2 diabetes mellitus,592 both
in established diabetic nephropathy with proteinuria and in
patients with microalbuminuria.593 ARBs also reduce mortal-
ity and morbidity in patients with HF.593,594 In elderly patients
with hypertension with diabetes mellitus, ARBs are consid-
ered first-line treatment and as an alternative to ACEI in
patients with hypertension and HF who cannot tolerate
ACEI.594 In patients with HF with an ejection fraction40%,
candesartan reduced HF hospitalizations but did not signifi-
cantly impact mortality.595
The LIFE study compared losartan with atenolol in patients
(age 55 to 80 years) with hypertension and LVH,592 showing
reduced stroke rate in the losartan-treated group despite
comparable BP reduction in both treatment groups. The first
occurrence of death, stroke, or CV mortality was reduced in
favor of losartan and there was also a greater effect on LVH
regression versus atenolol. In SCOPE, candesartan reduced
nonfatal stroke by 28% and showed a trend for reduction of
fatal stroke among patients 70 to 89 years of age. In the
MOSES (Morbidity and Mortality After Stroke–Eprosartan
Compared With Nitrindipine in Secondary Prevention) study,
eprosartan reduced stroke by 25% in patients with mean age
68 years.596 The ACCESS (Acute Candesartan Cilexetil
Therapy in Stroke Survivors) study was stopped early be-
cause of reduction in death, CV event, or cerebrovascular
event (OR: 0.475; 95% CI: 0.252 to 0.895; P0.026).597
ONTARGET showed similar efficacy between telmisartan
and ramipril in a large (n25 620) elderly (mean age 66
years) population,598 the majority of whom had hypertension.
4.2.2.1.7. Direct Renin Inhibitors. Aliskiren is an orally
active direct renin inhibitor approved for hypertension; 150
mg to 300 mg once daily appears as effective as ARBs and
ACEIs for BP management599–601 for 24-hour BP lowering
with no evidence of dose-related increases in adverse events
in elderly patients.602 In another group of elderly patients with
systolic hypertension, aliskiren, with optional add-on HCTZ
(12.5 mg/d to 25 mg/d) and amlodipine (5 mg/d to 10 mg/d),
appeared more effective and better tolerated overall versus
ramipril.603 Combining aliskiren with HCTZ, ramipril, or
amlodipine causes greater BP lowering than with either agent
alone.601,604 Evidence is lacking with combination aliskiren
and beta blockers, or with maximal dose ACEIs, and only
limited data are available in black patients with
hypertension.605
In patients 75 years of age, including those with renal
disease with a GFR 30 mL/min/1.73 m2, aliskiren appears
well tolerated with no dose adjustment necessary.602 The
major side effect is a low incidence of mild diarrhea, which
usually does not lead to discontinuation.606 There are no data
on treating patients with a creatinine level 30 mL/min/1.73
m2. There are no outcome data available at this time, but the
AGELESS (Aliskiren for Geriatric Lowering of Systolic
Hypertension), and APPOLO (Aliskiren in Prevention of
Later Life Outcomes) studies, as well as the ALOFT-Age
substudy (Aliskiren Observation of Heart Failure Treatment)
(HF trial and the majority have history of hypertension)603
have a large number of elderly patients and are in progress.
4.2.2.1.8. Nonspecific Vasodilators. Hydralazine and mi-
noxidil are potent vasodilators, but due to unfavorable side
effects, they are fourth-line drugs as part of a combination
drug regimen. Hydralazine as a monotherapy causes
tachycardia, and minoxidil causes fluid accumulation and
atrial arrhythmias. Nitrates, which are a mainstay of antiangi-
nal treatment in the elderly, have no role in chronic hyper-
tension management because of tolerance.
4.2.2.1.9. Centrally Acting Agents. Centrally acting agents
(eg, clonidine) are not first-line treatments in the elderly
because many patients experience troublesome sedation or
bradycardia, and abrupt discontinuation leads to increased BP
and heart rate, which aggravates ischemia and/or HF. These
agents should not be considered in patients who may be
noncompliant. They can be used as part of a combination
regimen to maximize BP control after other agents have been
deployed.
4.2.3. Combination Therapy
Combination therapy provides more opportunity for creative
solutions to a number of problems. Five issues in combined
therapy—some practical, some speculative—are listed in
Table 9.607 The most obvious benefit of drug combinations is
enhanced efficacy. Theoretically, some drug combinations
might produce synergistic effects that are greater than pre-
dicted by summing efficacies of component drugs. More
commonly, combination therapy achieves a little less than the
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sum of its component drug efficacies. In contrast, some
combinations of drugs produce offsetting interactions that
may weaken rather than strengthen antihypertensive effects.
A second benefit concerns avoidance of adverse effects
because each drug can be administered in a lower dose. A
third issue concerns convenience although a combination
regimen could be confusing and distracting to elderly pa-
tients, and could lead to poor treatment compliance. Con-
versely, a well-designed, combination pill that incorporates
logical doses of 2 agents enhances convenience and compli-
ance. Further potential value may result from the reciprocal
pharmacokinetic effects that 2 drugs have on each other.
Although this has not been well studied, there may be
situations where the duration of action of the drugs becomes
longer when used in combination. Finally, it is interesting to
consider the attributes of ACEIs, ARBs, and CAs, which
exhibit antimitotic or antiatherosclerotic actions in addition to
BP lowering. Some combinations of these newer agents may
provide even more protective effects on the CV system
(Figure 10). The ACCOMPLISH trial of high-risk hyperten-
sion patients (mean age 67 years) compared combination
therapy with benazepril plus either HCTZ (12 mg to 25 mg
daily) or amlodipine and found clear superiority for the
ACEI-CA combination in terms of reduction in morbidity and
mortality.8 Both combinations had the same effect on 24-hour
mean daytime and nighttime BPs, and surges in BP. Thus, the
greater reduction in clinical events with the benazepril-
amlodipine combination could not be explained by a greater
reduction in BP. Although multiple combinations of diuretics
with other antihypertensive drugs have been used to reduce
BP, outcome data from RCTs in elderly patients are lacking.
The beneficial effect on outcomes was only present for
patients with an eGFR 60 mL/min; for those with reduced
renal function there was no difference in CV outcomes
between the 2 combinations.607a Multiple RCTs, including
HYVET, EWPHE, MRC, and STOPHTN (Swedish Trial in
Old Patients with Hypertension), have shown combination
therapy with a diuretic to be efficacious in the elderly.4,12,15,18
4.2.4. Uncomplicated Hypertension
The 2009 updated ESH guidelines recommend initiating
therapy in the elderly with either thiazide diuretics, CAs,
ACEIs, ARBs, or beta blockers based on a meta-analysis of
major hypertension trials.608,609 When BP is 20/10 mm Hg
above goal, consideration should be given to starting with 2
drugs.22 Most elderly persons with hypertension will need2
drugs to control their hypertension.22,610
4.2.5. Complicated Hypertension
When additional comorbidities complicate hypertension, at
least 2 drugs should generally be used. In elderly patients
with hypertension at high risk for CV events, a benazepril–
amlodipine combination was more effective in reducing CV
events than a benazepril–HCTZ combination with a 2.2%
absolute risk reduction in CV events by the former combina-
tion.8 Recommended antihypertensive agents for specific
comorbidities are detailed in the following text.
4.2.5.1. Coronary Artery Disease
In elderly patients with hypertension and stable angina and/or
prior MI, the initial choice is a beta blocker.22,26,611 A
long-acting dihydropyridine CA should be administered in
addition to the beta blocker when the BP remains elevated or
if angina persists. An ACEI should also be given, particularly
if LV ejection fraction is reduced22,524,588,612–614 and/or if HF
is present where an aldosterone antagonist should be added in
the absence of hyperkalemia or significant renal dysfunc-
tion.22,615 The INVEST demonstrated that a verapamil SR–
trandolapril-based strategy was as clinically effective in terms
of BP control and adverse outcomes as an atenolol–HCTZ-
based strategy in elderly patients with hypertension with
CAD, including those with prior MI.584 Angina was better
controlled with the verapamil SR–trandolapril strategy. El-
derly patients with hypertension at high risk for coronary
events should be treated with beta blockers plus
ACEI.22,26,524,612–614
In elderly patients with acute coronary syndromes, hyper-
tension should be treated with beta blockers and ACEI, with
additional drugs added as needed for BP control.22,26,616
Verapamil and diltiazem should not be used if there is
significant LV systolic dysfunction.26,616
Some26 recommend reducing BP to 130/80 mm Hg in
CAD patients, yet there is limited evidence to support this
lower target in elderly patients with CAD.584 In INVEST, the
nadir BP for risk was 135/75 mm Hg among 6126 patients 70
to 80 years of age, and 140/70 mm Hg for 2180 patients 80
years of age.13 Beta blockers with intrinsic sympathomimetic
activity must not be used after MI. The hydrophilic beta
blocker atenolol may not be as efficacious as propranolol,
timolol, metoprolol, or carvedilol in treating hyperten-
sion,617,618 but in most of the patients in these studies (eg,
LIFE), it was used only once daily.
4.2.5.2. Left Ventricular Hypertrophy
LVH associated with hypertension is an independent risk
factor for coronary events, stroke, PAD, and HF. LVH can
regress with antihypertensive therapy except for the direct
vasodilators hydralazine and minoxidil.22 A meta-analysis of
109 treatment studies found that ACEI was more effective
than other antihypertensive drugs in decreasing LV mass.619
Losartan was superior to atenolol in reducing first occurrence
of CV death, stroke, or MI in elderly patients with ISH and
electrocardiographic LVH.620 Thus, antihypertensive therapy
with ACEI or ARBs should generally be used in elderly
persons with hypertension and LVH. However, all antihyper-
Table 9. Rationale for Combination Drug Therapy
for Hypertension
● Increased antihypertensive efficacy
 Additive effects
 Synergistic effects
● Reduced adverse events
 Low-dose strategy
 Drugs with offsetting actions
● Enhanced convenience and compliance
● Prolonged duration of action
● Potential for additive target organ protection
Reprinted from Weber et al.607
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tensive agents except for direct-acting vasodilators will re-
duce LV mass if BP is controlled.
4.2.5.3. Heart Failure
Elderly patients with hypertension and systolic HF should be
treated with diuretics, beta blockers, ACEI, and an aldoste-
rone antagonist if necessary.22,585,615,621–627 If a patient cannot
tolerate an ACEI because of cough, rash, or angioedema, an
ARB should be used.594,621 Elderly black patients with hyper-
tension and HF may benefit from isosorbide dinitrate plus
hydralazine.628 Based on expert opinion, the BP should be
reduced to 130/80 mm Hg in HF patients with CAD.26
Elderly patients with hypertension and asymptomatic LV
systolic dysfunction should be treated with ACEI and beta
blockers.22,26,588,629 Because HF may improve in elderly
patients with hypertension and RAS after renal revascular-
ization, a search for RAS should be considered when HF is
refractory or recurs with conventional management.630 Dia-
stolic HF is very common in the elderly.625,631 Fluid retention
should be treated with diuretics, hypertension should be
adequately controlled, and when possible, comorbidities
should be treated.
4.2.5.4. Cerebrovascular Disease
Elderly patients with hypertension with prior stroke or tran-
sient ischemic attack should be treated with a diuretic plus an
ACEI.22,246 Despite this, recommendation by “The Seventh
Report of the Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pres-
sure,” the overall data suggest that reduction of stroke risk
among elderly persons with hypertension is related more to
reduction in BP than to type of antihypertensive drugs.632
Ischemic stroke was reduced 37% (18% to 52%), and
hemorrhagic stroke reduced 54% (2% to 79%) (95% CI:
0.21 to 1.02).
4.2.5.5. Diseases of the Aorta and Peripheral Arteries
The presence of aortic aneurysm requires very intense BP
control to the lowest tolerated level, and therapy should
include an ACEI or ARB plus a beta blocker, because in
addition to lowering BP, beta blockers decrease peak LV
ejection rate.633,634
In acute aortic dissection (acute aortic syndrome), control
of BP, with multiple drugs including beta blockade, is needed
for both type A and B (not involving the ascending aorta)
dissection. Surgery is indicated for type A dissections (those
involving the ascending aorta), and endovascular techniques
may be used in elderly patients with high operative risk.301
For PAD patients, lifestyle interventions including smok-
ing cessation, weight loss, a structured walking program, and
management of hypertension, as well as coexistent CAD and
HF, are essential, as is control of blood glucose and lipids.
ACEIs or ARBs, as well as antiplatelet therapy, are re-
quired.635 Patients with critical limb ischemia, (defined as
PAD resulting in ischemic pain at rest), ulceration, or
gangrene should be evaluated for revascularization. In the
HOPE study, compared with placebo, the ACEI ramipril 10
mg daily significantly reduced CV events in persons with
symptomatic and asymptomatic PAD, most of whom had
increased BP and were elderly.636,637 The absolute reduction
in CV events was 50 events per 1000 patients with an
ankle-brachial index 0.9 compared with 24 events per 1000
patients with an ankle-brachial index of 0.9. Multiple
professional societies suggest the BP target should be below
130/80 mm Hg in patients with PAD. But in the INVEST,
elderly patients with CAD and hypertension with PAD
(n2699, mean age 69 years, 44% 70 years old), followed
for a mean of 2.7 years (6970 patient years), showed a
J-shaped relationship with BP treatment. Adverse out-
comes22,26,28,29,608 (death, MI, or stroke) occurred least fre-
quently on treatment with SPB 135 to 145 mm Hg and DBP
60 to 90 mm Hg,638 suggesting that PAD patients may require
a different BP.638 Specific data in very elderly patients with
PAD regarding benefits of treatment and optimal BP target
are sparse.
4.2.5.6. Diabetes Mellitus
In the absence of RCT data, guidelines recommend that
patients with diabetes mellitus should have BPs
130/80 mm Hg, if tolerated,22,28,29,613,639 and often multiple
drugs are required to meet this goal. However, recent RCT
data from the ACCORD BP (see Section 1.4) found no
benefit of a SBP goal of 120 mm Hg compared with 140 mm
Hg on CV endpoints in 4733 patients (mean age 62 years)
with type 2 diabetes mellitus.32 Observational data from
extended follow-up of the 6400 INVEST diabetes mellitus
cohort of mostly elderly patients (mean age 66 years) showed
an increase in mortality when on treatment; SBP was
115 mm Hg or DBP 65 mm Hg.640 Based on available
data, reduction of macrovascular and microvascular compli-
cations in elderly diabetics with hypertension depends more
on reducing the BP than on the type of drugs used: drug
choice depends on associated comorbidities.22,28 However,
thiazide diuretics will increase hyperglycemia and risk for
incident diabetes mellitus. Incident diabetes mellitus has been
associated with increased HF hospitalizations and other CV
events in elderly patients with hypertension.556,641 In ALL-
HAT, patients with pre-existing diabetes mellitus appeared to
receive the same benefit on future coronary events from
diuretics as patients without diabetes mellitus9 over an inter-
mediate follow-up period. Elderly persons with diabetes,
hypertension, and nephropathy should be treated initially with
ACEIs or ARBs.22,642–645 In ACCOMPLISH, over the back-
ground of ACEI, patients with diabetes mellitus who were
treated with amlodipine had a 21% relative risk reduction and
2.2% absolute risk reduction in CV events8 compared with
HCTZ plus the ACEI.
4.2.5.7. Metabolic Syndrome
Initially attempts should be made to reduce BP in elderly
persons with metabolic syndrome and prehypertension using
lifestyle modification.646 In those who are hypertensive, drug
therapy should be used if needed to achieve BP
140/90 mm Hg.646
4.2.5.8. Chronic Kidney Disease and Renal Artery Stenosis
4.2.5.8.1. Chronic Kidney Disease. Based solely on expert
opinion and observational data, elderly patients with hyper-
tension and CKD should have BP 130/80 mm Hg, if
tolerated.22,29,409 Drug regimens that include ACEIs or ARBs
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are more effective than regimens without them in slowing
progression of advanced proteinuric nondiabetic CKD.647
ACEI therapy is also indicated in patients with nondiabetic
nephropathy. It should be noted, however, that there are no
data on outcomes with any class of antihypertensive agents
among elderly patients with hypertension with CKD. In the
absence of proteinuria (ie, 300 mg/d), there are no data that
ACEIs or ARBs are better than BP control alone with any
agent that is well tolerated.648,649 ACEIs or ARBs should be
administered to elderly hypertension persons with CKD if
proteinuria is present.22,29,409,642–645,647,650
Hypertension and HF are associated with a more pro-
nounced decline in renal function in older age.324 With the
recognition of early renal dysfunction, more patients should
benefit from aggressive therapy. A retrospective cohort of
elderly individuals with CKD and acute MI found benefit
from combination cardioprotective therapy with aspirin, beta
blockers, and ACEI.651 In an observational study of elderly
(mean age 79 years) hospitalized patients with acute systolic
HF and advanced CKD (mean serum creatinine 2.9 mg/dL),
ACEI use was associated with a 31% absolute mortality
reduction.652
4.2.5.8.2. Renal Artery Stenosis
4.2.5.8.2.1. Surgical Revascularization. Revascularization
has been used to treat hypertension, preserve renal function,
and treat HF and unstable angina in patients with RAS and
ischemic nephropathy. Techniques range from aortorenal
bypass with graft of autogenous hypogastric artery or saphe-
nous vein, to aortorenal endoarterectomy.298 Nephrectomy is
used only in select patients after revascularization failure or
when benefit in BP control or decrease in CV morbidity is
expected after kidney removal.298,653
Surgical results in patients with atherosclerotic RAS (age
699 years, mean serum creatinine 2.6 mg/dL) showed that
at discharge, renal function remained unchanged in 41%,
declined in 16%, and improved in 43%, including 7 patients
removed from dialysis.654 At 1 year, renal function was
improved or unchanged in 72%. Aortorenal bypass was used
in 38%, endoarterectomy in 24%, combined aortic and renal
artery revascularization in 24%, and bilateral renal artery
revascularization in 27%, with perioperative death in 4.1%.
Predictors of worsened excretory function included decline of
renal function at hospital discharge, unilateral RAS, and
elevated baseline creatinine level. In another study, mean age
668 years with RAS who underwent repair, 83/232 under-
went unilateral and 149 bilateral renal artery repair, including
17 with repair to a solitary kidney.655 A total of 332 renal
arteries were reconstructed and 32 nephrectomies performed;
58% of patients had improved renal function after surgery,
including 27 removed from dialysis. Renal function was
unchanged in 35% and worsened in 7%. Death within 30 days
of surgery occurred in 7.3% of the patients, and advanced age
and HF were independent predictors of mortality.
In patients 669 years of age, the Nationwide Inpatient
Sample of all hospital discharges in the United States re-
ported a 73% decrease in combined aortic and renal surgical
revascularization; and in patients aged 6312 years, a 56%
decline in surgical renal revascularization between 1988 and
2001.656 However, catheter-based renal revascularization pro-
cedures increased 173% in patients aged 6712 years during
the same period.
4.2.5.8.2.2. Catheter-Based Interventions
4.2.5.8.2.2.1. Percutaneous Transluminal Renal Artery Bal-
loon Angioplasty. Risks of surgical renal revascularization
and relatively good results with catheter-based interventions
have shifted therapy toward more percutaneous catheter-
based interventions. In 1 study, patients with hypertension
and RAS (stenosis 50% and serum creatinine 2.3 mg/dL)
were assigned to percutaneous balloon angioplasty (BA) or
medical treatment and followed for a total of 12 months.657
Average ages were 5910 years and 6110 years for the
angioplasty and drug therapy groups, respectively. At 12
months, there were no significant differences between groups
in BP, daily antihypertensive drug doses, or renal function.
However, 40% of patients assigned medical treatment
crossed over to BA after 3 months. Other studies658–660
confirmed that BA is associated with low procedural success
and high restenosis rates in RAS, the most common pathol-
ogy in the elderly. BA stent placement has consistently
proven superior when compared to BA alone. Based on these
results, stenting with BA has replaced BA alone.
4.2.5.8.2.2.2. Percutaneous Renal Artery Stenting. Because
atherosclerotic RAS usually involves narrowing of the ostium
by aortic plaques extending into proximal vessels, BA results
in recoil, and stent use better maintains patency.661 A study of
patients (average age 65 years) found that angioplasty with
stent placement was more effective than BA for ostial
atherosclerotic stenosis.662 Primary patency rate at 6 months
was 79% in the stent versus 28% in the BA group and in
patients with restenosis, secondary patency was also higher in
the stent than in the BA group: 82% versus 46%, respectively.
No differences occurred between groups in the distribution of
patients with improved BP or improved, unchanged, or worse
renal function; the number of antihypertensive medications
did not change in either group after revascularization. Com-
plications, including bleeding, femoral artery aneurysm, renal
artery injury, and cholesterol embolism, were similar in both
groups. This prospective study concluded that stenting pro-
vides improved vessel patency in the elderly population with
ostial atherosclerotic RAS; however, it does not prove that the
clinical evolution of the disease will change following
revascularization.
One study summarized experience with angioplasty and
stenting in 39 patients (mean age 69.9 years) with recurrent
episodes of HF and flash pulmonary edema.630 Following the
procedure, 77% of patients had no hospitalization for HF over
21 months, and 9 patients died. In another study, the presence
of HF was examined in a cohort (mean age 73 years) of
patients with significant hypertension and RAS. Approxi-
mately one third (31%) of the patients referred for BA with
stenting presented with HF. Outcomes in HF and BP control
were improved by revascularization compared with outcomes
of patients who underwent medical management, but mortal-
ity was not affected.663
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Investigators from the ASPIRE II (renal Artery Stenting
After Unsuccessful Balloon Angioplasty) study analyzed
safety and durability of renal stenting after suboptimal or
failed renal artery BA in patients, average age 699.9 years.
Stenting was immediately successful in 80.2% lesions
treated, and at 9 months, the restenosis rate was 17.4%. The
SBP/DBP decrease was significant, but creatinine was un-
changed after 24 months, as adverse events occurred in
19.7%.664 Others665 found patients 75 years of age have
similar findings in follow-up after BA; however, patients who
are 75 years of age have a higher mortality at 2 years.
Uncertainty regarding the effect of stenting on BP control
and progression of kidney failure continues. Some suggest
that stenting for atherosclerotic RAS can stabilize declining
kidney function; however, for patients with stable renal
function, the benefit is less clear.666 Others advise caution in
performing percutaneous revascularization in patients with
CKD.667
Early acute functional renal injury related to renal inter-
ventions in patients with atherosclerotic RAS was analyzed in
a prospective study of patients who averaged 70 years of
age.668 Indications for the procedure were poorly controlled
hypertension, associated CKD (creatinine 1.5 mg/dL), dia-
betes mellitus, and hyperlipidemia. Acute functional paren-
chymal renal injury occurred in 20%. In the injury group,
there were more current smokers with non–insulindependent
diabetes mellitus and presence of AAA. The CKD was more
advanced (GFR 20 mL/min), and contralateral renal artery
disease was more frequent in patients who suffered acute
kidney injury after the procedure. Acute kidney injury was
associated with more kidney morbidity 3 months after the
procedure and decreased survival at 5 years; in addition, 3
times more patients progressed to hemodialysis as compared
with those without acute kidney injury. It seems that patients
with unrepaired AAA, diabetes mellitus, and persistent renal
disease are more predisposed to acute functional injury
following RAS. Medical therapy or use of a distal renal
protective device may be beneficial until results of prospec-
tive trials (eg, CORAL) help to address appropriate use of
renal interventions.
The ASTRAL trial669 recruited 806 patients with RAS
(mean age 70 years, range 42 to 88 years) including patients
who quit smoking and those with a history of diabetes, PAD,
CVD, and stroke. Eighty percent were treated with statins,
90% with antiplatelet drugs, and 90% with antihypertensive
agents. Participants were randomized between renal artery
revascularization (BA-S) plus medical therapy versus medi-
cal therapy alone, and the primary outcome was rate of
decline of renal function; the secondary outcomes were BP
control, renal events (acute renal failure, dialysis), serious
vascular events, or mortality. At 12 months, there were no
differences between groups in renal function, SBP or DBP,
combined renal events, and CV events, inducing death.
During 4-year follow-up, there was slight benefit in favor of
revascularization for creatinine (10 mmol/L difference), SBP,
combined renal (17% versus 23%), and CV events (34%
versus 41%), but the study was underpowered. Serious
complications associated with revascularization occurred in
23 patients (6%), including 2 deaths and 3 amputations of
toes or limbs. Based on this definitive trial, there is no
evidence for benefit of BA-S for RAS. The authors concluded
that in patients with a range of radiologically significant RAS
lesions, there was no benefit in any outcome measure but
significant risk from additional revascularization when both
groups were treated with optimal medical therapy.669 The
ongoing CORAL study670 will analyze response to medical
treatment versus revascularization and might also provide
evidence about diagnostic tests that may predict the best
treatment.
Technical improvements in percutaneous renal artery in-
terventions have evolved. These include polyurethane filter
and basket (Angioguard XP emboli capture guide wire
system)671 to decrease the number of microembolic particles
introduced into the renal artery. Analysis of a retrospective
cohort of consecutive patients undergoing with and without
distal embolic protection, ages 697 years and 756 years,
Figure 11. Absolute risk of ischemic
heart disease mortality in relation to
blood pressure. (A) Systolic blood pres-
sure. (B) Diastolic blood pressure. The Y
axis is logarithmic. CI indicates confi-
dence interval; IHD, ischemic heart dis-
ease. Reprinted from Lewington et al.42
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respectively, did not show a difference between groups in
renal function or SBP changes. The authors concluded that
renal artery stenting improves GFR and SBP, however distal
embolic protection did not enhance this effect.672
4.2.5.9. Other Conditions/Situations/Special Populations
Resistant hypertension: Resistant hypertension is defined as
BP that remains above goal when a patient adheres to lifestyle
measures23 and maximum tolerated doses of 3 complemen-
tary antihypertensive agents including a diuretic,673 has an
unknown prevalence in the elderly. Data from NHANES
(2003 to 2004), show hypertension prevalence progressively
increases with age, reaching 77% in people 77 years of
age,674 so increasing age, particularly 65 years of age, is
associated with a higher prevalence of resistant
hypertension.675,676
There are no studies specifically powered to address
prognosis of older patients with resistant hypertension. In
adults 40 to 69 years of age with no previous vascular disease,
each difference of 20 mm Hg in SBP or 10 mm Hg in DBP
was associated with more than a 2-fold difference in the
stroke death rate (Figure 8), and with 2-fold differences in the
death rates from vascular causes (Figure 11). This association
was consistent for the entire range of BP studied, about
115/75 to 180/110 mm Hg. Differences in vascular mortality
were about half as extreme at 80 to 89 years of age versus 40
to 49 years of age, but the annual absolute differences in risk
were greater in old age. Agespecific associations were similar
for men and women, and for cerebral hemorrhage and
cerebral ischemia.42
Increasing age was the characteristic that was most signif-
icantly associated with lack of SBP control among treated
subjects. The FHS showed that subjects 75 years of age are
4 times less likely to achieve SBP control compared with
those 60 years of age.677 This was confirmed in another
study where BP control gradually declined with age, from
74% among those 40 years of age to 33% for those 70
years of age.674 Reasons for resistant hypertension in the
elderly include excess dietary salt intake, weight, alcohol, and
nicotine; decrease in efficacy of antihypertensive medication
with higher baseline BP; higher incidence of organ damage
comorbidities (eg, dyslipidemia, metabolic syndrome, diabe-
tes mellitus, CKD, stroke, HF, PAD, CAD674); poor adher-
ence to drug treatment; volume overload; pseudohyperten-
sion; and use of pain medications such as NSAIDs. NSAIDs
inhibit prostaglandin production, followed by sodium and
fluid retention215 and volume overload, especially in elderly
patients with organ damage.675
Elderly subjects with higher baseline SBP typically have a
more severe or longer duration of hypertension that makes it
more difficult to treat. Higher baseline SBP is also often
associated with dysfunction or damage of organs that play a
key role in BP regulation. In elderly patients, volume over-
load is a common finding because of excessive salt intake,
inadequate kidney function, or insufficient diuretic therapy.
Physicians are less aggressive in treating elderly patients, as
25% of physicians believe that hypertension treatment in an
85 year old has more risks than benefits.678
Pseudohypertension represents another reason for resistant
hypertension in the elderly population. Increased arterial
stiffness and the presence of heavily calcified arteries that
cannot fully compress makes BP readings falsely higher than
the intra-arterial BP.679 Managing resistant hypertension in
the elderly requires a careful medical history, followed by BP
measurements in seated and in erect posture because of the
increase risk of postural hypotension. Complete investigation
of comorbidities and concomitant medications, as well as
suboptimal compliance and dietary indiscretions may help
explain the difficulties in BP control.
Recommendations for modification and intensification of
antihypertensive regiments for elderly patients taking 3
drugs are based on pharmacological principles, underlying
pathology, clinical experience, and comorbidities. We wish to
reinforce the importance of dietary sodium restriction, reduc-
tion in alcohol intake, and the DASH diet in resistant
hypertension. Most patients should receive a RAAS blocker
along with a CA and an appropriately dosed diuretic. It is
extremely important that the agents be given in adequate
dosages and at appropriate time intervals. An appropriate
diuretic to decrease volume expansion remains the corner-
stone of therapy in elderly patients. Thiazides can be selected
if the eGFR is 30 mL/min/ 1.73 m2; if hypoalbuminemia or
hypokalemia is not present. If eGFR is below 30 mL/min/
1.73 m2, a loop diuretic is recommended.675 Next, add either
a CA or vasodilating beta blocker if pulse rate is not 50
bpm. Blockade of aldosterone should be considered espe-
cially in certain settings, (ie, those with HF, obesity, or sleep
apnea).680 Peripheral alpha blockers may be considered,
especially in older men with coexistent symptoms from
benign prostatic hypertrophy, but these will increase ortho-
static hypotension and are associated with excess HF and
stroke (Section 4.2.2.1.3, Alpha-Adrenergic Blocking
Agents).
As discussed previously, RAS and other secondary causes
of hypertension should be considered in elderly patients with
resistant hypertension. A key point in the management of BP
in this cohort of patients is that volume depletion with
diuretics, especially during summer months, is to be avoided.
Hence, CAs become useful agents as they are efficacious for
pressure reduction and avoid increases in serum creatinine
and volume depletion.
Osteoporosis: Thiazide diuretics preserve hip and spine
bone mineral density in older patients,681–683 so those with
hypertension and osteoporosis should generally receive a
thiazide,22 which can increase blood calcium levels. Loop
diuretics (such as furosemide and bumetanide) can decrease
calcium levels. Amiloride (a potassium-sparing diuretic) may
decrease the amount of calcium excreted in the urine (thus
increasing blood calcium levels), and may also be considered
for people with calcium oxalate kidney stones.
Arrhythmias: Beta blockers, verapamil, or diltiazem should
be used for ventricular rate control with supraventricular
tachyarrhythmias such as AF in elderly persons with hyper-
tension.22,286 Beta blockers should also be considered in
treatment of elderly persons with complex ventricular ar-
rhythmias with abnormal684 or normal685 ejection fraction.
Beta blockers are also useful to treat elderly persons with
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hypertension who have hyperthyroidism, preoperative hyper-
tension, migraine, or essential tremor.22 CAs are useful in
patients with Raynaud’s disease, asthma, or chronic obstruc-
tive lung disease, in whom beta blockers are relatively
contraindicated.
Blacks: In general, treatment of hypertension is similar for
all racial/ethnic groups22 including blacks.686 Blacks have
reduced BP responses to monotherapy with beta blockers,
ACEIs, ARBs, and some CAs compared with diuretics, but
this is eliminated by including a diuretic in combination.22
RAAS686 inhibitors appear less effective than other classes in
decreasing BP in elderly blacks, unless combined with
diuretics or CAs. ACEIs prevent adverse outcomes such as
decline of renal function in those with hypertensive nephrop-
athy.558 The SHEP demonstrated benefit in an older black
cohort with chlorthalidone-based treatment versus placebo.16
Patients were60 years of age with SBP 160 to 219 mm Hg,
and DBP 90 mm Hg. Over 4.5 years, stroke was reduced in
black women (RR: 0.36; 95% CI: 0.16 to 0.83), but not in
black men. In LIFE, black patients aged 55 to 80 years with
stage 2 hypertension and LVH showed greater benefit with
atenolol plus diuretics versus losartan plus diuretics in pro-
tection against stroke and CAD.687
The initial agent in blacks with uncomplicated hyperten-
sion should be a thiazide diuretic. In ALLHAT, chlorthali-
done was unsurpassed in blacks decreasing BP and major CV
events versus regimens based on lisinopril, amlodipine, and
doxazosin (9688). CAs effectively lowered BP in blacks and
decreased CV event, especially stroke.688 Amlodipine in
ALLHAT was effective with similar protection against CAD
and stroke, although less effective for new onset HF when
compared with chlorthalidone.688 Because ALLHAT com-
pared those agents with diuretics and CAs, patients random-
ized to chlorthalidone or amlodipinebased therapies could not
additionally take lisinopril, despite the fact that a diuretic or
CA combination with an ACEI would be a reasonable
combination in blacks. In ALLHAT, a 40% higher incidence
of stroke in blacks with lisinopril-based therapy was noted
versus the diuretic.68 This occurred, to a large extent, related
to 4 to 5 mm Hg less SBP reduction in the lisinopril-based
versus chlorthalidone-based cohort, although BP reductions
did not fully explain outcome differences.
In the AASK, ramipril-based therapy versus metoprolol
succinate and amlodipine was renoprotective in those with
hypertensive nephropathy, especially with proteinuria. The
AASK results confirm benefit of ACEI when needed in
blacks, such as protection against progression of renal disease
in concert with diuretics558 however, the diuretic used was
furosemide.
Although ACEIs and ARBs may be less efficacious for BP
reduction in blacks, at higher doses or combined with a
diuretic or long-acting CA, blacks benefit from these agents.
ACEIs are associated with a higher rate of cough and
angioedema among blacks versus whites.688 Nevertheless, in
blacks, socioeconomic status, dietary, and other lifestyle
considerations must be examined and addressed, because, to
a large extent, these non-drug aspects of elevated BP are of
primary significance. Blacks, many of whom have more
severe and complicated hypertension, usually will not reach
control with monotherapy. Aldosterone antagonists, spirono-
lactone, and eplerenone are beneficial in patients with resis-
tant hypertension, including blacks.689
Hispanics: Recommendations for pharmacological man-
agement of elderly Hispanic patients are the same as for
elderly patients in general. In INVEST, elderly Hispanic
patients with CAD had better BP responses to combination
therapy with either a CA plus ACEI or beta blocker plus
HCTZ versus white patients.76,77
Women: There is no evidence that elderly women respond
differently than elderly men to antihypertensive drugs.690,691
Recent studies have shown that multidrug therapy is needed
for elderly high-risk men and women with hypertension.691 A
recent meta-analysis of randomized trials showed that differ-
ent antihypertensive drug classes protected similarly against
major CV events in persons 65 years of age and persons
65 years of age.251
Octogenarians: Successful treatment of hypertension in
octogenarians may be expected to substantially reduce CV
risk and mortality based on available data. Benefits on
cognitive function and appearance of dementia are less
certain. Although a BP 140/90 mm Hg was recommended
for all patients by “The Seventh Report of the Joint National
Committee on Prevention, Detection, Evaluation, and Treat-
ment of High Blood Pressure,”22 except for a lower level in
special populations, randomized trial evidence to support this
BP level in the very elderly is not robust. Nevertheless, data
available from RCTs, which included patients over the age of
80 years, come largely from subpopulations, which in some
trials and collectively are larger than HYVET. These trials
(eg, ACCOMPLISH, INVEST) noted no difference in the
effects on outcomes among those 80 years of age versus
80 years of age (8584). Based on these results and limita-
tions, the following recommendations can be offered for
persons 80 years of age. Those with SBP 150 mm Hg are
candidates for antihypertensive drugs with target SBP 140 to
145 mm Hg if tolerated (ie, somewhat more conservative
target than in individuals 80 years of age).
Initiate treatment with a single drug followed by addition
of a second drug if needed. Low-dose thiazides, CAs, and
RAAS blockers are preferred. Concomitant conditions will
often dictate which drugs are appropriate, as detailed in the
preceding text. Indeed, because of the evidence that the
benefits of antihypertensive treatment largely depend on BP
lowering per se,22 all drugs (alone or in rational combina-
tions) may be used provided that they have a suitable safety
profile and no excessive effect on orthostatic BP.
In starting or continuing treatment, use precautions even
more stringent than those employed in younger patients.
Octogenarians should be seen frequently and the medical
history accurately updated at each visit. Standing BP should
always be checked for excessive orthostatic decline. Al-
though BP values below which vital organ perfusion is
impaired are not known, SBPs lower than 130 mm Hg and
DBP 60 mm Hg should generally be avoided, if possible.
Drug treatments for concomitant diseases should be carefully
monitored to prevent adverse interactions with antihyperten-
sive drugs.
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Drug treatment should not indiscriminately involve all
patients with hypertension who are 80 years of age. In
deciding whether to initiate treatment, physicians should
consider the general health condition of their patients. Treat-
ment may be withheld in more frail or medically compro-
mised patients, and there is less evidence of benefit in patients
approaching 90 years of age or who are 90 years of age.
4.2.5.10. Compliance With Pharmacological Therapy
Compliance may be defined as the extent to which a patient
takes medication as prescribed. The term compliance is often
used interchangeably with adherence, but compliance is
preferred because it implies a responsibility shared by both
patient and physician.692,693 Compliance rates are often re-
ported as percentage of prescribed dose of medication actu-
ally taken over a period of time. Measurements of blood or
urine drug metabolites or serum drug concentrations can also
be used,694 but these have limited applications in a primary
care setting as they are invasive and potentially costly.
Clinicians are more inclined to evaluate compliance by
questioning the patient, taking pill count assessments at
checkup, and using electronic medication caps that record
when a bottle is opened.694,695 Unfortunately, patients do not
always report nonadherent behavior, and such indirect mea-
sures can mislead providers to overestimate compliance.694
Definition and Predictors: Unfortunately, a large propor-
tion of elderly patients will discontinue or take the drugs
inappropriately.692,696,697 This noncompliance often results in
failing to reach guideline-recommended BP targets and im-
pacts outcomes; patients are much more likely to be hospi-
talized and have greater healthcare costs than those who
follow their prescriptions.22 About 1 in 3 patients remain
highly adherent to antihypertensive medication after 12
months, and after that, adherent patients are much less likely
to discontinue medication. Older age, in addition to previous
noncompliance, low risk for CV events, competing health
problems, nonwhite race, low socioeconomic status, com-
plexity (eg, multiple dosing, pill burden), side effects, and
cost of medication regimen predict noncompliance.698,699
Compliance Barriers: The asymptomatic state associated
with hypertension appears to be a common barrier.692,697,700 A
prospective study found that only 37% of patients surveyed
reported consistent compliance to antihypertensive regi-
men.701 In a cross-sectional study, 21% of patients with
hypertension stopped treatment without being advised to do
so. A factor most commonly found to distinguish nonadherent
patients from those adherent to medication regimens was
perception of health status.700 The poorer the patients per-
ceived their health, the more likely they were to adhere to
prescribed treatment; the reason given most often for discon-
tinuation was that they felt well without the medication.
Although the mean age of this cohort was only 58, elderly
patients with hypertension are likely to be asymptomatic with
a variety of serious comorbidities (eg, AF, CAD, diabetes
mellitus, HF).700 Prevalent comorbidities, polypharmacy, and
high cost of medications also contribute to lower BP control
rates in the elderly.610
Some patients with hypertension are more likely to adhere
to their medication regimen. Patients who viewed hyperten-
sion as a symptomatic disease and believed treatment had
beneficial effects on symptoms were more adherent and had
better BP control.702
Side Effects: Side effects are another common reason for
therapy discontinuation in the elderly703–705 and may be more
apparent in patients with hypertension. This because the
illness is often asymptomatic, which may increase awareness
of side effects associated with therapy. A drug’s side-effect
profile has been demonstrated to contribute to poor compli-
ance by affecting a patient’s QoL.701,706 In patients with
hypertension, approximately 10% of poor compliance was
due to adverse effects of prescribed medication.707 In addition
to side effects, new symptoms that may be unrelated to the
medication regimen can also impact compliance. It is there-
fore important to advise patients of side effects that may be
related to medications, as patients tend to blame their drugs
for any new symptoms they experience (Table 10).708
Pill Burden and Dosing Complexity: Complexity of a drug
regimen influences compliance709 and is especially problem-
atic for hypertension and HF, as dosing complexity and
number of medications increases with disease severity. This
problem has been growing as the number of medications and
evidence-based guidelines have increased.710 An average of 2
to 4 antihypertensive medications are required for BP control
in most high-risk patients with hypertension and comorbid
conditions such as renal disease or diabetes mellitus.711 As
Table 10. Adverse Effects of Antihypertensive Therapy in
the Elderly
Drug Class Adverse Effect
Thiazide and loop diuretics Hypokalemia, hyponatremia, hypomagnesemia,
volume-depletion hypotension, renal impairment,
hyperuricemia, gout, hyperglycemia
Potassium-sparing diuretics Hyperkalemia, hypotension
Beta-adrenergic blockers Sinus bradycardia, fatigue, AV nodal heart
block, bronchospasm, intermittent
claudication, confusion, aggravation of acute
heart failure, hyperglycemia
Alpha-beta adrenergic
blockers (vasodilator-beta
adrenergic blockers)
Hypotension, heart block, sinus bradycardia,
bronchospasm
Alpha1-adrenergic
antagonists
Orthostatic hypotension
Angiotensin-converting
enzyme inhibitors
Cough, hyperkalemia (only with eGFR 50
mL/min), angioneurotic edema, rash, altered
taste sensation, renal impairment
Angiotensin receptor
blockers
Hyperkalemia, renal impairment
Central-acting drugs Sedation, constipation, dry mouth
Calcium antagonists
(Non-dihydropyridines) Rash, exacerbation of GERD symptoms, sinus
bradycardia, heart block, heart failure,
constipation (verapamil), gingival hyperplasia
(Dihydropyridines) Peripheral edema, heart failure, tachycardia,
aggravation of angina pectoris (short-acting
agents)
Direct vasodilators Tachycardia, fluid retention, angina pectoris
AV indicates atrioventricular; eGFR, estimated glomerular filtration rate; and
GERD, gastroesophageal reflux disease.
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seen in Figure 12,2 antihypertensive agents were needed to
achieve target BP goals in the majority of patients.712 As new
treatment strategies are added, the increased pill burden may
contribute to problems with compliance.
There is an inverse relationship between the number of
daily drug doses and the adherence rate.692,699 A meta-anal-
ysis for chronic conditions including CVD showed that mean
dose-taking compliance was 79% for 1 dose, 69% for 2 doses,
65% for 3 doses, and 51% for 4 doses (P0.001 among dose
schedules).699 Thus, it is important to prescribe therapies that
will help to alleviate pill burden. Reduction in dose frequency
through selection of once-daily agents improves medication
compliance,713 particularly in hypertension treatment.698
Once-daily dosing was shown to have the highest compliance
rate among dosing schedules for a range of CV disorders: as
the number of doses per day increased, compliance rates
declined.699,714 Although these data are from cohorts that
included few elderly patients, reducing daily dose frequency
was found to produce a significant improvement in compli-
ance. The average compliance rate was significantly higher
for once-daily dosing compared with multiple-daily dosing
(91.4% versus 83.2%, P0.001). Average compliance was
higher for once-daily (92.7%) versus twice-daily dosing
(87.1%, P0.026).
One concern regarding once-daily formulations is that
when patients are not adherent, they miss an entire day of
medication as opposed to missing half a day or less with
multiple dosing. Although this is an important consideration,
the properties of long-acting oral formulations may help to
provide protection from adverse events even when compli-
ance is not perfect. Although BP control was significantly
reduced in patients who were only partially adherent (80%
of prescribed pills taken) to short-acting, twice-daily dilti-
azem, this was not the case in patients who were only
partially adherent to the once-daily amlodipine formula-
tion.715 This suggests that the negative consequences of
partial compliance for BP control may be offset by selecting
agents with a longer duration of action beyond the dosing
intervals. Overall, use of once-daily drug formulations pro-
vide a significant improvement in compliance to a prescribed
regimen and may improve outcomes.
Cost Considerations: Although higher out-of-pocket med-
ication costs are associated with reduced compliance in the
overall population, this is a particular concern in the elderly
because of their generally lower incomes. Clinicians should
use generic and formulary drugs when possible. Conversely,
an impact on overall healthcare costs is also observed with
poor compliance. An analysis of the association between
interruption or termination of therapy and total healthcare
costs716 using paid claims data (California Medicaid) found
each patient with interrupted antihypertensive drug therapy
accumulated an additional $873 in healthcare costs during the
first year. These costs were primarily the result of increased
hospital expenditures.716 These findings were confirmed in a
patient primary database in the United Kingdom.717
5. Future Considerations
5.1. Prevention of Hypertension
Most consideration of preventing hypertension has been
targeted at young people, and little information is available
about preventive strategies in the elderly. Increases in SBP
occur with aging in most societies around the world. Unfor-
tunately, there are no clear explanations for these exceptions
and thus no clinical guidance.721 It is likely that patterns of
decreasing physical activity and weight gain with age in
industrialized societies partially explain this trend for increas-
ing SBP with age.
Usual recommendations for hypertension prevention are
based on the following lifestyle changes: reduced sodium
intake; weight loss; moderation of alcohol use; diets centered
on fresh produce; and physical activity.722 Excess weight is
Figure 12. Percentage of people in outcomes trials of the elderly taking 2 or more antihypertensive medications. ACCOMPLISH8 indi-
cates Avoiding Cardiovascular Events in Combination Therapy in Patients Living with Systolic Hypertension; ALLHAT,9 Antihypertensive
and Lipid-Lowering Treatment to Prevent Heart Attack Trial; Australian HTN,718 Australian Hypertension Study; CONVINCE,719 Con-
trolled Onset Verapamil Investigation of Cardiovascular End Points Trial; EWPHE,12 European Working Party on High Blood Pressure in
the Elderly; HYVET,4 Hypertension in the Very Elderly Trial; INVEST,584 International Verapamil-Trandolapril Study; LIFE,14 Losartan
Intervention For Endpoint Trial; MRC-Elderly,15 Medical Research Council Trial of treatment of hypertension in older adults; SBP, systol-
ic blood pressure; SHEP,16 Systolic Hypertension in the Elderly Program; STONE,17 Shanghai Trial of Hypertension in the Elderly;
STOP-2,720 Swedish Trial in Old Patients with Hypertension; Syst-China,19 Systolic Hypertension in China Trial; and Syst-Eur,20 Systolic
Hypertension in Europe Trial.
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common in older people, so weight loss represents an
opportunity for slowing progression to hypertension. Like-
wise, use of the DASH diet, based on increased intake of
fresh produce and discussed elsewhere in this report, has a
BP-lowering effect. Although dietary strategies are not easy
to achieve or sustain in younger people, it is possible that
elderly people might be more acutely sensitive to the CV
consequences of rising BPs and thus more motivated to make
lifestyle changes, including the assumption of increased
physical activity such as walking.
Perhaps the best documented of these approaches in elderly
people is reduced dietary sodium. A study in China demon-
strated that switching to sodium intake at the lower end of the
usual dietary range produced meaningful BP reductions in
older persons.723 A possible explanation for this is that the
reactive increase in activity of the RAAS that blunts antihy-
pertensive efficacy of salt restriction is less active in the
elderly.724,725 From a mechanistic point of view, sodium and
the RAAS have synergistic effects accelerating arterial dis-
ease, including arterial stiffening that leads to systolic hyper-
tension of the elderly.726 Indeed, it has been suggested that
aging may increase sensitivity of arteries to sodium.727
Integrity of endothelium, vascular smooth muscle cells, and
connective tissue are all compromised by sodium so as to
reduce vascular compliance, particularly in concert with
effects of AII and aldosterone. Evidence implicates the role of
the high vascular tissue concentrations of AII found in the
elderly in amplifying adverse changes in extracellular tissues,
so increasing rigidity of the wall structure.727
These considerations would support the dual strategies of
dietary salt restriction and RAAS blockade for preventing or
modifying the appearance of hypertension in older people.
One trial, albeit in a young-to-middle-aged cohort, showed
2-year intervention with an ARB in patients with prehyper-
tension modestly but significantly reduced progression to
overt hypertension.728 It is not known whether this strategy
would be effective in an older group. On theoretical grounds,
addition of a CA to a RAAS blocker might provide additional
inhibition of adverse vascular proliferative changes.729
At present, prevention of hypertension in the elderly should
be based primarily on a strategy of dietary salt restriction,
weight control, and physical activity. This could be aug-
mented by relatively early introduction of RAAS blockade in
stage 1 hypertension with the intent of limiting further
progression of hypertensive disease.
5.2. Unanswered Questions
There remain many important but unresolved issues regard-
ing hypertension treatment in the elderly. One is to agree on
a working definition of the term elderly. Another is to
establish BP values for making the diagnosis of hypertension
as well as setting targets for treatment. A third is to identify,
for those patients in whom pharmacological therapy is indi-
cated, which drugs will be most effective for reducing CV
events. A final question is whether there is a subgroup of
elderly patients with hypertension in whom treatment is not
beneficial.
Defining elderly is a difficult task, as discussed earlier in
this document. Because of the great heterogeneity among
individuals in the aging process, it is not possible to readily
assign an overall chronological value that establishes the state
of being elderly. Some octogenarians can be fully active in
the work environment or elsewhere on a daily basis, but
others are not so fortunate. Given this marked heterogeneity
of health and physiological function in older adults, it is more
important to focus on defining the extent of these age-
associated conditions than on using chronologic age to define
and treat the elderly patient with hypertension.
Ongoing and future research will further explore the causes
and mechanisms of age-related development and progression
of vascular disease. It is clear that age, apparently indepen-
dent of other CV risk factors, is a powerful predictor of
events. In the future, it should be possible to apply objective
measurements of vascular or other clinical properties to better
define hypertension and to tailor therapy.
The most practical definition of hypertension in the elderly
should describe a BP level above which medical interven-
tion—lifestyle changes or drugs—could be expected to pro-
vide clinical benefits. Although several clinical trials have
reported beneficial results of treating hypertension in the
elderly, these studies have not provided clear guidance for
selecting a specific BP value that could be used to diagnose
hypertension or to use as a target for treatment. A report from
INVEST found that patients who had BP 140/90 mm/Hg at
75% of their follow-up visits had the lowest risk for adverse
outcomes.730 As a simple generalization, it could be stated
that pretreatment SBP 160 mm Hg would fit the profile of
most of these studies, including HYVET,4 as would a target
SBP 150 mm Hg. These studies have shown clinical
benefits with achieved SBP values averaging in the 140s,
150s, and 160s. Thus, unlike previous guidelines that ad-
dressed the full spectrum of adults,22,23 there is limited
evidence in the elderly to support a value of 140 mm Hg as
a diagnostic and therapeutic threshold. There are also limited
data as to whether patients with initial SBP between 150 and
159 mm Hg would benefit from treatment.731 Nevertheless,
achieved values 140 mm Hg for those 79 years of age are
appropriate; but for those 80 years of age, 140 to
145 mm Hg, if tolerated, can be acceptable.
Until recently, no randomized trials had compared effects
on clinical outcomes of achieving different BP values in older
adults. However, in 2009, the Cardio-Sis (Studio Italiano
Sugli Cardiovascolari del Controllo della Pressione Arteriosa
Sistolica) trial, in 1111 nondiabetic patients (mean age 67
years) with baseline SBP 150 mm Hg reported a reduction
in the primary outcome, the rate of ECG LVH at 2 years
median follow-up in patients randomized to a SBP goal
130 mm Hg versus a goal of 140 mm Hg using open-label
drugs (11.4% versus 17%, OR: 0.63; 95% CI: 0.43 to 0.91;
P0.013). In addition, a composite CV endpoint occurred in
9.4% in the usual control group versus 4.8% in the tight-
control group (HR: 0.50; 95% CI: 0.31 to 0.79; P0.003).732
Although the age–treatment group interaction was nonsignif-
icant, the greatest reduction in the primary outcome was seen
in the subgroup 70 years of age.732 Other than Cardio-Sis,
comparisons of different BP treatment targets in the elderly
are limited to post hoc interpretations of previously con-
ducted studies comparing different achieved BP lev-
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els.4,11,15,16,18,20,526,529 However, as discussed earlier in this
report, these studies varied, not only in their target BPs, but
also in patient selection, drug choices, and duration of
therapy. Furthermore, they were all based primarily on SBPs
and generally did not attempt to reach the aggressive BP
goals used in more contemporary hypertension trials in
younger cohorts.8,9,21
Until additional data from RCTs comparing various BP
targets in the elderly become available, existing epidemio-
logic and clinical trial data suggest a diagnostic and thera-
peutic threshold for hypertension of 140/90 mm Hg remains
reasonable in adults 65 to 79 years of age. As mentioned
previously (see Section 1.4), the ACCORD BP, although
limited to high-risk persons with type 2 diabetes mellitus,
found no additional benefit from an intense BP-lowering
strategy targeting SBP of 120 mm Hg, with an increase in
adverse experiences related to antihypertensive drugs in the
cohort 65 years of age. The soon-to-be-launched SPRINT
(Systolic Blood PRessure INtervention Trial) should provide
additional information about the optimal BP treatment goal in
older adults. Among individuals 80 years of age, HYVET
data suggest a SBP of 150 mm Hg as the diagnostic criterion
for hypertension and the treatment target in octogenarians and
beyond. Should SBP fall readily to lower levels, it would be
reasonable to maintain this level of control, provided treat-
ment is well tolerated. Yet it is the low DBP that concerns
many clinicians from the J-curves reported.268 Clinicians,
however, should consider 2 exceptions to this recommenda-
tion. First, in those elderly patients in whom a SBP
150 mm Hg is readily and safely obtained with just 1 or 2
drugs, a further modest intensification of treatment to achieve
a value140 mm Hg could be considered, even though there
is no firm evidence to support this target. The second
exception to the recommendation applies to patients whose
SBP remain 150 mm Hg under the following 3 circum-
stances that: 1) despite taking a regimen of 4 well-selected
and appropriately dosed drugs, this goal has not been
achieved; 2) prescribed therapy is causing unacceptable side
effects, particularly postural changes that could result in the
potentially disastrous consequences of physical injury; and 3)
in attempting to reach the SBP target, the DBP is being
reduced to a potentially dangerous level 65 mm Hg. Under
any of these circumstances, the lowest safely achieved SBP
150 mm Hg is acceptable.
Finally, there is no evidence in older people to support the
use of lower BP targets in patients at high risk because of
conditions such as diabetes mellitus, CKD, or CAD.
Drug choice to treat the elderly is often dictated by
concomitant conditions (eg, CAD, HF, diabetes mellitus, and
kidney insufficiency). Diuretics, CAs, and RAAS blockers
have all been effective in reducing events in the elderly.
There are no authoritative comparison trials that would
indicate superiority of monotherapy with 1 class over the
other. As discussed elsewhere, most patients will require
combination drug therapy (Table 9). Diuretic-based regimens
were effective in earlier studies, although a large hyperten-
sion trial that included mostly elderly patients indicated that
amlodipine is preferable to a thiazide in combination treat-
ment for reducing fatal and nonfatal CV outcomes.579
5.3. Future Research
Future research should include both fundamental and clinical
investigation directed toward defining the pathogenesis of
increased vascular and LV stiffness, characteristic of elderly
patients with hypertension. The goal of this research should
be to develop strategies to both prevent and reverse this form
of vascular pathology, which is the cornerstone of systolic
hypertension in the elderly. Another direction should be
well-designed randomized controlled outcome trials to define
appropriate thresholds and goals for antihypertensive treat-
ment in the elderly. These might include randomizing persons
with SBP 160 mm Hg to SBP goals of either 150 mm Hg
or 140 mm Hg. Safety considerations would be important in
these trials. Finally, comparative effectiveness trials are
needed to test various treatment strategies (ie, different drug
regimens and different intensities of lifestyle modification)
and to assess the relative safety and efficacy of these
approaches in the prevention of CV mortality and morbidity
and total mortality. Strategies using non-physician providers
(nurses, pharmacists, and trained laypersons) should be
tested, given the increasing demands of an expanding elderly
population and the growing shortage of physicians.
Potential New Therapeutic Strategies: Because several
efficacious and well-tolerated antihypertensive drug classes
are now available, there are relatively few new classes in
development. It is likely that advances for the foreseeable
future will focus primarily on innovative strategies for select-
ing and combining available drugs. Thiazide diuretics and
dihydropyridine CAs have been the best-studied drugs in
older cohorts. However, there is growing evidence both of the
fundamental role of RAAS mechanisms in the genesis of
vascular pathology and hypertension in the elderly and of the
benefits of pharmacologically blocking this system.
As emphasized elsewhere in this document, a limiting
factor for therapy in older people is uncertainty about
appropriate BP targets. Whereas the general BP goal in adults
has been 140/90 mm Hg, HYVET results in octogenarians
showed meaningful event reduction with SBP in the mid-
150s.4 However, the Cardio-Sis trial showed lower event
rates in “younger” elderly hypertensive patients with a goal of
SBP130 mm Hg versus140 mm Hg.732 Yet the results of
ACCORD BP (Section 1.4), found no benefit targeting
120 mm Hg versus 140 mm Hg in high-risk patients with an
increase in drug-related adverse experiences. A trial now
underway in Japan is comparing event rates in elderly
patients whose SBPs are reduced to140 mm Hg versus 140
to 160 mm Hg.733 The SPRINT trial, sponsored by NHLBI, is
comparing SBP targets of 120 mm Hg versus 140 mm Hg in
higher-risk adults, and oversampling elderly patients. These
trials and others will hopefully cast more light on 1 key
treatment objective in older patients: avoidance of cognitive
dysfunction, perhaps most readily accomplished by effective
BP control.260
Future treatment strategies should evaluate sodium restric-
tion together with therapeutic blockade of the RAAS. In fact,
RAAS blockers are all effective in elderly patients with
hypertension.602,734 Further research with bradykinin and
related targets, including newly developed angiotensin immu-
notherapy,735 may also be warranted. Innovative combina-
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tions of CAs with RAAS blockers have demonstrated benefit
in high-risk patients and could be especially useful for the
elderly.8
Endothelin antagonists could also be valuable in older
patients. Endothelin antagonists provide efficacy in resistant
hypertension, and their main drawback, teratogenicity, is not
an issue in elderly patients.736 Likewise, increased use of
aldosterone antagonists could be anticipated, for in low doses,
they can also be effective for adjunctive therapy.737 More-
over, a new progestogen, drospirenone, has exhibited antial-
dosterone activity and BP-lowering effects in post-
menopausal women and may represent a novel strategy.738
There is limited information on non-drug substances for
hypertension treatment in the elderly. Soy nuts, for instance,
reduce BP in elderly women, though it is not clear whether
soy proteins or other components produce this effect.739,740
Studies with calcium and vitamin D supplements or vitamin
C have not demonstrated useful BP effects.241
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Appendix 3. Abbreviation List
ACEI  angiotensin-converting enzyme inhibitors
AF  atrial fibrillation
AMD  age-related macular degeneration
ARB  angiotensin receptor blocker
BA  balloon angioplasty
BP  blood pressure
CA  calcium antagonist
CHD  coronary heart disease
CKD  chronic kidney disease
CV  cardiovascular
CVD  cardiovascular disease
DBP  diastolic blood pressure
eGFR  estimated glomerular filtration rate
GFR  glomerular filtration rate
HCTZ  hydrocholorothiazide
ISH  isolated systolic hypertension
LV  left ventricular
LVH  left ventricular hypertrophy
NSAIDs  nonsteroidal anti-inflammatory drugs
QoL  quality of life
RAAS  renin-angiotensin-aldosterone system
RAS  renal artery stenosis
RCT  randomized control trial
SBP  systolic blood pressure
TSH  thyroid stimulating hormone
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